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ABSTRACT
The overall objective of this project is to develop methods that can help us to understand 
the movement of drugs and carriers along their routes inside solid tumors. The origins and 
current paradigm of targeted drug delivery offer a lot of promising strategies. However, 
the carriers often struggle with challenges in optimizing their own characteristics against 
that of the tumor's. Ultimately, they struggle with translation into the clinical setting. 
It is apparent that solid tumors pose a unique challenge in drug delivery. Many drug 
carrier characteristics are designed to take advantage of the pathophysiology of the tumor 
environment. However, this passive delivery and accumulation is constrained to partial 
distribution within the tumor. Many uncertainties remain regarding how nanoparticles 
enter and travel through the tumor environment. The barriers to intratumoral distribution 
are still currently being probed.
The research herein identified transport barriers using human fibroid tumors known to 
have impaired drug transport. After perfusing human uteri containing fibroids with stains, 
probe distribution was found to correlate with features of the pathophysiology such as blood 
vessel characteristics, tissue and collagen density, interstitial fluid pressure, and solid stress. 
Methods, including custom MATLAB code, were developed to analyze the spatiotemporal 
distribution of two uniquely fluorescent nanoparticle doses in xenograft mice. It shows how 
three-dimensional distance measurements of nanoparticles from nearest blood vessels are 
more precise than two-dimensional measurements. Colocalization analysis on the fluorescent 
signals showed the two different doses (administered hours apart from each other) did not 
accumulate in the same locations with the tumor. Furthermore, intravital imaging showed 
that some vessels of the tumor would only provide access to the first dose of nanoparticles.
Future work suggests further analysis of multidose interdependence and implementing 
these methods to screen strategies in the literature of modifying drug carriers and the tumor 
environment to improve intratumoral distribution of cancer drugs. The more understanding 
we have of the solid tumor environment and its barriers, the better we can navigate 
treatments to reach the tumor.
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW
Drug delivery strategies seek to increase the efficacy and reduce the toxicity of thera­
peutic drugs. Cancer drugs are in need of drug delivery innovations to overcome special 
challenges such as the toxicity or solubility of the drug and barriers presented by the 
disease. To improve drug delivery, many therapies under investigation implement advanced 
technologies that have specially designed characteristics to aid in distribution of the drug. 
These will be termed drug carriers as they carry or act as a drug. While advances have led 
to seemingly improved drug delivery over traditional chemotherapy, challenges remain in 
effectively treating solid tumors (Fig. 1.1).
This chapter will introduce the current paradigm on drug delivery and the challenges 
facing it. Challenges lie in the carrier design, the tumor environment, and in translation to
F igure  1.1. Distribution of cancer drugs. A) Traditional chemotherapy’s toxicity (orange 
flames) spreads throughout the entire body in hopes of killing off the tumor (green with 
arrow). B) Drug carriers seek to be a magic bullet to direct toxicity to only the tumor, but 
iv administration still relies on passive delivery. While distribution is more selective and 
toxicity is often reduced (even clinically), it is still present in many major organs (C) and 
distribution throughout the tumor is limited (D).
2the clinic. It is known that advanced strategies using drug carriers have a low success rate in 
the clinical setting [1]. While the literature boasts of miraculous efficacy in animal models, 
mediocre clinical results limit their approval or relegate them to secondary or combination 
treatments after traditional chemotherapy fails [2]. The review will show an interesting 
trend in approved targeted drug delivery therapies. A common denominator is access to 
the tumor, as solid tumors have special challenges to drug delivery. The included published 
work will provide tools and methods to understand intratumoral drug delivery that may 
help overcome access barriers that limit effective treatments in reaching the clinic.
1.1 Ideal Drug Delivery
Ideal drug delivery for these drug carriers targets all the toxicity at the tumor site and 
very little in normal tissues. Essentially, having control over distribution in the body and 
in the tumor is the goal of targeted drug delivery. Targeted drug delivery is an umbrella 
term where “targeted” may refer to a number of different functions. It may refer to passive 
targeting, active targeting, or loosely as a goal of the design.
Targeted drug delivery seeks to improve the therapeutic index (i.e., lower the toxicity 
but increase the efficacy) of a drug. Some designs try to minimize side effects and allow 
a higher dose to remain bioavailable longer for increased therapeutic effects (most passive 
carriers like liposomes). Other designs focus on increasing efficacy to require less drug 
that could cause side effects (might incorporate active targeting). The methods of targeted 
drug delivery often control both when and where the drug is effective. If the drug can be 
presented only to the disease in the body, then there will be no side effects and efficacy will 
be improved with high concentrations in the target area. Research has been ongoing for 
years to accumulate a significant amount of knowledge into the field and fill the literature 
with the seemingly subjective term “targeted drug delivery” (Fig 1.2).
Some have very aggressive claims regarding targeted drug delivery and others, perhaps 
more accurately, state a goal of improving targeted drug delivery [3,4]. While clear delin­
eations of what targeted drug delivery is and is not would help, there are challenges with 
the current state of targeted drug delivery that extend beyond defining the term. These 
challenges, which are present in both the carrier and the target, make translation into the 
clinic difficult. Carrier technology has improved greatly yet still has trouble delivering drug 
to the target. The target, solid tumors in the clinical setting, is still resisting treatment. 
The systems may be targeted by design, but they are not hitting the target thoroughly nor 
exclusively. The challenges associated with this problem need to be addressed in order to
3Figure  1.2. What is effective targeting? Targeting strategies in drug delivery do not 
guarantee that drugs will be delivered exclusively to the target. Often, a spread distribution 
reaching other sites is unavoidable. Many targeted therapies are designed to be less effective 
outside the target (blunt tips). Nevertheless, these systems can fail.
move forward.
The current paradigm of targeted drug delivery is linked to its origins, which are tied to 
chemotherapy and immunology. Paul Ehrlich was a pioneer in chemotherapy and is known 
for the metaphor of a magic bullet. The vision of the magic bullet was inspired from his 
ability to selectively stain bacteria cultures [5]. He reasoned a toxic molecule could be tied 
to the stains to selectively kill only that target. Targeted drug delivery has been guided 
by Paul Ehrlich’s vision, particularly in the field of cancer therapy [6]. Targeting designs 
are usually incorporated in a variety of drug carriers such as lipid-based, polymer-based, 
protein-based, viral-based, and various other nanoparticles (Fig. 1.3).
Liposomes are composed of lipids that assemble into vesicles with a bilayer capable of 
carrying drug molecules. Gold and iron oxide nanoparticles are among the more popular
1.1.1 Origins in targeted  drug delivery
Drug or imaging agent # " Polymer or linker Targeting group w
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F igure  1.3. Various drug carrier types. Besides having specific targeting groups, sometimes 
the size or other characteristics provide targeting effects.
4inorganic compositions used. Viral carriers, made by modifying existing viruses or by using 
certain aspects from them, have also been used in targeted drug delivery of therapeutics 
[7,8].
Polymer chemistry is a major tool for drug carriers that seek to provide the properties 
of a magic bullet. Helmut Ringsdorf suggested a standard model that could be used to 
improve targeted drug delivery by suggesting that a biocompatible polymer can serve as a 
backbone to link drugs and targeting groups together [9]. The Ringsdorf model has been an 
inspiration for many polymer designs in drug delivery for cancer therapy [10]. It has led to 
a trend of polymer therapeutics with researchers devising various ways to give properties to 
polymers. The versatility in chemistry and molecular architecture is one of the advantages 
of polymers in targeted drug delivery. Often, other categories of drug carriers will have 
polymer components to furnish additional characteristics. With polymer therapeutics and 
the rapidly expanding field of nanotechnology, the possibilities are only limited by one's 
imagination.
“Affinity therapy” is a term used over 30 years ago to describe designs that involve 
forces between molecules that cause them to bind [11]. Besides polymer therapies, other 
categories such as inorganic nanoparticles have also included this type of active targeting 
into their design. These targeting groups with ligand-receptor binding are often referred 
to as targeting moieties. While various carriers have used ligand-receptor binding over the 
years, antibodies are one of the best forms of this. Advances in immunology and the advent 
of monoclonal antibodies have become an important part of pursuing the vision of a magic 
bullet.
All of these carrier types have dimensions on the scale of nanometers and can be 
described as nanoparticles. While colloidal chemistry and even targeted drug delivery have 
a long history, additional advances in nanotechnology and applications in drug delivery 
are quickly becoming popular topics. Review articles list various drug carriers that are 
approved or in clinical trials, the majority of which can be found in Table 1.1 [1,12-18].
1.1.2 Current paradigm
The current paradigm associated with targeted drug delivery shapes the design of the 
drug carriers. However, even selectivity of the base drugs can help in localizing treatment 
to the tumor. Given a good base drug, there are additional carrier properties thought to 
maximize drug delivery to the tumor.
5Table 1.1: V arious d rug  carrie rs  approved or in 
developm ent.
Product Name Category Approval status
Abraxane Protein FDA approved
AD-70 Polymer Phase I
Adcetris Antibody FDA approved
ADI-PEG20 Polymer Phase I
ALN-VSP Nanoparticle Phase I
AP5280 Polymer Phase I/II
Arzerra Antibody FDA approved
ASG-22ME Antibody Phase I
ASG-5ME Antibody Phase I
Atu027 Liposome Phase I
Aurimune Nanoparticle Phase II
AuroLase Nanoparticle Phase I
Avastin Antibody FDA approved
Bexxar Antibody FDA approved
BIND-014 Micelle Phase I
CALAA-01 Nanoparticle Phase I
Campath Antibody FDA approved
Cea-scan Antibody FDA approved
Combidex Nanoparticle Phase III
CPX-1 Liposome Phase II
CPX-351 Liposome Phase I
CRLX101 Nanoparticle Phase II
CT-2106 Protein Phase I
C-VISA-BikDD Liposome Phase I (withdrawn)
Cyclosert Nanoparticle Phase I
DaunoXome Liposome FDA approved
DE-310 Polymer Phase I
Depocyt Liposome FDA approved
Docetaxel-PNP Nanoparticle Phase I
Doxil Liposome FDA approved
Endorem Nanoparticle Europe
Erbitux Antibody FDA approved
EZN-2208 Polymer Phase II
Feridex Nanoparticle FDA approved
Genexol-PM Micelle Several other countries
Herceptin Antibody FDA approved
INGN-401 Liposome Phase I
Kadcyla Antibody FDA approved
Keytruda Antibody FDA approved
LE-SN38 Liposome Phase II
MAG-CPT Polymer Phase I
Marqibo Liposome FDA approved
6Table 1.1: (continued)
MBP-426 Liposome Phase II
MCC-465 Liposome Phase I
Mepact Liposome Europe
Mylotarg Antibody Withdrawn
Myocet Liposome Europe and Canada
NC-4016 Micelle Phase I
NC-6004 Micelle Phase I
NK-012 Micelle Phase II
NK-105 Micelle Phase II
NK-911 Micelle Phase I
NKTR-102 Polymer Phase III
NL CPT-11 Liposome Phase I
Oncaspar Polymer FDA approved
Onivyde Liposome FDA approved
Ontak Protein FDA approved
Opaxio Protein Phase III
Opdivo Antibody FDA approved
OSI-211 Liposome Phase II
OSI-7904L Liposome Phase II
Paclical Micelle Phase III
Pegamotecan Polymer Phase II
PegAsys Polymer Phase I/II
PegIntron Polymer Phase I/II
PEGPGA and DON Polymer Phase I/II
Perjeta Antibody FDA approved
PK1 Polymer Phase II
PK2 Polymer Phase I/II
PK3 Polymer Phase I
PNU166945 Polymer Phase I
ProLindac Polymer Phase II
Prostascint Antibody FDA approved
Prothecan Polymer Phase II
Resovist Nanoparticle Europe
Rexin-G Viral Philippines/FDA Phase III
Rituxan Antibody FDA approved
S-CKD602 Liposome Phase I/II
SGN-75 Antibody Phase I
SGN-CD19A Antibody Phase I
SGN-CD33A Antibody Phase I
SGT-53 Liposome Phase I
SGT-94 Liposome Phase I
SP1049C Micelle Phase II
SPI-077 Liposome Phase II
Sylatron Polymer FDA approved
7Table 1.1: (continued)
Thermodox Liposome Phase III
Vectibix Antibody FDA approved
Verluma Antibody FDA approved
XMT-1001 Polymer Phase I
Yervoy Antibody FDA approved
Zevalin Antibody FDA approved
Zinostatin Stimalmer Polymer Japan
8First, a stable carrier for the drug can help reduce side effects and increase the ther­
apeutic effect. A stable carrier will mean that the drug is protected from the body and 
that normal (nontargeted) tissues are protected from the drug. Second, the carrier will 
accumulate into the tumor via the enhanced permeability and retention (EPR) effect. Third, 
the carrier can target the tumor with additional means based on environmental or cellular 
components.
Small molecule drugs can, by their mechanism of action, provide some targeted drug 
effect. It is often through targeting resources the cancer needs. Many anticancer drugs 
interfere with microtubules or DNA and affect cancer cells more because they divide more. 
The base drug in Oncaspar, asparaginase, can deplete asparagine levels that affect tumor 
cells more as they do not have the ability to synthesize asparagine like normal cells. These 
selective drugs can be augmented with stable drug carriers to increase their chances of 
reaching the tumor.
The first requirement of a stable carrier is simply the ability to carry the drug. The 
majority of anticancer drugs are hydrophobic and do not dissolve in aqueous solutions. 
As the carriers transport the drug, they need to form a stable barrier between the drug 
and the body. Protecting the body from the drug requires that the drug not interact 
with nontargeted cells, tissues, or organs. Protecting the drug from the body provides 
long circulation in the blood stream. To achieve long blood circulation, it needs to avoid 
interaction with the reticuloendothelial system (RES), also known as the mononuclear 
phagocyte system (MPS). Cell uptake by the MPS will decrease the efficacy of the treatment 
and can limit the chances of it reaching the target. There should be protection against 
blood-born proteins that would lead to inactivation, destabilization, or opsonization. The 
carrier should also be designed to limit accumulation into the kidney, liver, spleen, and 
other nontargeted organs. Administration of the chemotherapeutic agent Taxol® is a good 
example of the need for good carriers. Taxol consists of paclitaxel solubilized in Cremephor 
EL® (also known as Kolliphor EL*®), which is a highly toxic mixture of ethoxylated castor 
oil. This excipient can cause hypersensitivity reactions in patients undergoing chemotherapy 
and can end up limiting their treatment [19]. Furthermore, the active pharmaceutical 
ingredient, paclitaxel, is known to cause dose-limiting neurotoxicity at high doses [20]. 
If stability and long circulation are achieved, it will be able to travel through the body 
long enough to reach the tumor site. Here, carrier technology can encourage preferential 
treatment to the tumor with designs tuned to target environmental characteristics or cellular 
components of the cancer.
9The carrier can take advantage of environmental characteristics of the tumor. Some of 
the environmental characteristics provide a means for passive accumulation via the EPR 
effect. EPR is possible with two hallmarks of cancer: unchecked growth and continued 
angiogenesis [21]. Continuous growth of the tumor leads to a chaotic tumor environment 
with cells in hypoxic regions producing angiogenic factors that stimulate the production of 
new blood vessels. These new blood vessels are poorly formed and have gaps or fenestrations 
in the endothelium that allow passage of macromolecules into the tumor from the blood 
[22,23]. Increased mass transport from the blood vessels is beneficial for a tumor that is 
starved for nutrients. Therapies can take advantage of this enhanced permeability (EP) that 
allows macromolecules to deposit into the tumor where this leakiness occurs. Furthermore, 
enhanced retention (ER) in the tumor is aided by the lack of functional lymphatics that 
would normally drain the tissue [24]. Thus, when the EP and ER allow the drug to 
accumulate in the tumor at a concentration higher than surrounding normal tissue, it can 
be said to have had an EPR effect.
The tumor environment allows for passive targeting via EPR, but it also has other 
characteristics that can be used to activate drug carriers when in the tumor environment. 
Some drug carriers use pH-sensitive groups to provide a triggered action in the acidic 
environment [25]. The low pH (from about pH 5.8 to pH 7.6) in solid tumors is a result of 
metabolism in hypoxic conditions [26,27]. Consequently, hypoxic conditions can also be a 
trigger for targeted drug action [28]. It also might be possible to use the high concentration 
of matrix metalloproteinases (MMPs) in the extracellular matrix of tumors to convert the 
carrier into an active form [29].
Once in the tumor environment, ligand-receptor binding can provide preferential treat­
ment via active targeting of specific molecules on cells [18]. Given access to the cancer cells, 
the drug is more likely to enter the cancer cell when a carrier with targeting moieties holds 
it in close proximity to the cell membrane. How quickly and by which route it enters is then 
dependent on the carrier properties [30]. Some cancer cell types overexpress certain surface 
markers. These markers are present in other cells, but can be much more abundant in some 
tumors. Overexpression of folate receptor and human epidermal growth factor receptor 2 
(HER2) has been shown to be a predictor of poor prognosis of breast cancers [31,32]. These 
and other overexpressed proteins have become a target implemented into the designs of 
drug carrier technologies [33-35].
Thus, the current paradigm is to have the carrier transport the drug in a stable manner 
while circulating through the blood stream so that it can accumulate in the tumor where
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a targeting mechanism will provide selective treatment. This paradigm has a plethora of 
opportunities for polymer therapeutics and nanotechnology. Designs can be custom tailored 
to fit certain aspects of the paradigm.
What often happens is a therapeutic approach will focus on one specific aspect of the 
paradigm to increase efficacy. Unfortunately, this can result in shortcomings in other areas. 
Overall, there is still a low rate of clinical success for drug carriers, especially those targeting 
solid tumors.
1.2 Challenges to Intratumoral Drug Delivery
Challenges to successful targeted drug delivery come from carrier-dependent factors 
and tumor-dependent factors. Biodistribution and EPR depend on carrier characteristics 
and these carriers are not always well characterized, stable, or biocompatible. On the 
other hand, the tumor is resisting treatment from the environmental to the cellular level. 
Furthermore, if good results with a drug carrier are seen in preclinical models, the success 
does not often translate into the clinical setting. Aspects of the paradigm need to be 
examined in order to see improvements. There have been critical examinations of targeted 
drug delivery for quite some time now and certain challenges are beginning to be understood 
more thoroughly [36,37].
Table 1.2 shows some trends in 24 FDA approved drug carriers for cancer treatment. 
The table was inspired by a 2007 review article summarizing strategies to improve exposure 
to solid tumors [38]. While this table may quickly become outdated, additional and current 
information on drug carriers can be found surveying drugs@FDA or on their respective FDA 
labels [39]. Some insight might be gained from these drugs that had to prove they were safe 
and more efficacious than what is currently used in human patients.
The first thing noticed is that few of these are approved for primary treatment. For 
many, there is not enough evidence to risk jeopardizing patient care to these advanced carrier 
therapies. Sometimes, the clinical trials require the patients to first have treatments with a 
known track record fail before becoming eligible for the trial. Subsequently, the approved 
drug carriers are limited in showing that they could be a capable first line treatment. 
Though not listed here, even approved carrier-imaging agents (like Cea-scan, Prostascint, 
or Verluma) cannot be used alone for diagnosing a tumor. They must be confirmed by 
biopsy or other means.
Another predominant feature is that out of 24 approved drug carriers, 15 are antibodies. 
It shows the boon that monoclonal antibodies have been to anticancer therapy. Antibodies 
are on the lower range of drug carrier sizes at approximately 5-20 nm in diameter (depending
11
Table 1.2. Trends in approved drug carriers.
Erbitux + + + +
Herceptin + + + +
Kadcyla + + + +
Perjeta + + + +
Vectibix + + + +
Avastin + + +* +
Adcetris + + +
Arzerra + + +
Bexxar + + +
Zevalin + + +
Doxil + + + +
Onivyde + + + +
Abraxane + ? + +
Sylatron + ? +*
Oncaspar + ? +






Yervoy + +* +
Keytruda + + +* +
Opdivo + + +* +
?: questions whether they are suited for EPR 
due to their characteristics or target.
*: indicated for solid tumor but has blood or 
vessel targets.
on the axis). They are made by cells resulting in uniform and biocompatible products. 
However, variation does exist due to metabolism/degradation, immune responses, organism 
of origin, drugs, and linkers. Still, there are more and more antibody therapies being 
approved by the FDA when compared to other targeted drug carriers. Preclinical studies are 
replete with polymers, liposomes, inorganic nanoparticles, etc., that contain multifunctional 
aspects, beyond just targeting moieties, that provide preferential treatment to the target
12
tissue; however, it seems relatively few of these enter clinical trials and they have yet to 
successfully navigate through clinical trials to market approval.
EPR is often repeated in the literature as a passive mechanism for delivering macro­
molecules to solid tumors in mice. It may be possible that some passive accumulation of 
antibodies also occurs due to their molecular weight of around 150 kDa. However, ideal 
sizes for taking advantage of EPR are often summarized as between 20 and 150 nm [40-43]. 
For 5 of the remaining 9 nonantibody carriers, EPR is likely not a dominant influence due to 
their size or target. Sylatron, at only 31 kDa, is smaller than most modern carriers designed 
to take advantage of EPR. Also, the attached interferon drug has active targeting through 
specific ligand-receptor binding. Abraxane is formulated into 130 nm nanoparticles [44]. 
However, the paclitaxel-bound albumin formulation likely dissolves in the blood stream 
into smaller molecules of approximately 7 nm in diameter. Ontak has a molecular weight 
similar to albumin at about 60 kDa and may benefit from some passive accumulation effects, 
but it is a fusion protein to direct action against cells expressing IL-2 receptor. Oncaspar 
has a molecular weight of around 300 kDa, but it also has a ligand target (asparagine) which 
circulates through the blood stream. DepoCyt is an exception in that 1) it is extremely large 
at 3-30 ^m and 2) it has a unique target in lymphoma that has spread to the central nervous 
system. Doxil is the poster child for having characteristics (tuned size and PEG for long 
circulation) that take advantage of the EPR effect in solid tumors. Onivyde deserves some 
attention for similar reasons, even if it is indicated only for metastatic tumors. Marqibo and 
DaunoXome also solely rely on passive accumulation, but delivery is considerably easier in 
blood or vessel tumors.
While 13 carriers approved for solid tumors seems promising, 5 of those actually have 
either blood or vessel targets. Avastin is antiangiogenic and treats the blood vessels rather 
than the tumor. Sylatron differs in that it can only be used after surgical resection of 
melanoma. Thus, the target is no longer a large solid mass. While the FDA label states the 
mechanism of Sylatron is unknown, the interferon cytokine has been shown to help stimulate 
immune responses against tumors [45]. Yervoy, Keytruda, and Opdivo all interact with T 
cells. Discounting those exceptions, we see more drug carriers are approved for blood or 
vessel cancers (12) rather than solid tumors (8). Not excluded, but worth noting, is the 
large fraction of carriers for solid tumors that have an indication for metastatic cancer with 
cells circulating in the vessels. This trend is not surprising as blood or vessels targets are 
more accessible with fewer barriers to transport.
Bexxar is FDA approved, but it has been discontinued by the manufacturer as of
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February 2014 due to limited use [46,47]. Absent from the list of approved carriers is 
Mylotarg®, an antibody-drug conjugate that was approved for clinical use to treat leukemia. 
However, it has since been withdrawn due to poor results from a postapproval clinical trial 
and continued postmarketing surveillance reveals lack of improved efficacy and unacceptable 
side effects. The antibody has no trouble binding to its target antigen of CD33, but lack of 
antigen exclusivity to the cancer and accumulation in the liver doomed this product [48,49]. 
Its story will be discussed in more detail in the Appendix, but illustrates the challenge of 
designing exclusive targeting into the carrier.
1.2.1 C hallenges present in th e  carrier
There are challenges in designing the carrier characteristics to be just right for targeting 
drug delivery to solid tumors. The carrier must be biocompatible in that it must be stable 
enough to perform its designed function in the body. This stability to its destination must 
not be left to chance, but should be verified with direct observations. A variety of targeting 
mechanisms can be use, but each have limitations or potential safety issues.
1.2.1.1 S tab ility  and traceability
As mentioned earlier, a carrier needs to be stable and this will have an effect on safety 
and efficacy. The biocompatibility of the carrier is determined by the chemistry of the 
monomer and degradation products [50]. Viruses serve as effective carriers but have the 
risk of a severe immune response against pathogen-associated molecular patterns (PAMPs). 
Physicochemical characteristics also affect the carrier's biocompatibility and are often tuned 
to maximize EPR and blood circulation half-life. When the drug interacts with normal 
tissue because of the carrier's instability or is unable to reach targeted tissue because of 
insufficient circulation time, the targeted drug delivery has failed.
Carrier sizes are usually sought to be small enough to escape out of fenestrations in the 
tumor vasculature and avoid excessive liver accumulation, but large enough to avoid renal 
clearance [51-53]. Specifically, size ranges between 20 and 150 nm with a spherical shape are 
ideal for avoiding the lungs, liver, spleen, and kidneys [41]. Synthesized drug carriers will 
possess a size distribution as it is extremely difficult to avoid polydispersity. Moreover, many 
carriers become more polydisperse during storage or while circulating in the blood. Stability 
may be challenged upon dilution in the blood for some self-assembly-based carriers such 
as liposomes or micelles [54]. Polymer shells that give unique characteristics to inorganic 
nanoparticles can be lost in vivo [55]. Other potential problems that all carriers face when 
introduced into the blood include destabilization from high salt concentrations, adsorption
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of proteins, interactions with lipids, opsonization, and phagocytosis from cells. Carriers with 
low hydrophobicity will quickly be cleared by the MPS and those with a positive charge 
are likely to be cytotoxic and taken up by the liver [40,56]. Thus, a common technique 
to increase circulation time is to add extremely hydrophilic poly(ethylene glycol) (PEG) to 
oppose molecular interactions and to shield positive charges [57,58]. PEG interacts with 
water to make it thermodynamically favorable for the PEG chains to extend and limit 
adsorption of proteins [59]. However, long circulation is only relative and there can still 
be some uptake by the MPS or other organs and eventual recognition from antibodies is 
also possible [60]. This is evident when PEG only increases the blood circulation half-life 
of liposomes in blood by just hours [61].
Essentially, only a fraction of the carriers may have the ideal characteristics for drug 
delivery. Furthermore, only a small percentage of the drug carrier’s population will reach 
the tumor as it is a matter of probability on whether the drug carrier will happen to be 
on the right path to hit the narrow opening in the vascular structure or if it will have to 
make another pass through the body and risk uptake by other means. Uptake can occur in 
normal tissues that have vascular fenestrations that are in a similar ideal range of 40-80 nm 
or as big as 150 nm in the liver [62]. Any particles too large to pass through fenestrations 
in normal tissues can still be engulfed by resident macrophages.
Carrier properties also determine how different nanoparticles will move within the tumor 
environment. Generally, a smaller molecule can more easily extravasate and diffuse to 
penetrate into the tumor; however, it can also diffuse away more quickly. On the other 
hand, a larger particle will be retained more readily in the tumor environment, but has a 
slower rate of extravasation and likely will not penetrate into the tumor core.
The probability of any given nanoparticle reaching the tumor, extravasating, entering 
a cancer cell, and ultimately causing an effect within that cell is extremely difficult to 
gauge. Imaging and tracking techniques have become increasingly popular to study this 
issue leading to the growth of theranostics where diagnosis is combined with therapy. 
Fluorescence resonance energy transfer (FRET) may be particularly useful as it will help 
to determine whether self-assembly-based or other complexes have dissociated [63, 64]. 
Tracking the dissociation or aggregation of these drug carriers is important as it directly 
affects the polydispersity and biodistribution of these particles. Furthermore, Nomoto et al. 
developed a new imaging method to allow in vivo real-time observation of how PEGylation 
limits aggregation [65]. In situ tracking of these nanoparticles will provide more accurate 
confirmation of delivery than analyzing statistical distributions.
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1.2.1.2 Targeting m echanism s
In Paul Ehrlich’s day, a magic bullet seemed an appropriate analogy for the vision he had. 
Modern-day scientists sometimes present this analogy as something more akin to a homing 
missile [66]. To overcome some of the problems in targeted drug delivery products, the 
exaggerations promoting these magic bullets will have to be called out. Current targeting 
drug delivery designs are not target-seeking as they cannot sense the target from a distance 
and adjust their trajectory to home in on it. Furthermore, current designs are not capable of 
self-propulsion. Instead, they are stochastic in that they rely on being carried to the target 
by convective blood flow and diffusion through tissues. Thus, a more honest comparison 
for these inanimate objects might be magic rafts. These magic rafts may not have paddles, 
but they can have an anchor.
As stated before, designs can target molecules, cells, conditions, or resources the cancer 
needs. Some means of targeting are more exclusive than others. Antibodies are excellent 
tools for providing mechanisms of binding. They can be selected to have high specificity 
and affinity for their target ligand. However, care must be taken to select the correct ligand 
target. It is difficult to find binding targets that are unique to cancer cells. This is even more 
challenging when solid tumors have less specific antigens than hematologic cancers [67]. 
Often, therapies have to rely on overexpression of certain proteins by cancer cells. For 
example, eligibility for HER2 treatment involves checking the levels of overexpression of 
these surface proteins and assigning a score. However, for the highest score of 3+, the 
FDA needs only 10% of tumor cells to stain positively for HER2, while an updated scoring 
systems defines it as a uniform staining of more than 30% [68]. Additionally, it is sometimes 
difficult—yet very important—to find cell surface proteins that are exclusive to the cancer. 
There is circumstantial evidence that the HER2 antibody Trastuzumab could interfere with 
cardiac myocyte signaling and lead to cardiac dysfunction [69-71].
Targeting with monoclonal antibodies for HER2 has been show to increase tumor inter­
nalization [72]. On the other hand, it has also been shown that carriers with less specific 
ligand targeting are more limited in tumor penetration. It is assumed that these carriers 
experience a “binding site barrier” effect that inhibits penetration [73]. There remains some 
discord related to some of these cell binding and penetration strategies. With these cell 
targeting strategies, there is a need to find the correct balance of causing cell interaction 
to encourage uptake, yet still allow penetration throughout the rest of the tumor. Some 
carriers have been functionalized with peptides for improved penetration. The iRGD peptide 
is referred to as the tumor-penetrating peptide, but specificity is questioned with its ability
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to bind with integrins beyond those on the tumor epithilium [74,75]. The TAT peptide is 
sometimes referred to as a cell-penetrating peptide that targets the cell surface to increase 
cell uptake in a nonspecific way [76,77]. Similarly, the surface charge and shape of the carrier 
influences penetration as well. Positively charged particles may encourage internalization 
into the cells and penetration via transcytosis [64]. Furthermore, a modified albumin with 
a positive charge was shown to have better distribution in rat skin and skeletal muscle 
compared to native albumin with a negative charge. This exclusion to the negative probe 
was attributed to the fixed negative charge of the interstitium [78]. Shape also influence 
cell uptake profiles and could lead to different pathways in the cell [79,80]. As mentioned 
in the stability section above, these charge and shape strategies could also have undesired 
effects of targeting the MPS [81].
Some fairly effective magic rafts have likely been made. While some may have failed 
because the design was flawed, others may have struggled with challenges that lie in tumor 
characteristics that make them difficult to target.
1.2.2 C hallenges in the solid tum or environm ent
Once the particle extravasates, it is confronted with various obstacles in the tumor envi­
ronment. While there is evidence explaining how EPR can benefit accumulation in tumors, 
there are also opposing influences from the tumor’s pathophysiology [82]. Unfortunately, 
simplified descriptions of the EPR effect do not include the various challenges to drug 
delivery in the intratumoral environment (Fig. 1.4).
For solid tumors, additional barriers seem to hinder intratumoral distribution. Once the 
carrier reaches the tumor, it cannot be assumed that it will invariably reach and enter the
F igure  1.4. EPR is often over-simplified. Various forms of the illustration on the left have 
been used in research articles. They leave out important challenges in drug delivery to solid 
tumors. Even the depiction on the right cannot accurately represent all of the factors that 
impede passive targeting via EPR. Moreover, the pathophysiology is more complicated in 
clinical tumors where EPR is less reliable [83].
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cancer cells. There are various factors that prevent the nanoparticle from penetrating into 
the tumor core [84]. Tumors grown in window chambers show heterogeneous permeation 
and the accumulation of nanoparticles adjacent to the blood vessel [85]. Other studies 
also show that the permeability varies and that liposomes do not diffuse far from blood 
vessels [86]. Distribution beyond the vicinity of blood vessels is a challenge even for viruses 
and free drug molecules [87,88].
Besides the cancer cells themselves, the extracellular matrix (ECM) may be one of the 
biggest influencing factors for a solid tumor’s progression. It can be thought of as the fertile 
soil for the developing tumor seed [89]. It supports the tumor in the form of survival signals, 
inhibition of the immune system, hindered diffusion of drug particles, and facilitation of 
cancer invasion and metastasis [90-93]. ECM in tumors is analogous to the biofilm that 
bacterial colonies will form for protection and continued growth. Under this protection, 
cancer cells can evolve, thrive, and multiply to a state of dense packing. The ECM has a 
higher stiffness and viscosity due to more fibronectin, collagen I, and cross-linking agents 
that can also limit diffusion [94,95]. Finally, the ECM is one of multiple contributors to 
high interstitial fluid pressure (IFP) in solid tumors [96].
1.2.2.1 Tumor IFP
Elevated IFP is a feature often discussed as opposition to the enhanced permeability and 
retention of macromolecules that could otherwise be transported by bulk flow and penetrate 
into the core of solid tumors [97,98]. In normal tissue, IFP is negative [99]. Thus, high IFP 
in tumors results in an outward convective flow preventing delivery and even promoting 
metastasis of detached cancer cells [100]. Interestingly, some of the same contributors to 
EPR (defective or permeable blood vessels along with dysfunctional lymph vessels) play a 
role in elevated IFP in tumors [101,102]. The difficulty of accurately measuring all possible 
contributors to IFP prevents a comprehensive description of its etiology, but it has been 
verified in a variety of tumors [103,104]. Explanations often say a combination of osmotic 
and hydrostatic pressures build up inside the tumor to nullify convective transport into the 
tumor [105]. Other possible contributing factors could be the ECM, contractile fibroblasts, 
or a high density of cells [106,107]. Finally, Table 1.3 shows how additional factors may 
affect IFP in tumors.
In addition to small leaks from intercellular openings, fluid can spill out of poorly formed 
blood vessels, as evidenced by blood lakes observed in tumors [109]. Solutes in leaked fluids 
can flow into the interstitium from blood vessels and accumulate into the dense packing of 
matrix and cells to create an osmotic pressure. Furthermore, there is a significant metabolic
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Table 1.3. Approaches for reducing IFP [107,108].
VEGF antagonist Normalize blood vessels, improve flow, and decrease permeability
PDGF antagonist Decrease contraction and interaction of fibroblasts
TGF^ antagonist Lower ECM content, inhibit macrophages, and normalize vessels
TNFa Damage tumor vessels
Hyaluronidase Degrade hyaluronan
Dexamethasone Decreased vascular permeability and ECM content
Thalidomide Anti-angiogenic
Bradykinin agonist Improve blood flow
Nicotinamide Decrease microvascular pressure
PGEi Decrease contractility of fibroblasts
Cytotoxins Decrease cell packing and decompress vessels
Nicotinamide Improve tumor blood flow
Pentoxifylline Improves flow by reducing blood viscosity
contribution to the buildup of osmotic pressure when cells produce extra lactate in the 
hypoxic environment [100]. A combination of osmotic and hydrostatic pressures contribute 
to the Starling forces that drive fluid flow in tumor tissues [107]. These Starling forces 
are often placed in diagrams to describe the balances between the tumor tissue and the 
capillaries. If those were the only two compartments, an equilibrium should be reached fairly 
quickly at that interface. However, those simplified models restrict the tumor tissue to be a 
homogeneous compartment and exclude the surrounding normal tissue compartment. Fluid 
that is driven into interstitium from blood vessels percolates to areas of least resistance. This 
percolation is the convective flow in tissues. In normal tissues, the path of least resistance 
for the removal of any excess fluid would be the lymph vessels. However, these are not 
functional in tumors and the fluid must instead seep through dense networks of cells and 
ECM towards surrounding tissues [110]. There is evidence for this seepage in the literature 
showing carried cancer cell detritus and edema in tissues surrounding tumors [111, 112].
This seepage also helps explain how IFP is a continuous feature. There is a source of 
fluid into the tumor from the blood vessels; however, the flow rate through the tumor is 
limited because it must percolate through the less permeable tumor interstitium. Darcy’s 
law can describe the flow rate (Q) of a fluid as being related to its viscosity (n) and the 
permeability (k) of the porous tumor interstitium [113]. Darcy’s law can be equated to a 
simplified form of Poiseuille’s law (where R is resistance to flow) to give the following [114]:
k x Area x Pressure drop Pressure drop 
n x Distance R
Thus, the flow rate will be slower or the interstitial fluid pressure will need to be elevated
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in order to overcome decreased permeability or increased resistance in the environment.
As an alternative, take the simplified example of filling a balloon. If water is constantly 
going into the balloon, there needs to be flow out of the balloon at the same rate or 
else pressure will build up. Of course, a normal balloon is elastic and will expand to 
relieve the pressure. Elasticity is the difference between high IFP in tumors and edema 
in normal tissue [115,116]. The fluid accumulation with edema has also been studied for 
causes and treatments. Pulmonary edema is a significant topic in the literature as the 
health implications are serious. Furthermore, the lung is a more compliant tissue where 
large amounts of fluid can accumulate [117]. Causes of edema can be summarized in the 
following list: increased capillary pressure, decreased plasma proteins, increased capillary 
permeability, and blockage of lymph return [118,119]. Tissue elasticity is related to ECM 
composition and its degradation can lead to edema [120,121]. In comparison, stiffening of 
the ECM is a progressive feature of many solid tumors and explains why the wound healing 
process in this context results in high IFP instead of edema [94].
As the tumor has been labeled as a wound that will not stop healing, a comparison 
of relevant features found in wound healing may offer some insight. Fibroblasts play an 
important role in wound healing by helping to stiffen and pull together the wounded tissue 
[122,123]. Fibroblasts can be differentiated to contractile fibroblasts (myofibroblasts) by 
growth factors present in wounded tissue and the tumor environment [124-126]. Performing 
as if in a wound, these differentiated fibroblasts in tumors can modulate the IFP through 
contraction and through production of ECM components [107,127,128].
Thus, we see multiple factors contribute to high IFP in tumors. However, if fluid can flow 
through tumors while maintaining an equilibrium of high IFP, other factors must prevent 
the even distribution of drug carriers within the tumors [98]. Results have shown that IFP 
is not sufficient for opposing penetration of antibodies [129]. The IFP had been lowered, 
but exclusion was assumed to be due to electrostatic opposition between the negatively 
charged antibodies and ECM [130].
Another contributor to uneven distribution is that convective flow of fluids and drug 
carriers in the tumors is likely through heterogeneously distributed rivulets in the tumor 
[131]. As stated previously, is should not be assumed that the tumor tissue is a homogeneous 
compartment. There will likely be some areas with high IFP and others with low IFP (i.e., 
paths of least resistance) within the tumor interstitium that allows for rivulets. Elevated 
IFP is often recorded by the wick-in-needle technique as homogeneous within the tumor 
and with a steep change at the periphery of the tumor [106]. As can be imagined, these are
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not high-resolution measurements. Resolution is limited by the size of the probe needle tip 
and by the difficulty in knowing where the tip is at inside of the tissue. Table 1.4 shows 
how IFP can vary in different cancers and each cancer can have a wide range of IFP values 
across the sampled patients. For example, the IFP in cervical carcinomas has a range of 
nearly 100 mmHg between patients. While IFP is predominantly elevated, some recorded 
tumors show negative IFP values. Furthermore, the rivulets in the tumor or perfusion in 
the capillaries is in a state of flux [132,133]. This intermittent perfusion could be caused by 
elevated IFP impeding flow or by solid stress compressing vessels [134-136]. The variability 
of IFP in tumors brings us to another major challenge in treatment: heterogeneity.
1.2.2.2 Cancer is heterogeneous
There is both inter- and intratumoral heterogeneity with differences in the cancer type, 
environment, individual cells, and signaling. This heterogeneity can undermine the precise 
targeting mechanisms that were designed into the drug carriers. Heterogeneity in the tumor 
environment also explains how EPR is not equally present in all tumors.
Ovarian cancer is classified into different disease types by the type of cell from which 
it originates [137]. In neuroepithelial tissues, there are more than one hundred entities 
that have been discovered [138]. Similarly, cancer heterogeneity has been imaged in tissue 
specimens using antibody staining combined with quantum dots [139].
Low pH was discussed as a target before, but not all tumors possess a markedly low 
pH. It has been shown that a glucose infusion in nondiabetic patients can lower the pH in
Table 1.4. IFP (mm Hg) variability [111].
Tissue n Average IFP Range
Normal skin 5 0.4 -1.0 to 3.0
Normal breast 8 0.0 -0.5 to 3.0
Metastatic melanomas 26 18.0 0.0 to 60.0
Breast carcinomas 21 23.7 4.0 to 53.0
Head and neck carcinoma 27 19.0 1.5 to 79.0
Cervical carcinomas 127 20.5 -2.8 to 94.0
Lung carcinomas 26 9.5 1.0 to 27.0
Brain tumors 28 4.6 -0.5 to 15.0
Rectal carcinoma 8 15.3 12.1 to 15.8
Colorectal liver metastasis 8 21.0 6.0 to 45.0
Lymphomas 7 4.5 1.0 to 12.5
Renal cell carcinoma 1 38.0 NA
Notes. Negative values imply flow into tissue. Positive values could indicate flow into
surrounding tissue.
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tumors [140]. However, this could have undesired consequences. It could cause elevated 
IFP through metabolic buildup and low flow in the tortuous tumor vessels [141]. It could 
also lead to increased angiogenesis and metastasis [142,143].
Variability in the environment is apparent in the tumor’s chaotic vasculature. Beyond 
shape, architecture, and density—tumors show differences in vascular permeability based 
on the type of tumor, location in the body, location in the tumor, hormone concentrations, 
and state of growth or regression of the tumor [144-146]. Differences in EP can exist for 
different types of tumors based on the characteristics of the capillaries: extravasation is 
limited in continuous capillaries, but possible in fenestrated or discontinuous capillaries. 
Passage can also be obtained via endothelial openings, transcytosis, or vesiculo-vacuolar 
organelles (VVOs) [62]. The different routes of extravasation might lead to the heteroge­
nous distributions adjacent to tumor vessels [86]. Unfortunately, heterogeneity in tumor 
vasculature makes it difficult to know specific size cutoffs for carrier sizes targeting EP.
Variability in the density and rigidity of tumors will affect designs hoping to take 
advantage of ER in solid tumors. Many articles talk about the dense packing of tumors [147], 
but there is a lot of variability in the amount of interstitial space [97]. The process of 
transformation in the tumor environment is perhaps a contributor to this heterogeneity. 
Normal ECM is being broken down to make room for cancer cells that are secreting proteins 
for new ECM to support the growing tumor [148].
There is a diverse collection of cells, cancerous and noncancerous, in the tumor envi­
ronment. Among the cancer cell population, there is a subdivision of cells that are cancer 
stem-like cells [149]. The properties of stem-like cancer cells make them a unique challenge in 
cancer therapy. They contribute to prosurvival signaling pathways, are able to differentiate 
into other cells, are more tumorigenic when injected into a new host, and imply increased 
metastatic potential [150-152]. Cancer stem-like cells seem to always be present and in 
equilibrium with other cancer cells [153]. While the source of these cells is debated (they 
may come from a mutated stem cell or a normal cancer cell mutates to become stem cell-like), 
the fact remains that they have characteristics that make them capable of resistance and 
renewal [154,155]. Efforts to categorize and target cancer stem cells have been made by 
seeking after specific surface markers [156, 157]. However, it could be beneficial to use 
a magic shotgun that is selective toward more than just one target to effect a complete 
response in a heterogeneous population of cancer cells [158,159]. Furthermore, multimarker 
therapies may reduce toxicity by giving cancer effectively a double-dose, but each drug will 
have nonoverlapping effects on normal tissue. The heterogeneity in the environment and
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cell population results from the molecular biology of cancer. The differences in cellular phe­
notype and states of growth and quiescence are influenced by random variations of protein 
concentrations and interactions that lead to dynamics in molecular signaling, some of which 
originate from environmental cues [160]. Furthermore, genomic and epigenetic instability is 
characteristic of cancer cells [161]. These dynamic and heterogeneous characteristics play a 
role in how cancer is able to resist treatments [162].
1.2.2.3 M ultidrug resistance
Tumor heterogeneity at the cellular level has a direct effect on multidrug resistance. 
Mutations cause diversity in cell characteristics and that diversity provides an opportunity 
to select for survival. Essentially, when a heterogeneous mixture of cells is treated with a 
drug, some will be able to resist the treatment. Furthermore, with treatment in solid tumors, 
cells at the periphery of the tumor often die off, leading to a smaller, yet more resistant, 
tumor mass. The apparent increase in resistance in the core could be due to conditioning 
from limited drug exposure, adaptations to survive in the already harsh environment, or 
the cells being more resistant inherently—as is the case with cancer stem-like cells.
Resistance comes from factors that range from the tumor environment down to cellular 
changes and mechanisms involving DNA. As stated before, only low amounts of drug are 
able to enter into the core of the tumor. Cancer cells are more easily able to adopt drug 
resistance to a low dose. This is apparent even in cultured cell lines as drug resistant lines 
are made by adding low doses of the drug into the growth medium [163,164]. Furthermore, 
the core of the tumor is hypoxic and acidic and the cells have already adapted to survive in 
these harsh conditions. Some of these adaptations and cellular mechanisms for resistance 
are: detoxification via active efflux pumps, exocytosis, sequestration in acidic vesicles, 
DNA repair, compensation in chemical pathways, triggering of specific oncogenes, and even 
quiescence [165]. For example, it is easy for a cancer cell to resist the effects of doxorubicin 
or paclitaxel when it is not actively dividing.
As seen in Fig. 1.5, cancer cells that are able to survive will be prepared to resist future 
treatment, repopulate the tumor, and metastasize. If the cancer relapses, more aggressive 
cell types have been selected and the prognosis for the patient is poor. While the immune 
system provides a great example of targeted cancer therapy, cancer is still able to escape 
and continue growing [167,168].
Immune evasion has become an emerging hallmark of cancer and is made possible by 
the heterogeneity inherent in cancer [169]. Understanding how cancer resists the immune 
system may lead to improved therapeutics in the future.
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Relapse and Metastasis Recapitulation Resistance
F igure  1.5. The 4 Rs of tumor treatment. Reduction, resistance, recapitulation, and 
relapse can occur when treating a heterogeneous collection of cancer cells. This process is 
similar to what occurs in immunosurveillance [166].
The process of immunoediting explains how the immune system can drive the progression 
of a tumor to a more resistant and aggressive state. Studies have shown that tumor 
formation is much more likely when the cancer cell line comes from a tumor grown in an 
immunocompetent mouse [170]. Tumors grown in immunodeficient mice are less aggressive 
than tumors that are grown in immunocompetent mice. Since most murine tumors are 
xenografts, they need to be placed in immunodeficient mice. Now we begin to see some 
shortcomings with the animal models in preclinical trials.
1.2.2.4 M odel lim itations
Modeling the tumor environment is difficult for some of the reasons related to hetero­
geneity mentioned above. There are a variety of models used in cancer research and each 
has its limitations. Animal models, specifically the mouse model, are routinely used to test 
the efficacy of new drug carriers. They have characteristics that make them easy to run 
the experiments in the lab and measure the results. These simplifications, of course, have 
shortcomings in their ability to provide accurate representations of clinical tumors.
Some of the disparity is present in the methods used to grow the tumors in animal 
models. As explained earlier, the environment plays a major role in cancer development. 
Unfortunately, mouse models are not always orthotopic. Breast cancer cells injected to grow 
a tumor in the hind quarters of a mouse will not accurately portray what a tumor in breast 
tissue will do. The rate and size of tumor growth in animal models is not representative 
of clinical cancers. Clinical tumors have many years to undergo genetic mutations, slow
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growth, and evasion of the immune system [171]. Mouse models can be controlled to 
develop cancers in a random nature and a more representative timescale; however, for 
convenience and efficiency, many mouse models can form tumors approximately ten days 
following inoculation [172,173]. Essentially, mice have a higher rate of metabolism that 
results in faster tumor growth and requires a more frequent dosing regimen for treatment. 
Additionally, the ratio of tumor to body weight is also much larger in mouse models 
compared to human patients. Having a large tumor mass may contribute to lower pH 
and increased EPR effect for mouse models. A good portion of targeting with drug carriers 
is passive and relies on the EPR effect. While EPR has a lot of evidence in animal models, 
it could be studied more extensively in human models as it can sometimes be notably 
absent [174]. An excellent study in human patients used scintigraphy to evaluate the 
effectiveness of EPR-based delivery and shows the difficulties of avoiding accumulation in 
normal tissues [175]. Study animals are generally sacrificed posttreatment to harvest tissues 
and accurately ascertain treatment efficacy. Tumor response is not always an accurate 
predictor of survival [176]. Furthermore, when the animal is sacrificed, there is no chance 
to check for tumor relapse. Overall, they simply do not provide as much of a challenge for 
treatment as clinical tumors. See the Appendix for an article comparing preclinical and 
clinical trial data for various drug carriers.
1.3 Included Work
The included work will address the limitations and challenges presented here by pro­
viding additional insights, models, and methods for analyzing intratumoral distribution. 
Specifically, it will provide a new model for drug distribution in the tumor environment, 
additional evidence for IFP as an inhibitor, real-time imaging to understand how nanoparti­
cles distribute, tracking multiple doses and measuring their interdependence, and measuring 
distance traveled from blood vessels in three dimensions. The work uses surrogates for 
smaller sized drug carriers such as Abraxane (in Chapter 2) and for larger nanoparticles (in 
Chapter 3).
An explanted human organ model may compliment the mouse model to accurately 
represent barriers in a clinical tumor. Using uteri with naturally occurring benign fibroids 
as a model for solid tumors proved useful in understanding drug distribution in the tumor 
and surrounding tissue. It provides a clinically relevant model because the tissue is human, 
the complex structure is maintained, and the tumor to organ size ratios are appropriate. 
Fibroids have a slower, more natural growth rate than xenograft tumors and can average
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around 9% growth in 9 months [177]. Furthermore, the observed lack of EPR in these 
tumors make it a good model for understanding distribution challenges in clinical tumors 
that do not show an EPR effect. The source is relatively plentiful, compared to other human 
tissues, due to the large number of hysterectomies performed each year. High collagen and 
hyaluronic acid content is already well established, but the research in this dissertation 
shows the tumor has transport barriers similar to other desmoplastic, malignant tumors. 
The research shows the following conditions within the fibroids: dense packing of cells 
and ECM, limited vasculature and transport, high IFP, and solid stress. An illustrative 
summary is provided in Fig. 1.6.
This work also takes a look at the distribution of multiple doses (each uniquely fluores­
cent) in xenograft tumors. It is acknowledged that xenograft tumors are a less than ideal 
model, but additional information can be gained from the new methods introduced and 
compared against the large collection of prior results obtained with that established model. 
Analyzing the distribution and interdependence of multiple doses is important as it fills a 
gap not prevalent in preclinical studies.
When patients undergo traditional chemotherapy or are treated with drug delivery 
technologies, multiple doses are required. Studies have not tested how multiple doses 
can interact with each other and possibly affect intratumoral distribution, even though 
dosing is clearly related to treatment efficacy. This work shows that distribution patterns 
of two different doses circulating in the blood stream at different times is influenced by the 
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Fibroids:
Small and sparse vessels
Figure  1.6. Chapter 2 illustrative summary. We perfused the uterus and studied 
distribution in the fibroids to understand transport barriers.
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passive mechanisms for extravasating into the tumor environment. Better understanding 
these dynamics may influence planning of dosing schedules and combination treatment 
strategies. Furthermore, it identifies limitations in measuring the distribution of drug in 
the tumor (relative to blood vessels) in two dimensions versus three dimensions. Research 
that tracks multiple doses independently and how it relates to intratumoral distribution is 
important to guide clinical treatment strategies. An illustrative summary is provided in 
Fig. 1.7.
The National Institutes of Health has a desire to see quantitative measurements of how 
cancer therapies affect the tumor in clinical trial settings [NIH PAR-14-116]. This work 
uses quantitative analysis of imaging data on a new model that could become an additional 
precursor to clinical trials. The work also tracks multiple doses and has the potential to 
influence how dosing and other clinical decisions are made. It identifies additional barriers 
in the translation from the laboratory to the clinic by using fluorescent probes, in addition to 
other methods, to characterize delivery to the tumor with implications to therapy response 
[NIH PAR-13-185].
The research presented in this dissertation uses models and methods in new applications 
to help shed light on some of the intricacies of passive delivery to solid tumors. These 
additional methods for distribution analysis can be employed in future work that seeks to 
get past some of the barriers inherent in solid tumors.
F igure  1.7. Chapter 3 illustrative summary. Spatiotemporal analysis of two uniquely 
fluorescent doses: administered as separate or mixed doses.
CHAPTER 2
UTERINE PERFUSION MODEL FOR ANALYZING  
BARRIERS TO TRANSPORT IN FIBROIDS
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Intratum oral distribution 
Interstitial fluid pressure 
Ex vivo model 
Clinical tum or model
This project uses an ex vivo hum an perfusion m odel for studying transport in benign, fibrous tum ors. The uterine 
arteries w ere cannulated to  perfuse the organ w ith  a buffer solution containing blood vessel stain and methylene 
blue to  analyze intratum oral transport. Gross exam ination revealed tissue expansion effects and a visual lack of 
m ethylene blue in the fibroids. Some fibroids exhibited regions w ith  partial m ethylene blue penetration into the 
tum or environment. Histological analysis comparing representative sections offibroids and norm al m yom etrium  
show ed a sm aller num ber o f vessels w ith  decreased d iam eters w ith in  th e  fibroid. Im aging of fluorescently 
stained vessels exposed a stark contrast betw een fluorescence w ithin th e  m yom etrium  and relatively little w ith ­
in the fibroid tissues. Imaging a t h igher magnification revealed th a t fibroid blood vessels w ere indeed perfused 
and stained w ith  the lipophilic m em brane dye; however, the vessels w ere only the size o f small capillaries and 
the blood vessel coverage w as only 12% th a t o f the norm al m yom etrium . The m ajority o f sam pled fibroids had 
a strong negative correlation (Pearson's r  =  - 0 .6 8  or beyond) betw een collagen and m ethylene blue staining. 
As m ethylene blue w as able to  passively diffuse into fibroid tissue, the true  barrier to transport in these fibroids 
is likely high interstitial fluid pressure, correlating w ith  high collagen content and solid stress observed in the 
fibroid tissue. Fibroids had an  average elevated interstitial fluid pressure of 4 m m  Hg com pared to  — 1 m m  Hg 
in norm al m yom etrium . Our findings signify relationships betw een drug distribution in fibroids and betw een 
vasculature characteristics, collagen levels, and interstitial fluid pressure. U nderstanding these barriers to trans­
p o rt can lead to  developm ents in  drug delivery for th e  trea tm en t of u terine  fibroids and tum ors  of sim ilar 
composition.
© 2015 Published by Elsevier B.V.
1. Introduction
Uterine fibroids are desmoplastic, benign tum ors—also known as 
leiomyomas—whose growth has been shown to be influenced by ovar­
ian steroid hormones and mediated by growth factors [1]. Current treat­
ments provide symptom control, and result in a short-term reduction in 
fibroid volume, but only hysterectomy can provide definitive treatment 
[2]. Approximately 600,000 hysterectomies are performed every 
year—200,000 of which are for uterine fibroids [3]. The prevalence of 
uterine fibroids and the frequency of hysterectomy provided an
* Correspondence to: M .-M.Janat-Amsbury, D epartm ent of Obstetrics and Gynecology, 
University ofU tah, Salt Lake City, UT 84132, USA.
** C orrespondence to: Y.H. Bae, D ep artm en t o f Pharm aceu tics and P harm aceutical 
Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
E-mail addresses: margit.janat-amsbury@ hsc.utah.edu (M.-M.Janat-Amsbury), 
you.bae@utah.edu (Y.H. Bae).
opportunity to study drug transport in solid tumors, while preserving 
the macro- and microenvironments.
We hypothesized that the pathophysiology of uterine fibroids con­
tains various barriers, similar to many other solid tumors, which impede 
the transport of macromolecules. To test this, we perfused human uter­
ine specimens ex vivo with stains and fluorescent probes. Methylene 
blue served to visualize drug transport in this study. We analyzed the 
distribution of methylene blue for correlation with any of the identified, 
inert pathophysiological tissue barriers. During the perfusion process 
we measured the interstitial fluid pressure (IFP) ofthe fibroids. Through 
gross examination, histological analysis, and fluorescent microscopy, 
we measured the nature of vessel perfusion, collagen density, and 
looked for relationships w ith inhibited methylene blue transport. The 
uterine perfusion model maintains the complexity of the target tissue, 
but offers more control by not involving the entire organism. It has pre­
viously been shown that fibroids have decreased and chaotic vascula­
ture [4-7]. Additionally, intercapillary distances have been linked to
http://dx.doi.org/10.1016/j.jconreL2015.07.006 
0168-3659/© 2015 Published byElsevier B.V.
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Table 1
Patient details.
P atient Reason for hysterectom y/diagnosis Fibroid characteristics
Location
O ther tissue features
M enorrhagia, fibroids
Abnorm al u te rin e  bleeding, dysm enorrhea, 
endom etriosis
Pelvic pain, abnorm al u te rin e  b leeding 
(ovulato ry  dysfunction), 
tubal ligation ablation  syndrom e 
Postm enopausal bleeding, com plex left adnexal mass, 
endom etria l a trophy
Abnorm al u te rin e  bleeding (ovulato ry  dysfunction) 
D ysm enorrhea, von W illebrand disease, fibroids 
H ysterectom y w ith  risk-reducing oophorectom y 
M enorrhagia, fibroid, u rinary  frequency, pain, p ressure  
Pelvic pain /dyspareun ia , high grade cervical dysplasia 
A denomyosis, pelvic pain  
D ysm enorrhea, dyspareunia, high grade dysplasia
Abnorm al u te rin e  bleeding (fib roids)
D ysm enorrhea, pelvic pain  




Subm ucosal; in tram ural
In tram ural
D om inant
Subserosal; in tram ural 
D om inant; o thers 
No fibroids 




Intram ura l; subm ucosal; 
subm ucosal-peduncu lated
~0.5 and  2 cm; ~1 and  1.5 cm
~1 cm 
8 cm
~1 cm; ~0.5 cm 
5 cm; m ultip le small
~1 and  < 1 cm
~0.4, 0 .8 ,1 .3 ,1 .3  cm; 
~0.4 cm; ~2.1 cm
Endom etrial polyp 
and  adenom yosis 
Endom etrial polyp 












Endom etrial polyp 








hypoxic conditions identified within these tum ors [8]. Other uterine 
perfusion m odels have dem onstra ted  successful perfusion of the 
tissue, while m aintaining viability, as various study drugs were 
delivered to the specimen [9,10]. Further, polymer resins have been 
perfused into u terine specim ens to provide inform ation on the 
vascular architecture of uterine fibroids; however, the highly viscous 
resin may not have reached the sm allest capillaries or the delicate 
casts may have become dam aged [11,12]. Radio-opaque dyes have 
also been perfused, but resolution limits would make discerning of 
the smallest vessels challenging. This project expands on previously 
reported efforts w ith additional methods as well as shifting to a new 
purpose of investigating drug distribution in solid tumors (fibroids) 
th a t can exist in the  uterus. For th is purpose, we chose light 
m icroscopy w ith resolution limits near 1 |im, the ability to capture 
mosaics of entire  tissue sections, and the  ability to use m ultiple 
probes w ith d ifferent fluorescence sim ultaneously. We therefore 
probed, stained, and imaged the fibroid environm ent to investigate 
the distribution of molecules administered arterially.
A large body of research suggests th a t delivery to solid tum or 
environm ents is possible via the  enhanced perm eability  and 
retention (EPR) effect. As some hemorrhagic leiomyomas may have 
leaky vessels [13], we sought to use this m odel to explore the 
existence and balance of the  EPR effect and barriers th a t m ight 
oppose it [14]. Furthermore, intratum oral transport in solid tumors 
continues to be a re levant research topic for understand ing  why 
some treatm ents may fail in the  clinical setting, especially because 
EPR does not seem  to be evident th roughout all various types of 
clinical tumors [15,16].
2. Materials/methods
Salts and reagents for the perfusate solution were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Masterflex silicone tubing was 
purchased from Cole-Parmer (Vernon Hills, IL, USA). The MicroLab 
FS-522 interface, therm istor, pH electrode, and redox probe 
w ere purchased from MicroLab, Inc. (Bozeman MT, USA). Insyte 
Autogaurd w inged 24-gauge catheters (BD381512) were purchased 
from the University of Utah general store. The incubator was fashioned 
from a clear plastic dessicator and the manometer from a 25 mL plastic 
pipette. The Falcon 40 |jm cell strainers were purchased from Fisher 
Scientific (352340, Pittsburg, PA, USA). 1,1/-Dioctadecyl-3,3,3/,3/-
tetramethylindocarbocyanine perchlorate (DiI) was purchased from 
Santa Cruz Biotechnology, Inc. (sc-213424, Dallas, TX, USA). Collagen
Fig. 1. A perfusion system  to  keep  the  u terus sam ple viable during experim ents. The per­
fusate reservoir (1) is h eated  and bubbled w ith  95% oxygen. The u terus (2) is placed in a 
clear plastic incubator (3 )  h eated  w ith  an infrared lam p  (4 )  connected  to  a tem peratu re  
regu lato r (5). A p erista ltic  p um p  (6) pushes p erfusate  throu g h  th e  tubing. The tubing 
passes through a bubble catcher (7) th a t also serves as a m anom eter and site for injections 
and sampling. Perfusate enters the  organ by cannulating the  tw o  u terine arteries. The per­
fusate trickles o u t o f the  organ and into  a small collection area and tubing retu rns the  per­
fusate to the  reservoir for recirculated flow. Samples can be taken from  th e  venous side of 
the  o rg a n v ia a s a m p lin g p o rtin  the  tubing (8).AM icroLab (9) c o n n ec ted to a lap to p  (10) 
records data  such as pressure, pH, and pO2 levels.
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Hours after start of perfusion
Fig. 2. Progressive perfusion o f the  ex vivo uterus. Perfusion is app arent in the  clearing of 
blood and w hitening of the  tissue (A) and subsequent staining w ith  m ethylene blue added 
to the  perfusate (B). C) Assay checking lactate dehydrogenase (LDH) levels to  quantify the 
am ount of cell lysis present in the  perfused organ. Our m ethod  of perfusing the  organ was 
able to stabilize tissue viability as m easured by LDH levels.
mimicking peptide (CMP) stain was generously given by Dr. Michael Yu 
in the Department of Bioengineering at the University of Utah.
2.1. Perfusion o f uteri
Human uteri were obtained according to an Institutional Review 
Board approved protocol. All patients consented  to procedures 
outlined and only patients who were already scheduled to undergo 
a surgical hysterectomy (based on various diagnoses listed in Table 1) 
through the Department of Obstetrics and Gynecology at the University 
of Utah Hospital were approached. Upon receipt, each specimen was 
weighed and measured prior to cannulation of the bilateral uterine 
arteries with catheters. The wings of the catheter were secured to the 
tissue and the cuff of the arterial stump was constricted around the 
catheter using suture to limit accidental removal and back flow. An 
initial flush of 10 mL of heparinized isotonic saline solution was 
used to ensure proper placem ent of catheters in the  arteries. The 
u terus was then  placed inside the incubator and connected to the 
perfusion system (Fig. 1) via the catheters. The perfusate was a mod­
ified Kreb-Henseleit (KH) buffer solution w ith a pH of 7.4 composed 
of: 118 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.25mM  CaCl2, 1.2 mM 
KH2PO4, 25 mM NaHCO3 11 mM glucose, 2.5 IU/mL heparin, 1 mM 
DTT, sacharose, glutathione, gentamicin, and a 100 IU insulin bolus. 
The initial flush volum e was approxim ately 1-2  mL/g of tissue to 
clear the vasculature of rem aining blood com ponents and cellular 
debris. This preparatory procedure lasted for approxim ately 30 min 
or until the solution in the venous line flowed clear. Following this 
initial flush, the venous return line was directed into the main reser­
voir for isovolumetric perfusion. The volume for the recirculated per­
fusion was approxim ately 300 mL in the reservoir plus the  volume 
contained in the tissue. Possible causes of vascular occlusion were 
detritus from cell or blood products and air bubbles. Occlusion was 
m itigated by designing the m anom eter in a way to catch air bubbles 
and by using the cell strainer to filter any aggregates present in the per­
fusate reservoir.
Methylene blue was added to the main reservoir to visually monitor 
effective perfusion and to mimic drug distribution. Perfusion was also 
monitored with the MicroLab data acquisition instrument. The instru­
m ent had probes to check the pH and pO2 levels. It was further equipped 
with a pressure reading port, used to check the pressures in the arterial 
lines via the manom eter site. A target pressure near 100 mm Hg was
B
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Methylene Collagen Blood 
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Fig. 3. A) Visible staining o f m ethylene blue is lim ited in the  fibroids (arrow s). B) Some regions can be identified th a t have slight staining (*) com pared to  no staining ( —). C) A high contrast 
binary im age of tissue section captured  w ith  a fluorescent m icroscope and processed w ith  M atlab reveals th e  sam e phenom enon  of lim ited stain in the  fibroid. The prim ary colors repre­
sen t unique locations o f fluorescence. Secondary colors are regions o f overlap—e.g., green for overlap of m ethylene blue and collagen. Arrowhead points to m yom etrium  (norm al tissue) 
and arrow s to fibroids. Scale bar is 1000 |um. (For interpretation  o f th e  references to  color in this figure legend, the  reader is referred to  th e  w eb  version o f this article.)
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obtained by adjusting the peristaltic flow rate and by adjusting the 
catheter as strain from the tubing can push the catheter tip against a 
bend in the torturous uterine artery, obstructing the flow. Every 
30 min, samples of the perfusate buffer were taken from the venous 
line to run a lactate dehydrogenase (LDH) assay probing for tissue dam­
age. For the final 30 min of perfusion, Dil—the lipophilic membrane 
staining dye—was added to the main reservoir to fluorescently stain 
the perfused vasculature [17]. The perfusion period would be terminated 
after a maximal duration of 8 h. Then the specimen was further proc­
essed by the Department of Pathology to ensure no interference with 
routine diagnostics.
22. Interstitial fluid pressure measurements
Interstitial fluid pressure measurements were taken during speci­
men perfusion with a 24-gauge needle manufactured with a side port. 
The needles fit snugly into capillary tubing. After priming the tubes 
with water, the needles were inserted into the tissue being perfused 
and the w ater lines were immediately marked with a marker and the 
tubes were erected vertically. The IFP was measured in fibroids that 
were palpable. At least 10 min passed before measuring the change in 
water level.
2.3. LDH assay
Reagents w ere purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Perfusate samples were collected every 30 min and stored at 
4 °C before adding to a 96-well plate containing the freshly prepared 
Tris buffered solution of lithium  lactate, phenazine m ethosulfate, 
iodonitrotetrazolium chloride, and nicotinamide adenine dinucleotide. 
Following a 5 minute incubation at room temperature, the absorbance 
was read at 490 nm to measure the amount of cytosolic LDH released 
from lysed cells. Richter et al. performed uterine perfusions and found 
LDH levels elevated to about 600 IU/L in control groups that resulted 
in damaged tissue [10]. Lactate dehydrogenase at a concentration of 
662 IU/L was used as the positive control and upper limit for acceptable 
cell lysis. Two negative controls of blank buffer w ith assay reagents 
and a perfusate sample w ithout reagents were also used.
2.4. Biospecimen analysis
Any visible or palpable fibroids were noted and measured if possible. 
The organ was weighed again after the procedure to assess any fluid 
retention during perfusion. Upon completion of perfusion, the organ 
was grossly examined in collaboration with the Department of 
Pathology. Pictures were taken with a consumer-level digital camera 
for qualitative assessment of perfusion of the uterine myometrium, en­
dometrium, and fibroids. At the pathology assistant's discretion, small 
excess tissue samples (approximately 1 x 1 x 0.5 cm) were obtained, 
embedded in optimal cutting tem perature (OCT) compound for flash 
freezing the fresh tissue, and stored at — 80 °C until cryo-sectioning 
and further analysis. Following routine medical diagnostics, additional 
fixed tissue was obtained and stored at room temperature in formalin 
before taking samples for additional analysis and benchtop experi­
ments. Fixed samples were also embedded in OCT, flash frozen and 
stored at — 20 °C before sectioning. As the fluorescent DiI vessel stain 
and methylene blue were introduced during the perfusion stain, the 
samples could be quickly cryo-sectioned into 50 |am thick slices and 
mounted for imaging without further preparation. Representative tis­
sue sections were additionally stained with the fluorescently-labeled 
CMP or with histological stains. The fixed tissue sections were stained 
for collagen by CMP as previously described by Li et al. [18]. A Nikon 
A1 confocal microscope imaged the CMP stain excited at a wavelength 
of 488 nm, Dil stain at 561 nm, and methylene blue at 638 nm. 
Formalin-fixed tissue was cut into 3 |jm sections and stained with either 
hematoxylin and eosin (H&E) or Masson's trichrome in the histology
88
division of the Department of Pathology at the University of Utah. 
When processed as part of routine diagnostics, it was paraffin embed­
ded. If the tissue sample was from our collection and to be compared 
with fluorescently imaged sections, it was OCT embedded. OCT embed­
ding was chosen to avoid washing away the fluorescent stains in the 
paraffin embedding process.
2.5. Experiments on isolated tissue chunks
Cylindrical tissue chunks (roughly 4 mm in diameter and 5 mm thick) 
were cut from representative parts of each fibroid and myometrium from 
a non-perfused control specimen. The tissue chunks were arranged in a
A B
Normal myometrium
Fig. 4. Reduced v asculatu re in fibroids. All scale bars represen t 1000 |jm. A) A reduced 
nu m b er and  average d iam e te r o f vessels in fibroids are  seen  in sections sta ined  w ith  
H&E. The norm al m y om etrium  has large d iam e te r vessels v isible th ro u g h o u t tissue 
w hile only limited, sm all-d iam etervessels are seen (red  circles) in the  fibroid (boundaries 
betw een norm al and fibroid tissue m arked  by blue lines). Fluorescent staining of vascula­
tu re  via perfusion is psuedocolored red  (B-D). B) The perfusion stain  o f th e  vasculature 
reaches th e  entire  thickness o f the  m y om etrium  and increased  vasculature is app aren t 
in  th e  end om etriu m . C) S tained  vasculatu re  is clearly seen  in  th e  m y om etrium  tissue 
bu t appears lacking in the  fibroid regions of the  uterine tissue. D) Higher resolution imag­
ing o f th e  fibroid tissue show s th a t  blood vessels do exist, albeit a t  sm aller d iam eters. 
E) Data for th e  v asculatu re  in  th e  fibroids are  p resen ted  a fte r norm aliz ing  th e  values 
w ith  respect to com parable norm al tissue of the  sam e organ. The averages for all three  fea­
tu res o f vessel m easu rem ent are  significantly sm aller in  th e  fibroid tissue com pared to 
norm al tissue (P < 0.05). (For interpretation  of the  references to color in this figure legend, 
the  reader is referred to the  w eb  version o f this article.)
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12-well plate and subm erged in 2 mL of perfusate buffer w ith and 
w ithout m ethylene blue for 2 h for the experim ent testing passive 
diffusion of methylene blue through the tissue. Larger tissue chunks 
(approximately 1 0 x 1 0 x 5  mm) w ere used when testing the effect 
of fluid pressure on m ethylene blue d istribution. Capillary tubing 
was passed through the tissue chunk by first impaling w ith a needle 
to guide the tube through the tissue. A w ater depth of 5 cm simulated 
IFP of approximately 3.7 m m Hg was sufficient to overcome the slight 
pressure of about 1.5 mm Hg exiting the fenestrae (made w ith a 
30 gauge needle—approximately 310 |am in diameter) in the tubing 
wall. Thus, pressure into the tube was approximately 2 mm Hg, which 
was intentionally set to mimic the high interstitial pressure reported 
for other solid tumors [19].
2.6. Image analysis
ImageJ was used to analyze fluorescent microscopy images [20]. 
Images of the fluorescently stained vasculature were auto-thresholded 
to de tect and analyze vessel objects providing average areas and 
Feret minimum diam eters to estim ate the vessel size (area), percent 
coverage (area fraction), and vessel diameters. The percent coverage 
was determ ined by dividing the total area of all vessels by the total 
area of the tissue analyzed. The Feret minimum diam eter estimated 
the vessel d iam eter quickly and w ithout user interference. Images 
of CMP and methylene blue fluorescence were combined into stacks 
and areas of interest were analyzed for average intensity values. Cus­
tom  Matlab code was used to generate the high-contrast image
89
show ing unique colors for distinct and overlapping fluorescent 
signals.
2.7. Statistical analysis
Values were averaged from multiple m easurements from the im­
ages. Error bars in graphs represent standard deviation. Statistical 
significance of Pearson's correlation values was determ ined w ith a 
critical value table for a One-Tailed test. All other instances of statis­
tical significance were calculated w ith a One-Tailed Student's test.
3. Results
3.1. Stain does not pervade fibroid tissue despite thorough perfusion of 
organ
Qualitative assessments of perfusion quality showed that the tissue 
would whiten with the flush perfusion and turn blue upon the addition 
of methylene blue (Fig. 2A-B). Furthermore, the LDH assay showed ac­
ceptable tissue viability during our experiments lasting fewer than 8 h 
(Fig. 2C). The perfusion system allowed us to observe and maintain 
physiological conditions such as tem perature, neutral pH, elevated 
pO2 level, and arterial pressure near 100 mm Hg (data not shown). 
Even with thorough perfusion, the fibroid regions seemed unaffected 
by the perfusion and would not be stained like the surrounding normal 
myometrium. This was observed during gross examination and with 
fluorescent microscopy of the sectioned tissue (Fig. 3 ). The interface
A B
Fig. 5. A) M ultiple fibroids had regions (m arked w ith  red circles in A and B) in their interior w h ere  the  tissue density appeared sim ilar to  tha t of the  m yom etrium . B) Shows successive 
sections o f fibroid tissue stained w ith  H&E, Masson's trichrom e, and fluorescence introduced during perfusion. The tissue in those regions appeared to be less dense w ith  less prom inent 
staining for collagen and higher accum ulation of m ethylene blue stain (psuedocolored blue) by fluorescent imaging. Fluorescence from  blood vessels is psuedocolored red. (For interp re­
tation of the  references to  color in  this figure legend, th e  reader is referred to  the  w eb  version of this article.)
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between fibroid and normal myometrium was evident in microscopic 
images of the sections with compressed lines of displaced tissue at the 
periphery of the fibroid.
3.2. There is limited vasculature in fibroids
The vasculature also appeared to be compressed and limited in 
the fibroid tissue. H&E stains and fluorescent imaging of fibroid and 
myometrium sections showed that vessels in the fibroid are sparse 
and consist mainly of capillaries. Fig. 4 shows representative examples 
of imaged vasculature and quantifies the vessel areas, percent coverage, 
and minimum diameters compared to respective normal myometrium. 
The vasculature was measured using two main param eters: area and 
minimum diameter. The minimum diam eter would estim ate the ves­
sel d iam eter while the vessel area m easurem ent includes informa­
tion about size and coverage. The average vessel d iam eter in the 
fibroids is only slightly smaller than that of the normal myometrium 
(approxim ately 9 |am compared to 14 |am, respectively). This is not 
surprising, as the  norm al tissue also includes capillaries w ith a 
large number of those affecting the average, being closer to the average 
vessel diam eter found in the fibroid. On the other hand, the squared 
value of the vessel area likely accentuates the disparity between the two 
tissue types. The Dil was successful in fluorescently staining the perfused 
vessels. The highly visible stain th roughout the m yom etrium
extending in to  the endom etrium  indicates th a t the entire organ 
was sufficiently perfused. However, only a t high magnification 
(20x  or above) can small vessels in the fibroids be seen more clearly. 
This confirms that vascular perfusion is limited, yet still present, in 
the fibroids.
3.3. There is a negative relationship between collagen density and 
methylene blue distribution
Results from stained tissue sections showing intratumoral features 
of the fibroids are shown in Fig. 5 . Comparing successive sections 
revealed relationships in different areas of tissue when comparing pack­
ing density, collagen density, and methylene blue distribution. The neg­
ative relationship betw een methylene blue distribution and collagen 
density was first observed qualitatively. By sampling different areas in 
fibroid and normal myometrium, it was found that areas with high 
methylene blue fluorescence had relatively low fluorescence for the 
CMP stain (Fig. 6). We further analyzed the relationship between the 
d istribution  of m ethylene blue and collagen density based on 
average fluorescence in tensities and found a negative correlation 
betw een the tw o w ith  the exception of one fibroid sample. The 
Pearson's correlation values (and significance) for 4 fibroids were 
— 0.89 (P < 0.01), — 0.92 (P < 0.01), — 0.68 (P < 0.1), and an outlier 
of 0.70 (P < 0.1). The controls had weaker correlation and were not
(19183) (10707) (7694)
(2206) (2643) (5893)
0% 20% 40% 60% 80% 100% 
Methylene blue fluorescence (% of total fluorescence) 
o Fibroid 1 □ Fibroid 2
o  Fibroid 3 a  Fibroid 4
x No collagen stain x No methylene blue stain
Fig. 6. Comparing fluorescence o f the  collagen stain  and m ethylene blue for various regions o f interest. A) Qualitatively show s how  different regions show  a negative relationship betw een 
collagen stain (psuedocolored yellow) and m ethylene blue (psuedocolored blue) according to the  average fluorescence intensity. B) Fluorescence values o f various areas for m ultiple fi­
broids (norm alized as a percentage o f total fluorescence to fit on one graph). Fibroids 1 through 3 have a negative correlation. Fibroid 4  does n o t show  the sam e relationship. Two addi­
tional fibroids used as controls for collagen stain and m ethylene blue appear a t the  tw o ends o f the  spectrum . (For interpretation  of th e  references to color in this figure legend, th e  reader is 
referred to the  w eb  version o f this article.)
34
D.L Stirland eta l. /  Journal o f  Controlled Release 214 (2015) 85-93
Fig. 7. A) High accum ulation o f stain  via passive diffusion w as evident after subm erging 
fibroid tissu e in a m eth y lene  b lue buffer solution. The grayscale im age w as colorized 
using the  royal lookup table. Scale bars are 1000 |jm. B) Perfusing tissue chunks w hile con­
trolling IFP confirm ed th a t high p ressure could p revent staining of the  tissue. C) Evidence 
for solid s tress in fibroids. The tissu e w as sliced d uring  gross exam ination  and  tissue 
expansion (double arrow s) was observed in th e  fibroids. (For interpretation  of the  refer­
ences to color in this figure legend, the  reader is referred to the  w eb version of this article.)
statistically significant (P > 0.1). On a larger, macroscopic scale, the 
negative relationship is clear w hen com paring the collagen and 
m ethylene blue content betw een the fibroid tissue and the normal 
m yom etrium  as a whole. Under the microscope, the interior of the 
fibroid tissue showed heterogeneous distributions of methylene blue 
and collagen content. Unsurprisingly, further heterogeneity existed 
amongst the different fibroid specimens. One fibroid in particular 
showed relatively low levels of collagen density in both the CMP and
Masson's trichrome stain (data not shown). Perhaps for that reason, 
the sample was an exception to the correlation analysis in that it did 
not show a negative relationship betw een methylene blue staining 
and collagen content.
3.4. Hydrostatic pressure is a barrier to transport
Fig. 7 shows results from experiments probing how passive diffusion 
and interstitial fluid pressure affect methylene blue distribution inside 
fibroids. W hen testing passive diffusion of methylene blue through 
the fibroid and myometrium tissue, a high fluorescence intensity for 
methylene blue was found within the fibroid tissue. As suspected, the 
mere presence of collagen is not sufficient to prevent transport of the 
methylene blue. Methylene blue can permeate into fibroid tissue as 
easily as, or more so, into the normal tissue with the passive diffusion 
tests. It has already been shown that diffusivity is less hindered through 
some neoplastic tissues [21]. Still, methylene blue distribution seems 
inhibited in the fibroids when delivered via arterial perfusion. This is 
likely due to high IFP in the collagen rich areas of the fibroid acting as 
a barrier. To further confirm these findings, experiments perfusing iso­
lated tissue chunks showed how pressure can overwhelm transport 
and therefore prevent staining of methylene blue into the tissue.
During the ex vivo perfusion of the organ, IFP measurements prob­
ing palpable fibroids saw an average hydrostatic pressure of about 
4 mm Hg (net flow out of fibroid tissue) while normal myometrium tis­
sue had an average pressure near — 1 mm Hg (net flow into tissue). 
Probing the IFP in two different locations of one fibroid in particular 
resulted in distinct pressure values of 2 and 6 mm Hg, which also repre­
sent the maximum and minimum values recorded from various fibroids. 
Our needle probing data affirm secondary evidences suggesting exis­
tence of high IFP. Fibroid tissue exerts forces on and displaces surround­
ing tissue. The solid-stress-induced tissue expansion of the fibroid tissue 
was observed during gross examination after the tissue was sliced 
cleanly and evenly. This built-up solid stress could be growth induced 
or due to the compressive nature of the myometrium tissue and corre­
lates with high IFP in the tumor [22]. Similar to lesional edema, the col­
lagen content in fibroids can increase filtration and restrict the volume 
from expanding to equilibrate the high IFP [23,24]. IFP has been 
shown to be almost uniformly high and a transport barrier in other 
solid tumors [19,25,26]. The challenge of teasing out heterogeneous 
IFP within the tumor could be due to the imprecise nature of the needle 
probing method with resolution limited by the size of the needle tip. 
Non-image guided introduction and positioning of the needle within a 
fibroid tumor proved challenging in our experiments. While we found 
two distinct pressure values in one fibroid, there was considerable 
variation amongst pressure values across all examined fibroids. This 
variation precludes statistical significance betw een the averages for 
normal and fibroid tissue; however, the pressure differences seemed 
meaningful in that all pressure measurements from the normal 
myometrium were at 0 mm Hg or below and all fibroid pressures were 
positive. These positive pressures found inside fibroids could inhibit con­
vective flow into interstitium and create a barrier to the intratumoral 
transport of molecules. Granted, failure to attribute a neutral or negative 
pressure to any undetected fibroid—assuming needles ended up being 
positioned within normal, non-fibroid m yometrium —could not be 
excluded. While technologies mapping the intratumoral IFP in high 
resolution are unknown to the authors at this point, our imaging data 
suggests rivulets of transport inside fibroids and is consistent with pre­
viously published research [27,28]. Such rivulets depend on areas of 
high and low pressure to dictate paths of least resistance out towards 
the normal tissue containing functional lymphatics.
4. Discussion
Poor penetration of visible stains, dense environments evident in 
histological sections, fewer vessels with decreased diameters seen in
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fluorescent microscopy, and higher IFP m easured by needle probes 
confirm barriers to transport in these fibrotic tumors. The distribu­
tion  of the  m ethylene blue w ith in  fibroids is likely dom inated  by 
pressure gradients and not solely by collagen packing or even vascu­
lature. These results may help to explain the pathophysiology of and 
improve treatm ent strategies for uterine fibroids as well as for o ther 
desmoplastic tumors.
Given an annual health care cost exceeding $2.1 billion and the inva­
siveness of the procedure, hysterectomy may not be an ideal solution for 
the treatm ent of fibroids [2,29]. Furthermore, hysterectom y is not a 
compatible option for women of reproductive age who have not com­
pleted childbearing, as well as for patients suffering from other comor­
bidities, making them  poor surgical candidates. Hormone therapy 
(gonadotropin-releasing hormone agonists) can show drastic effects 
by shrinking the fibroids after 3 months of treatm ent, but the fibroids 
can quickly return to pretreatment size when treatm ent is discontinued 
[30]. Furthermore, hormone therapy longer than 6 to 12 m onths is 
avoided to prevent bone loss [31]. Hormone therapy is able to function 
despite the barriers found in this research because the medications do 
not need to be delivered directly to the fibroid. Rather, they function 
by changing the hormonal balance of the environment that feeds the 
fibroids. It has been shown that fibroids within the same uterus can 
respond differently to their hormonal environment, w ith some shrink­
ing and others growing in size [32]. This may be due to the presence 
of additional growth factors present within the fibroid tissue, which 
can influence their progression [33-35]. Thus, drug or gene therapies 
targeting growth factors that mediate fibroid growth may be a viable 
treatm ent alternative benefiting from this research on access and distri­
bution barriers.
These results also describe some physiological features that relate 
to the  clinical stra tegy of em bolization. First, blood vessels inside 
fibroids appear to be very small and prone to embolization. Second, 
the norm al myometrium  contains larger vessels that are not as easily 
obstructed. If embolization occurs in the myometrium, anastomosis 
is a characteristic of u terine tissue and will allow collateral vessels 
to com pensate for the blocked vessels [36]. Likewise, redundancy 
can exist in the blood supply to the fibroids and can result in failure 
of the embolization treatm ent [37].
As similarly reported by a group pioneering ex vivo uterine perfu­
sion, w e found that some uteri were more difficult to perfuse than 
others [38]. Physiologically occurring variations in uterine vasculature 
could make it difficult to locate the main arteries supplying the uterus. 
In some cases, anastomosis allowed the entire organ to be perfused 
even w hen some vessels were cauterized or otherwise occluded. The 
uteri that did not perfuse well, as indicated by lack of blood clearing 
and blue staining, were not included in the correlation analysis of m eth­
ylene blue distribution. At times, specimen numbers were limited by the 
availability of tissue following routine medical diagnostics. However, 
some specimens contained multiple fibroids, each providing an inde­
pendent sample. Despite the challenges in the model, the ability to 
study transport in human tissue containing naturally occurring benign 
tumors provided valuable and clinically relevant insights into factors 
that affect drug distribution.
The results from this research expand on our current understanding 
of transport barriers in desmoplastic tumors within their intact macro- 
and microenvironments. Jain et al. investigated the effects of reducing 
collagen content to reduce interstitial fluid pressure and improve perfu­
sion in dense fibrotic tumors such as adenocarcinomas [39,40]. Collage- 
nase and hyaluronidase have also been shown to improve transport of 
monoclonal antibodies and liposomes in hum an osteosarcoma xeno­
grafts [41,42]. Some tumors are more fibrotic than others and therefore 
our results and m ethods m ay be cautiously relevant to malignant 
tumors such as leiomyosarcomas, malignant fibrous histiocytomas, 
mesotheliomas, pancreatic adenocarcinomas, and desmoplastic small 
round cell tumors—all desmoplastic, solid tumors where drug delivery 
is limited by similar physiological barriers.
Our focus in this study was to better characterize the access a poten­
tial drug can have throughout tissues harboring tumorous growths. 
However, this model does have potential to study the efficacy of some 
treatm ent strategies. Testing some of the slower-acting treatm ent 
m ethods for overcoming transport barriers, such as ECM degradation 
by enzymes or inhibition of collagen synthesis by drugs such as Losartan 
in uterine fibroids, ex vivo perfusion might be required to reach a point 
w here tissue viability can be maintained longer than 48 h. In vivo pre­
operative testing may be possible, but is limited by patient safety con­
cerns. Additional alternatives could include hyperthermia treatm ent 
(to increase diffusivity), elevated vascular pressure (to overcome IFP), 
or penetrating peptides (to increase permeability)—all of which can be 
readily administered and observed within our model.
5. Conclusion
The ex vivo uterine perfusion model allowed us to perfuse entire, 
intact hum an organs w ith solid benign tumors present. Furthermore, 
this strategy enabled us to observe barriers to transport ofstaining mol­
ecules introduced via the vasculature and assess the tumor's macro- and 
microenvironments. Our findings include: limited staining inside the 
fibroid, limited intratumoral vasculature, high levels of intratumoral 
collagen, solid stress, and elevated IFP. These observations are consid­
ered clinically relevant to better understand why some similar solid tu­
mors may have an ability to inertly impede drug therapy treatments. 
Limited access to and decreased diffusion inside solid tumors are diffi­
cult challenges currently hampering clinical treatm ent outcomes that 
need to be better understood for improved drug delivery. We plan to 
investigate treatm ent strategies seeking to overcome access barriers 
(currently being studied in other desmoplastic tumors) by applying 
them to the uterine perfusion model.
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2.7.1 Im age R esolution
The resolution defined in Fig. 2.4 applies to all figures in Chapter 2. Essentially, all 
scale bars in all figures and widths of images in call-outs (Fig. 2.5 B and Fig. 2.6 A) are 
1000 ^m. There is no defined scale for images taken with a hand-held digital camera (Fig.
2.2 A and B, Fig. 2.3 A and B, and Fig. 2.7 B and C).
2.7.2 Clarifications on m ethods
The needles used for IFP measurements were taken from the Insyte Autogaurd winged 
24-gauge catheters (BD381512) used for cannulation. These needles have a side port (a 
notch cut on the side of needle near the tip) that can interface with the tissue in case the 
tip of the needle is clogged upon insertion. The tissue chunks (or excised tissue samples) 
were placed at the bottom of a cylinder with a water height of 5 cm to simulate an IFP 
that could prevent transport. A diagram for this is provided in Fig. 2.8.
2.7.3 O ther corrections
Various instances of “psuedocolored” should be spelled “pseudocolored” .
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F igure  2.8. Supplementary: Diagram of methods for Fig. 2.7 B. The tubing was 
perforated to simulate extravasation potential. Staining of tissue via perfusion in an artificial 
environment of elevated IFP was observed and compared against buffer without stain and 
stain without pressure. “M” stands for myometrium tissue and “F” stands for fibroid tissue.
CHAPTER 3
ANALYZING SPATIOTEMPORAL DISTRIBUTION  
OF UNIQUELY FLUORESCENT NANOPARTICLES 
IN XENOGRAFT TUMORS
D. L. Stirland, Y. Matsumoto, K. Toh, K. Kataoka, and Y. H. Bae, Analyzing spatiotem- 
poral distribution of uniquely fluorescent nanoparticles in xenograft tumors, J. Control. 
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A dose circulating through the blood a t one tim e will have different opportunities to access the tum or compared 
to  a dose circulating hours later. M ethods to  test this hypothesis allowed us to differentiate tw o uniquely fluores­
cent doses o f nanoparticles (adm in iste red  as a m ix ture  o r sequen tially) and to  m easure th e  distribution  and 
correlation of these nanoparticle doses in three dim ensions. M ultiple colocalization analyses confirm  th a t silica 
nanoparticles separated into different dose adm inistrations will not accumulate in the sam e location. Decreased 
colocalization betw een separate doses implies dynamic extravasation events on the scale of microns. Further, the 
perfusion sta te  o f different blood vessels can change across th e  dosing period. Lastly, analyzing the distance 
traveled by these silica nanoparticles in tw o dim ensions can be an overestim ation w hen com pared w ith  th ree­
dim ensional distance analysis. B etter understanding intratum oral distribution o f delivered drugs will be crucial 
to  overcom ing the various barriers to transport in solid tum ors.
© 2016 Elsevier B.V. All rights reserved.
1. Introduction
In the past few decades, nanoparticles have become popular tools to 
make inroads into treating cancerous tumors. Traditional chemotherapy 
causes widespread toxicity to the entire body in order to treat the can­
cer. Drug delivery via nanoparticles seeks to be a magic bullet that limits 
toxicity to the cancer. However, nanoparticles still must rely on passive 
delivery mechanisms. There are numerous barriers that stand in their 
way of treating the tumor. They pass through the blood circulation 
and encounter other organs or tissues where they may become seques­
tered by the mononuclear phagocyte system (MPS). Even w hen they 
encounter the tumor there are still more barriers that inhibit transport 
and delivery.
This research focuses on understanding distribution in the 
intratumoral environment. Many nanoparticle based treatm ents rely 
on the enhanced permeability and retention (EPR) of macromolecules 
in solid tumors, but more research needs to be done to test some of 
the assumptions. The way to access an inoperable solid tum or is via 
the vasculature. Often the vasculature of the tumor does not cover the 
entire tum or volume evenly. That limits access to certain parts of the
* Corresponding au th o r at: D ep artm en t o f Pharm aceu tics and Pharm aceutical 
Chem istry, College of Pharm acy, U niversity  o f Utah, Rm 2972, Skaggs Pharm acy 
Institute, 30S 2000E, Salt Lake City, Utah 84112, USA.
E-mail address: you.bae@ utah.edu (Y.H. Bae).
tumor. Studies show that solid tumors often prevent the penetration 
of macromolecules far beyond the proximity of blood vessels [1-3]. 
Furthermore, the distribution of these extravasation locations appears 
to be heterogeneous within the tum or environment [3]. This is likely 
due to the remodeling of the vascular networks in a nutrient hungry 
tumor with increased angiogenesis.
The details of intratumoral distribution are still uncertain. Beyond 
the assumptions made related to accumulation via the EPR, it is difficult 
to predict how the drug dose will be distributed inside of the tumor en­
vironment. This research builds on research seeking to quantify drug 
distribution in the intratumoral environment. This research tests the 
hypothesis that these extravasation events are not only heterogeneous 
in location, but also dynamic in time. Specifically, we sought to explore 
how the drug distribution may change over time by differentiating an 
earlier dose from a later dose. Furthermore, w e sought to glean 
additional information by observing the distribution ofthe two unique­
ly fluorescent doses in real-time with intravital microscopy. Finally, we 
hypothesized that calculating the distance to the nearest blood vessels 
would be different for two dimensions (2D) and three dimensions (3D).
As an analogy for the value of understanding accessibility changes 
over time, m odern online maps w ith navigation suggestions allow us 
to select a day and time to see typical traffic patterns for the given con­
ditions. It provides information on which routes are going to be blocked 
and which routes have access. If similar predictions for access to a tumor 
could be offered, this would be valuable information when delivering
http://dx.doi.org/10.1016/j.jconrel.2016.02.016 
0168-3659/© 2016 Elsevier B.V. All rights reserved.
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drug to a tumor given certain conditions. As we currently treat clinical 
tumors, the tumor mass can be reduced with delivered drugs; however, 
partially due to the limited delivery of drug to the entire tumor, the 
tumor will eventually resist treatm ent and grow back in a more aggres­
sive state.
This research will help characterize EPR as it exists in the majority of 
tumors used in preclinical studies. For that reason, a xenograft mouse 
model is used. Perhaps by understanding EPR in this model, we might 
discover some flaws that explain why results do not always translate 
to the clinical setting.
2. Materials/methods
Red and green fluorescent silica nanoparticles were purchased from 
micromod (40-00-701 and 42-00-701, Rostock, Germany) and their 
sizes and surface charges w ere verified w ith dynamic light scattering 
and zeta potential measurements using a Malvern Zetasizer. Athymic 
nude mice (Simonsen Labs, Gilroy, CA) were injected subcutaneously 
with a 100 |jL PBS solution (20% FBS) containing HeLa cells (7.5 x 106 
cells) or HT29 cells (1.25 x 106 cells) in the rear flank to initiate tumor 
growth. W hen the tum or volume reached approximately 100 mm3, 
the mice would receive tail vein injections of silica nanoparticle 
solutions at a concentration of 20 mg/kg for each dose. The red and 
green silica nanoparticles were either administered as a mixed solution 
or separately with varying intervals, ranging from 30 min to 12 h. Unless 
otherwise stated (two groups in SF3 and one mouse in Fig. 3C), the 
green silica nanoparticles were injected as the first dose followed by 
red silica nanoparticles as the second dose. Three hours after the 
final dose, the mice were sacrificed and 1,1'-Dioctadecyl-3,3,3',3'- 
tetramethylindodicarbocyanine iodide (DiD) (84903, Anaspec, 
Fremont, CA) was introduced by cardiac perfusion to fluorescently 
stain the blood vessels. This vessel staining protocol was previously 
found to be adequate in staining even the small vessels of densely 
packed hum an fibroid tissue [4]. Following perfusion, the liver and 
tumor tissues were collected and placed in Optimal Cutting Tempera­
ture compound for at least 5 min before flash freezing with isopentane 
in a metal beaker cooled by liquid nitrogen. Samples were stored at 
- 8 0  °C until sectioning w ith a cryotome at a thickness of 100 |jm for 
m ounting on microscopy slides. As all probes and stains were intro­
duced before harvesting tissues, no further staining was required and 
this also facilitated acquisition for 3D image stacks. A Nikon A1 confocal 
microscope with a motorized stage automated the process of acquiring 
3D Z stacks and stitched mosaics of the entire tissue section. Sequential 
imaging was performed to isolate each fluorescent signal: green silica 
nanoparticles were excited at 488 nm, red silica nanoparticles at 
561 nm, and the DiD stain at 638 nm. The acquired images were then 
processed in batches with custom MATLAB code to determine the distri­
bution and colocalization of the multiple doses.
Binary images were created by applying a threshold to the images. A 
distance map was created from the binary blood vessel image. The pixel 
values in the distance map gave the Euclidean distance from that pixel 
to the nearest blood vessel (in 2D or 3D). This distance map was multi­
plied by the binary image for the nanoparticle signal to assign distance 
values for each pixel representing nanoparticles. The code also assigned 
primary colors and unique values to each binary channel to facilitate 
qualitative observation and quantitative summation of overlapped or 
unique pixels.
The percent overlap provides the simplest and m ost intuitive 
measure for colocalization of the two signals by showing the overlap 
of detected signal objects relative to the total signal from either the 
first or second dose of silica nanoparticles.
2nd Dose % overlap = J^R tnG t 100
where G t  and R t  represent the thresholded binary values of signal com­
ing from the green and red silica nanoparticles, respectively, for each 
pixel. The intravital images were only analyzed for percent overlap to 
simply show whether or not the signal was there and overlapping.
The end-point analysis of extravasated silica nanoparticles used 
Pearson's and Mander's coefficient values to look at more than just bina­
ry presence of the signal, but also at the intensity (or concentration) cor­
relation which was present. The colocalization analysis by these means 
was more robust even ifthe signal was dim or had background noise [5, 
6]. These further colocalization analyses were performed by first creat­
ing a mask or region of interest based on the thresholded silica nanopar­
ticle images. W ith the region of interest defined, the original, non- 
thresholded images were used to calculate the correlation betw een 
green and red signals. Defining a region of interest for colocalization 
analysis eliminated the large areas of background containing common 
blackness or random signal noise which could erroneously increase or 
decrease, respectively, the correlation value.
The Mander's value describes the fraction of overlap from the two 
signals' intensities.
Mander s = E i Ri • Gi 
X iR i2 • X iG i2
w here R i  and G i  represent the intensities for red and green signal, re­
spectively, in each pixel. The equation for Pearson's value subtracts the 
average value for red or green (Ra v g  or Ga v g ) and provides information 
on the covariance of the two signals: if the two signals tend to increase 
together the value is closer to 1.
D ' ( (Ri Ravg) (Gi Gavg)) Pearson s = -----— ----------------------------—
1st Dose % overlap = RtnGt X 100
i Ri- R avg 2 • i Gi- G a vg 2
Furthermore, this subtraction allows for a value as low as - 1  which 
indicates that one signal tends to increase while the other decreases.
Multiple areas from numerous Z stacks were analyzed for correlation 
between the nanoparticle signals. A p value was produced by the built in 
MATLAB corrcoef function to represent the chances of getting the same 
correlation by random chance. Only images with a p value less than 0.05 
w ere included in the averages. The MATLAB code generated both 
Pearson's and Mander's values describing the colocalization of the two 
silica nanoparticle signals. Finally, these values were averaged for the 
groups of mice and statistical significance of the separately dosed mice 
having a lower value was calculated with a Student's t-test.
Intravital imaging was performed using a Nikon A1R confocal laser 
scanning microscope system attached to an upright ECLIPSE Ni-E 
equipped w ith a CFI Plan Apo Lambda 20 x objective. The blood circula­
tion half-lives of the two colors of silica nanoparticles were determined 
by checking the fluorescence intensity in the blood vessels of the ear­
lobe of mice using the microscopy m ethods described in previously 
published work [7]. To prepare the tum or bearing mice, 6 -8  week old 
female BALB/c nu/nu mice (Charles River Laboratories Japan, Inc., 
Kanagawa, Japan) were subcutaneously inoculated w ith murine colon 
carcinoma C26 cells (American Type Culture Collection, Manassas, VA, 
USA). Mice were anesthetized and maintained with 1.0-1.5% isoflurane 
onto a stage-top tem perature-controlled pad calibrated at 37 °C. The 
tumor was imaged as 6 dimensions composed of XY Large Scan (using 
a motorized stage), Z stack (10 |jm thickness, three slices), Time-Lapse 
(10 min interval), and 2 Channels (green and red). Two mice were ad­
ministered w ith green silica nanoparticles 10 min after the imaging
39
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was initiated. After 2 h, the red silica nanoparticles were administered. 
The order was switched for one mouse as a control.
3. Results/discussion
The silica nanoparticle batches of different colors were characterized 
and it was confirmed that both have a hydrodynamic diameter of about 
73 nm, a strong negative surface charge, and half-life in the blood of 
about 30 min (SF1).
We chose simple, inorganic, fluorescent nanoparticles because the 
characteristics could be controlled and verified to be nearly identical. 
Although it is anticipated that protein adhesion and aggregation will 
occur upon entering the body (like any nanoparticle), degradation 
into smaller particles was not a concern as the in vivo experiments 
lasted no longer than a day and significant degradation of non-porous 
silica nanoparticles takes longer than a week [8,9].
Two uniquely fluorescent doses of silica nanoparticles were admin­
istered either as a mixed dose or separately at varying intervals for tem ­
poral analysis. W hen the two uniquely fluorescent silica nanoparticles 
are administered separately, the two colors can be distinguished with 
some non-overlapping signal. Fig. 1 shows qualitative and quantitative 
differences in colocalization betw een mixed and separate doses for 
representative images in liver and tumor tissue.
The two fluorescent signals were analyzed for colocalization in the 
tum or environm ent and compared with values from the liver as a 
positive control. The liver was chosen as it has more reliable silica nano­
particle accumulation and a better signal/noise ratio. The better signal to 
noise ratio, the more consistent the correlation was. This accumulation 
in the liver is characteristic of hepatic circulation from tail vein adminis­
tration [10]. Notoriously leaky vessels in the sinusoids allow for high 
accumulation of nanoparticles and the Kupffer cells in the liver could 
phagocytose the nanoparticles into concentrated, bright bundles. As a 
comparison for showing dynamic events, the phagocytosis is clearly 
not a static event and the dynamic leakiness of liver sinusoids has 
been summarized in a review article [11]. W hen the two doses were 
mixed together and then administered, there was a high percentage of 
signal overlap in both the tum or and liver tissue. However, the lower
percentages of signal overlap for separately administered doses suggest 
dynamics in both the liver and tumor environments.
The overlap analysis in Fig. 2A merely shows a trend supporting the 
hypothesis that separate doses will have decreased colocalization. Un­
like Fig. 1, the data in Fig. 2 only includes images of tum or tissue 
where the signal was weaker and not as consistent. Simple overlap anal­
ysis is not as robust for the weak nanoparticle signal outside of the blood 
vessel in the tumor tissue where there is also more background noise. A 
noteworthy difference is that the 2nd dose signal had a better signal to 
noise ratio and the data was significant. In contrast, the 1st dose 
appeared more diffuse and weak. Quantifying the colocalization with 
additional, more sophisticated, colocalization techniques found a statis­
tical difference when comparing the Pearson's and Mander's values for 
mixed and separate doses in the tumor (Fig. 2B).
Correlation analysis for various dosing intervals sought to identify a 
spectrum of temporal dynamics in the tum or environment. Unfortu­
nately, we were not able to discern significant differences between the 
various dosing intervals, but merely the difference betw een mixed 
and separate doses. The analysis may result in false negatives for 
dynamic extravasation or false positives for colocalization (it is unable 
to resolve two different nanoparticles that are spaced only 100 nm 
apart). The point spread function for the Nikon A1 microscope used 
for these experiments gives a theoretical resolution of 147 nm along 
the X and Y axis and 368 nm along the Z axis in ideal conditions. Fur­
thermore, the 3D image acquisition with certain step sizes effectively 
set the resolution as low as 5 |am along the Z axis. Other processing 
techniques, such as thresholding for distance or object overlap analysis, 
further reduced the resolution. Explorative calculations based on re­
gions of interest determ ined by thresholds generally only varied by 
10 |am. Thus, the figures of merit for this approach put our resolution 
near 5 to 10 |am. This allows for detection of dynamic extravasation 
events from blood vessels (as a result of remodeling) that are at least 
50 |am (length of endothelial cell) apart from each other. Thus, we 
could still determine whether dynamic extravasation events occurred 
in intratumoral drug delivery. To observe dynamics on a larger scale, 
intravital microscopy was performed with a purpose of verifying and 
teasing out additional results.
Fig. 1. Representative images of the  fluorescent signals from tw o silica nanoparticle doses in liver and tum or tissues. A) The exam ple im ages are thresholded to show  high-contrast images 
of the  signals for blood vessel (red), 1st dose (yellow), and 2nd dose (blue). Furtherm ore, secondary colors represent overlapping signal (e.g., green for overlap of th e  tw o dose signals). 
Scale b a ris1 0 0  |jm  and applies to  all images. B) The exam ple images w ere quantified for the  percen t overlap o f each dose. (For interpretation  of the  references to color in this figure legend, 
th e  reader is referred to the  online version o f this chapter.)
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Fig. 2. Colocalization analysis of silica nanoparticle doses in tum or tissues. Error bars are standard  deviation. * p < 0.05. ** p < 0.01. A) Average values for percen t overlap analysis for a larger 
data set o f 10 different mice: 4  w ith  m ixed doses and 6 w ith  separate doses. B) Average M ander's and Pearson's values for 24 d ifferent mice: 4  w ith  a m ixed dose and 20 separately dosed.
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Real-time intravital microscopy showed strong signals for the 
fluorescent nanoparticles in the blood vessels (Fig. 3 ). Analysis of the 
fluorescent signals through the perfused vessels suggests dynamics in 
entire blood vessels within the tumors. Overlap analysis demonstrates 
that a dose can have as much as 98% or as little as 34% of its perfusion 
overlapped with the other dose. Some vessels maintained high signal 
levels for both doses and showed high overlap. Other vessels showed 
strong signals, only to fade with blood clearance of the nanoparticles. 
Finally, some vessels appeared to only show signal for one of the two 
doses (often the first dose). Averaging the 3 mice, the first dose had 
more unique signal locations and the second dose had a higher percent­
age of signal overlap. Image C of Fig. 3 appears to be an exception to this, 
but further inspection reveals that the two doses perfuse through many 
of the same vessels (Fig. 4 ). Due to the blood circulation half-life being 
shorter than the administration interval, the overlap of signal in these 
vessels was low. This implies that the majority of dynamics (on this 
time scale) results in blood vessels closing off and preventing access 
for the second dose. The trend of high overlap for the second dose was 
not observed in the end-point analysis of extravasation into the tumor 
tissue. In that case, the second dose can continue to have low overlap 
due to dynamic extravasation events beyond dynamic perfusion events.
Dynamic extravasation and perfusion events are each on a different spa­
tial scale which greatly affects determination of colocalization.
The spatial analysis (presented qualitatively and quantitatively in 
Fig. 5) found that measuring the distance of extravasated nanoparticles 
from the blood vessel in only 2D often overestimates the distance 
traveled. This can be seen qualitatively w hen comparing the 2D and 
3D distance maps. The 3D distance map shows a similar pattern for all 
slices of the Z stack because blood vessels in one slice influence the 
distance map in slices above or below. For our collection of images, we 
found that the average overestimation of distance traveled by 2D 
m easurements compared to 3D was about 25 |am. The distance 
measurements in 2D had a large spread of values when comparing the 
different Z stacks of a given tissue volume. If investigators were to 
analyze a 2D slice from region 4 in Fig. 5C, there is the potential to 
overestimate the distance by about 150 in that case. Three regions 
of negative control result in very low distances as would be expected 
when no nanoparticles are administered, but one had some speckles 
of background noise or non-specific staining that was included in the 
distance analysis. Other regions had low distance values simply because 
some tum or regions had stronger signal from silica nanoparticles 
than others.
Fig. 3. T hresholded  im ages from  in trav ita l m icroscopy for th ree  d ifferent m ice (A, B, C) show ing  blood vessels perfu sed  w ith  silica nanoparticles. For (A and  B), th e  g reen  silica 
nanoparticles w ere  adm inistered  first; th en  a fter 2 h, th e  red  silica nanoparticles w ere  adm inistered . The o rd er o f adm inistra tion  w as reversed for (C). Scale bars are  each 200 |im. 
D) Overlap analysis o f the  respective images. (For interpretation  of the  references to color in this figure legend, the  reader is referred to  the  online version o f this chapter.)
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Fig. 4. Additional images for Fig. 3C: rig h t after th e  first dose, right before and after th e  second dose, and near the  end o f th e  perfusion period. Some regions (a selection m arked w ith  
arrow s) appear to  be unique perfusion events, b u t instead they  are ju s t  tran sien t perfusion events for both  doses such th a t there  is little to  no overlap a t a given time. In o th er words, 
the  areas designated  by the  arrow s are reached by b oth  doses b u t n o t a t  the  sam e time. O ther areas (a selection m arked w ith  arrow heads) app ear to be only accessed by a single dose 
for the  entire  perfusion period. Scale bar is 200 nm.
Fig. 5. Overestim ation o f d istance traveled  by 2D m easurem ents. A) Comparison o f MATLAB g enerated  distance m aps for 2D and 3D analysis. Increased brightness signifies increased 
d istance from  th e  blood vessel. B) Image slices are  thresholded  to show  high-con trast im ages o f th e  signals for blood vessel (red), 1st dose (yellow), and 2nd  dose (blue). Secondary 
colors rep resen t overlapping signal. Scale b ar is 100 |um and  applies to  all images. C) Selection o f different tum o r regions (and  different m ice) show ing h ow  th e  distance traveled  is 
overestim ated w h en  m easuring in 2D versus 3D. The box plots rep resen t the  spread o f 2D distance values for each tum or region. Clearly, there can be m ultip le 2D distance values (one 
for each 2D im age slice through the volum e o f each tum or region). The open circles represent the  average o f all th e  2D distance values for each region. The open squares represent the 
3D distance values for each region. The d o tted  and  d ashed  line rep re sen t th e  average 2D and 3D, respectively, d istance value for all the  d ifferent tu m o r regions. The red  rectangle 
encloses th e  data  points from  negative controls. **p < 0.01. (For interpretation  of th e  references to color in this figure legend, the  reader is referred to  the  online version o f this chapter.)
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The overestimation in distance traveled occurs as most 2D methods 
cannot include any possible vessels above or below the frame of inter­
est. However, even with imaging tissue sections in 3D, there is still the 
chance for slight overestimation of distance traveled as there may be a 
vessel just beyond the tissue section being imaged. It is possible to 
image all sections of the entire tumor; however, the increase in accuracy 
is likely not proportional to the increase in required resources. Similarly, 
some meaningful trends can still be observed with 2D distance analysis. 
Still, given the ease of obtaining 3D stacks with confocal microscopes, 
we recommend distance m easurements be performed in 3D when 
possible for increased accuracy.
Calculating distance between vessel and nanoparticle objects identi­
fied by thresholding relies heavily on the threshold value chosen. 
Thresholding can shift the mean distance from the nearest blood vessel, 
but two things will rem ain: the 2D distance m easurem ent will be 
greater than the 3D measurement and the 2D m easurement will have 
greater variability. Finally, it is possible that the DiD stain introduced 
via cardiac perfusion may not stain all blood vessels. The high interstitial 
fluid pressure may cause some blood vessels to collapse or have limited 
perfusion. We chose to m easure distances from perfused vessels 
because w e were not interested in measuring distances from occluded 
vessels, from which the particles likely did not extravasate from. With 
our results confirming dynamic perfusion of blood vessels, it becomes 
more challenging to know from which blood vessels you should 
measure the distance traveled.
Researchers are looking into the effect of size and shape on extrava­
sation and penetration into the tumor environment [12-14]. Generally, 
the smaller particles have higher permeability and diffuse more rapidly 
in tumors [15]. Future experiments could investigate w hether different 
sizes could be susceptible to different extravasation events (from the 
cellular level w ith fenestrae and intercellular gaps to larger events 
resulting in blood lakes or w hen vessels change their perfusion state) 
and thus be sensitive to different dynamics relating to colocalization
[16]. Analyzing different sizes is also relatable to determining how ag­
gregated particles are influenced by the dynamics. We have already 
built computer models to understand how extravasation events occur
[17]. We will continue to develop these and other numerical models 
to test various parameters. Future experiments will also need to test 
the effects of pro or anti-angiogenic factors on the dynamic leakiness 
of these tumor blood vessels. These experiments should determine the 
cause of the dynamics at the different levels and w hether the multiple 
doses have a direct effect on each other via saturation or blocking 
effects. It is possible that vessels could become embolized from aggre­
gated nanoparticles and new  perfusion events could occur from 
sprouting vessels. On the other hand, solid stress inside the tumor 
could play a role in the opening and closing of vessels. It is known that 
tumors can cause lymph and blood vessels to collapse, but treatments 
can reverse this and increase the num ber of patent vessels [18,19]. 
Even w ithout therapeutic intervention, Debbage et al. previously 
showed dynamic perfusion using lectin stains [20]. The results herein 
confirm that phenomenon using fluorescent nanoparticles in the 
blood circulation. We further showed how dynamics influence the 
extravasation of the doses to different locations in the interstitial 
space. Understanding these dynamics will educate how access to the 
tumor via the vasculature can be in an open or closed state.
Knowing how access to the tum or may change over time may 
influence planning of dosing schedules and combinatorial strategies in 
the clinical setting. W ith a lower fraction of unique perfusion for the 
second dose 2 h after the first, long circulation may not be beneficial 
in all aspects. A relevant clinical trial showed that filtering liposomal 
doxorubicin 24 h after administration reduced side effects yet did not 
discern a change in efficacy [21]. The authors speculate that the tumor 
tissue had become saturated and all other drug particles circulating 
were likely to cause toxicity in healthy tissue. This is backed up by the 
fact that the non-PEGylated version of Doxil (Myocet) has a lower oc­
currence of palmar plantar erythrodysesthesia syndrome [22,23].
Clinical dosing schedules are often around 2 weeks apart. The dosing 
schedule is primary limited by the toxicity of treatm ent, but this is 
much longer than the half-life of the drugs administered. Thus, each 
dosing may have different access to the tumor. Many first line cancer 
therapies involve combinations of drugs to improve efficacy and limit 
resistance. The efficacy of concurrent versus sequential administrations 
has been studied in cells, xenografts in mice, and even in patients. 
Though not conclusive, concurrent therapy tends to be more favorable 
than sequential [24-28]. In addition to cell cycles, dynamics in vascular 
access may be a contributing factor in these studies. Concurrent therapy 
is more likely to deliver the combinatorial drugs to the same location in 
the tum or and allow synergistic benefits. Newer drug carrier formula­
tions are considering w hether it is better to combine two drugs into 
one carrier as opposed to having each drug in separate carriers [29]. 
Some clinicians may prefer the control afforded by having each drug 
in separate carriers. This would allow different release rates for each 
carrier and the ability to modify drug ratios by adjusting the carrier 
weight ratios. However, until more details on dynamic extravasation 
events over time and dynamic perfusion events of vessel segments 
within the tum or can be elucidated, a single carrier housing both 
drugs best ensures they reach the same locations (at the ratios 
intended) in the tumor.
4. Conclusion
While dynamic perfusion and extravasation events have been 
shown in animal tumors that grow faster with chaotic vasculature, sim­
ilar experiments need to probe clinical tumors for similar dynamics. 
Targeting the tumor environment through EPR is passive delivery and 
relying on passive delivery in the complex tumor environment appears 
to be inconsistent—especially in clinical applications [30]. Perhaps 
nanoparticle characteristics can be tuned to provide a way to mitigate 
the dynamic events observed in the chaotic tum or environment. 
Alternatively, methods of altering the tumor environment (via the vas­
culature or other contributors to pressure) may prove to be necessary to 
return  the tum or environm ent to a more predictable and consistent 
state for delivering multiple doses.
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Appendix A. Supplementary data
Supplementary material in a PowerPoint file is provided for addi­
tional figures and video. The figures show data characterizing the silica 
nanoparticles, the original (non-thresholded) versions of the example 
images shown in Fig. 1, more comprehensive graphs for Mander's and 
Pearson's values showing the different experimental groups (varying 
intervals for separately dosed administrations), and an additional set 
of images from different time points for Fig. 3B analyzing transiently 
overlapped and unique perfusion events. The videos are the intravital 
imaging data. This material is available via the Internet. Supplementary
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data associated with this article can be found in the online version, at 
http://dx.doi.org/10.1016/jjconrel.2016.02.016.
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CHAPTER 4
CONCLUSIONS AND FUTURE WORK: 
STRATEGIES TO IMPROVE 
DISTRIBUTION  
4.1 Summary of Included Work
As evidenced by limited success in the clinic and known challenges studied in the 
literature, intratumoral distribution in solid tumors requires special considerations. This 
work used a novel application of the uterine perfusion model to analyze distribution in solid 
tumors. We also sought to bring further understanding to knowledge gained with xenograft 
models by developing and applying methods of analyzing the distribution of multiple doses 
with respect to each other and the blood vessels.
In Chapter 2, the uterine fibroid model using human tissue was shown to have resistance 
to drug delivery correlated to characteristics within the tumor environment. These results 
are directly relevant to drug delivery problems that limit uterine fibroid treatment options. 
However, it also suggests the uterine fibroid model could be a valuable tool for studying bar­
riers to drug distribution in solid tumors within their original macro- and microenvironment. 
The fibroids most closely mimic desmoplastic tumors (pancreatic cancer, desmoplastic small 
round cell tumors, mesotheliomas, etc.).
Of course, no one model will completely replicate the conditions of every clinical tu­
mor. As the statistician George E. P. Box said, “... all models are wrong, but some 
are useful” [178]. The uterine fibroid model may supplement other models to provide 
a collection of data to better guide treatment against tumors in patients. For example, 
genetically engineered mouse models (GEMMs) are emerging as an advanced model to 
study tumors [179]. GEMMs have the distinction of including the entire organism where 
the ex vivo uterine model is limited to only the organ. Including the entire organism would 
be an advantage when interested in interactions with other parts of the body. However, it 
may be a disadvantage when seeking more simplicity and control at the organ of interest.
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Additionally, potential treatments can be given to the human explant organ and thoroughly 
analyzed without the risk of causing harm to the organism.
Currently, the duration of the ex vivo uterine perfusion is limited and it cannot test the 
efficacy of treatments. Considerable methods optimization is needed to perfuse the organ 
for longer than 72 h without compromising the tissue. Also, we do not know for sure if 
stain patterns in tumors are indicative of flow patterns (from heterogeneous IFP within 
tumors). It could be possible that flow seeps through a larger portion of the tissue but only 
stains select portions due to other interactions: stained areas could be rich in albumin or a 
similar molecule to which the methylene blue stain can easily bind. Future research could 
elucidate the binding tendencies of methylene blue. More importantly, it should include 
various, well-defined probes to better understand how carriers are distributed in this model 
for desmoplastic, solid tumors.
With the work presented in Chapter 3, we analyzed the spatiotemporal distribution of 
multiple doses. Xenograft models have chaotic, heterogeneous, and dynamic natures that 
affect drug delivery transport. Nanoparticles, compared to small molecules drugs, are slow 
to diffuse away from the blood vessel. Thus, accurate means of measuring the distance 
from the blood vessels in three dimensions is a useful tool for researchers seeking to design 
penetrating drug carriers. In the end point colocalization analysis, separately administered 
doses were less likely to colocalize. However, we do not know how these doses affect each 
other. Still, the intravital data show the second dose had a larger percentage of signal 
overlap. With these data, we hypothesize that the first dose has more access to the tumor 
and the second dose may reach and collide with the accumulated concentration gradient 
of the first dose, inhibiting further penetration to new frontiers in the tumor environment. 
Future work can test this hypothesis with slight adjustments to the current methodology.
The xenograft models we used have limitations as previously stated. However, the point 
of this work was to gain additional understanding surrounding already established data 
found using xenograft models and to test additional tools that would also work in other 
models. The spatial and temporal extravasation dynamics observed may be bad news in 
the clinical setting by being unable to provide a consistent dose to the tumor or it could be 
good news by spreading the dose around eventually. Further research analyzing dependency 
between multiple doses should be performed.
Included work did not explore variability in carriers (challenges present in the carrier). 
Furthermore, there are treatment strategies that have been developed to overcome some 
of the barriers discovered in this work. We can test these strategies, such as making
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changes to the nanoparticle and the tumor environment, side-by-side while using additional 
experimental methods included in this work. Better understanding will also come from a 
new model of distribution in a human tumor that continues to resist current drug therapy. 
The information from these items of focus will provide valuable insight into the problems 
of intratumoral distribution of anticancer drugs and it will help other researchers design 
better drug therapies for solid tumors.
4.2 Future Work
There are two specific areas that may be interesting to pursue further. The first is specific 
analysis on the interdependence of multiple doses. More specifically, it will determine if the 
second dose is limited in distribution by the prior dose acting as a roadblock. The second 
area will use the models and methods developed thus far to test different nanoparticles 
characteristics or environmental treatments that seek to improve drug distribution in solid 
tumors. Both of these areas could benefit from computational models that could test 
or verify certain parameters for nanoparticles or tumors, but that will not be discussed 
herein [180].
4.2.1 R oadblock effect
Ours and other published data show that drug extravasation is heterogeneous, limited 
to certain regions of the tumor, and not penetrating far from blood vessels [85-87]. The 
majority of nanoparticle drug delivery data show high concentrations built up immediately 
adjacent to the tumor vessels [25, 105, 181]. Once this accumulation has taken place, 
the resulting decreased concentration gradient could hinder or serve as a roadblock to 
subsequent nanoparticle extravasations into the tumor.
As mentioned in Chapter 3, there was a clinical study that removed excess Doxil from 
blood two days after administration. The authors hypothesized further extravasation was 
limited. The excess drug particles were removed from blood circulation so as not to enter 
other organs. The small trial showed that toxicity was reduced and efficacy was not affected
[182]. On the other hand, a preclinical study showed that the liver could become saturated 
and lead to increased accumulation of Doxil in the tumor [183]. However, saturating normal 
liver tissue with drug is unacceptable for human patients. The same author later showed 
the need for adjustments in subsequent doses to minimize toxicity [184].
To explore the plausibility of a roadblock effect by previous doses, some accessible 
volumes were calculated through meta-analysis as a proof of concept. While many published 
imaging data show intense pockets of extravasation localized near the blood vessel, it is
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not known whether the signals are coming from particles located in void empty spaces 
(where there might be small rivulets or vesicles of free fluid), from those stuck in the 
ECM, or whether they are being taken up into cells. Some estimates of void spaces were 
calculated from SEM images of a pancreatic tumor [185]. However, some inaccuracy may be 
present due to shrinking or other artifacts from sample preparation for SEM. Exploratory 
calculations were made with particles ranging from 100 nm to 1 ^m (aggregation in the 
blood stream is highly possible) to fill void spaces represented by spheres with diameters 
ranging from 800 nm to 8.5 ^m. It was found only 1x10' -4% to 1x10-10% of an injected 
dose (50 mg/kg) would be needed to fill up some of the void spaces, making it a relevant 
investigation.
While the work in Chapter 3 was not able to quantitatively measure a roadblock effect, 
the intravital data showed the first dose penetrating into more unique areas than the second 
dose. Additional experiments are recommended to investigate the possibility of a roadblock 
effect. Simply administering two nanoparticle doses and comparing their unique fluorescence 
will not be sufficient to distinguish a diminished signal from any blocking effect versus a 
diminished signal from the later dose not having as much time to accumulate a strong signal. 
Instead, distributions will be well defined with reliable signals for a nanoparticle dose. 
Those distributions will be compared between groups with and without a prior blocking 
dose administered. The blocking dose of nanoparticles need not be fluorescent, but labeling 
would confirm the presence of the blocking dose and allow for further colocalization analysis. 
In situ real-time imaging would be beneficial to more easily detect any blocking effect as 
the entire administration period can be observed for individual blocking events (rather than 
just the accumulated events present at the end point).
4.2.2 N anoparticle and environm ental changes
The majority of research on biocompatibility and biodistribution of nanoparticles has 
been done with spherical nanoparticles [40,41]. This work adds some new methods for 
studying distribution, but is still limited only to spherical shapes. Additional work should 
be done with different shapes and surface properties.
New knowledge can be obtained by applying known methods that have been developed 
to improve intratumoral distribution. Of course these strategies have been studied before, 
but not in this human tumor model that is resistant to carrier penetration and not while 
being able to look at how multiple doses might distribute in relation to each other in three 
dimensions.
Specifically, methods that improve intratumoral distribution in solid tumors by affecting
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the extravasation and diffusivity of nanoparticles can be screened. Numerous researchers 
have investigated how different geometries and surface modifications affect intratumoral 
distribution [72,73,186,187]. Furthermore, a tumor’s environment plays a role in its ability 
to resist treatments. As not all solid tumors have the same characteristics, it will be 
necessary to learn how to change the tumor environment to be more favorable to drug 
carriers.
Table 4.1 shows the different strategies that will be implemented to screen methods 
that improve intratumoral distribution. The variables tested will be changes in the char­
acteristics of silica nanoparticles and the tumor environment. Specifically, changes to the 
size, shape, and surface chemistry of silica nanoparticles will be explored to see changes in 
penetration or diffusion rates. Changes to environmental characteristics will be effected with 
coadministration of iRGD, high arterial pressure, hyperthermia, paclitaxel, and collagenase. 
The analysis and controls will be simplified such that only one treatment strategy is either 
present or absent. For example, 30 nm, negatively charged, silica nanoparticles with a red 
fluorescent tag will be compared against 80 nm, negatively charged, silica nanoparticles with 
a green fluorescent tag. Appropriate controls should be considered to ensure the fluorescent 
intensity is compensated and comparable for the nanoparticles with different sizes. For 
simplicity of testing maximum possible effect, combination treatments, such as collagenase 
and hyaluronidase, would be administered together for one group and compared with mice 
that receive neither.
Silica nanoparticles will serve as the probe nanoparticles as they are relatively inexpen­
sive and easy to make batches with low polydispersity. A modified Stober synthesis will be 
used where tetraethoxysilane (TEOS) is added to a mixture of water and ammonium hy­
droxide in an ethanol solution and stirred for at least 6 h [194]. During this time, the TEOS 
will undergo hydrolysis and condense at nucleation sites to form the silica nanoparticles.
Table 4.1. Select strategies to improve distribution.
Effect Treatment/Formulation Model




Collagenase and hyaluronidase Mouse/Fibroid
Increase Extravasation iRGD Mouse/FibroidHyperthermia and high arterial pressure Fibroid
Increase accessible area Paclitaxel priming Mouse
References: [101,187-193]
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The characteristics of silica nanoparticles can also be easily modified and verified. Size can 
be controlled by choosing methanol or ethanol for the alcohol solvent and by adjusting molar 
ratios of ammonium hydroxide, water, and TEOS. Providing primary amine groups on the 
surface of the silica nanoparticles via condensation (3-aminopropyl)triethoxysilane (APTES) 
will give a positively charged surface and could even allow further functionalization (such as 
linking RITC and FITC via their isothiocyanate groups). Silica nanorods can be synthesized 
through the use of the surfactant cetyl trimethylammonium bromide (CTAB) [195]. The 
resulting mesoporous silica nanorods will be complimented with mesoporous spheres as a 
control for any effects due to porosity.
These are suggested methods of extending the current work by providing additional 
carriers characteristics for testing. These are still not representative of all possible carriers 
characteristics. Any type of carrier could be administered to the perfusate buffer for the 
uterine perfusion model. The spatiotemporal analysis methods are compatible with any 
drug carriers that provide unique signals for multiple doses.
From a different perspective, cancer can be considered as an organ with its own ecosys­
tem where disturbing the ecology may be an effective treatment method [126,196,197]. 
There is increased interest in causing a therapeutic effect or improving intratumoral distribu­
tion by changing the tumor environment [108]. These methods of changing the environment, 
along with some combination therapy, will be screened in the context of the included work.
It may be possible to try to increase permeability in the tumor with hyperthermia or with 
iRGD peptides, the latter having been classified as tumor penetrating peptides [190,191]. 
To test whether iRGD peptides can help extravasation, two typical examples (CRGDK and 
RPARPAR) will be examined [74]. A peptide concentration of 2 ^M will be administered at 
the same time as the nanoparticles [190]. It also may help to artificially increase the vascular 
pressure to slightly improve tumor extravasation [192,198]. Increasing the arterial pressure 
to 180 mmHg, to compensate for the high IFP, will be done by increasing the flow speed 
of the perfusion. Hyperthermia will be easily applied by adjusting the temperature of the 
incubator in which the uterus is perfused. Investigation will begin with the temperature of 
42 °C for a period of 1 hour. In order to reduce cell packing and allow more accessible area 
for extravasation and diffusion, the mice will be treated with a priming agent, paclitaxel, at 
a concentration of 40 mg/kg for a period of 24 h [193]. After 4 h, the probe nanoparticles will 
be administered via tail vein injection and after another 4 h the mice will be sacrificed and 
tumors harvested to ascertain the priming effect. Validation of sufficient perfusion of oxygen 
and nutrients will be of increased importance to verify cell death is a result of only paclitaxel
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treatment. Alternatively, other cytotoxic drugs may be tested that have a faster effect on 
clearing the accessible area for extravasation and diffusion of nanoparticles. Administration 
of hyaluronidase (30 kU/kg) and collagenase (2 mg/kg) will also help to clear a path for 
improved distribution of nanoparticles [188, 189]. However, in using hyaluronidase and 
collagenase, there are concerns that this treatment may increase the metastatic potential of 
a given cancer. The perfusate can be checked for any cellular components that may suggest 
the potential for migration.
Again, these are not novel treatment strategies related to improving distribution in 
the tumor environment. Rather, the purpose is to test already established strategies in 
combination with methods from the included work. How will these strategies fare in a 
clinical tumor dense in cells and fibrous content? Alternatively, do these treatment strategies 
affect the extravasation dynamics and possible interdependence of multiple doses discovered 
in this work? Answers to these questions will also help explain why distribution in solid 
tumors is so challenging.
It is anticipated that the presence of some treatment methods will increase drug con­
centration adjacent to the tumor vasculature while other methods will aid distribution 
throughout the tumor. If extravasation and distribution can be improved in dense fibroids, 
that represent a severe case of drug delivery resistance, we suspect that many other desmo- 
plastic, clinical tumors will also respond positively.
Some methods for improving intratumoral distribution are questionable in terms of 
safety. Environmental treatments like high arterial pressure, collagenase/hyaluronidase, and 
hyperthermia could not be tested for efficacy in humans without a proven safety record. As 
mentioned previously, the ex vivo uterine perfusion model has an advantage to be able to 
test aggressive strategies without concern for toxicity or pain caused to a living organism. 
This model will not be able to show if a method is safe as it excludes many other organs 
that can be affected by treatments. It can, however, show if it is unsafe. Still, the focus 
of this project would be testing these methods for efficacy (in terms of drug distribution), 
not safety. If the methods are shown to be effective, further studies with other models 
can investigate means to ensure or improve their safety. The methods and models in this 
project are meant to supplement existing strategies to bring a more complete vetting process 
of therapies before testing in human patients.
4.3 Revolution: A Thought-Provoking Detour
A lot has been discovered and accomplished with nanotechnology research as applied to 
cancer therapies. However, right now we are at an asymptote or an inflection point and we
54
may need a paradigm shift to ensure progress in the positive direction.
In 1962, Thomas Kuhn wrote a book about paradigms and scientific revolution [199]. 
Right now we are in a state of collecting knowledge with only slow improvements in targeted 
drug delivery occurring. It is possible that a shift of paradigm can be a catalyst for a massive 
leap forward in targeted drug delivery.
It is true that there are new targeting moieties and new technologies, but progress is 
in a seemingly slow evolution and the fight against cancer needs a revolution. This is 
not discrediting the value of basic science; useful tools will find meaningful applications. 
Nanotechnology is an incredibly useful and versatile tool. For example, there are more 
polymeric therapeutics approved for various other diseases [200,201]. However, it has not 
proven to be a pancea for cancer treatment—that would be extremely unlikely for this 
collection of diverse diseases.
As an observer, the conclusion drawn is that passive delivery to solid tumors have a chal­
lenge in thoroughly treating solid tumors. They can do better than standard chemotherapy 
(or else they would not be approved), but they still have limitations. The limitations also 
apply to carriers that have active targeting groups. If their target is within the solid tumor, 
passive carriers will have difficulties in exclusively and thoroughly hitting it. Thus, a change 
of paradigm is needed for nanomedicine: to recognized its weaknesses and take advantage of 
them. For example, they accumulate in the periphery and are often taken up by the MPS. 
These two characteristics, initially perceived as weaknesses, can become strengths in drug 
carrier design. They will have more success reaching targets in or near the blood vessels. 
Furthermore, it is suggested that activating T cells in the blood stream will be easier to 
access and they can act more like a magic bullet that can move about, detect, and ensure 
destruction.
4.3.1 Target th e  periphery
The market success of drug carriers has occurred mostly when designs have targets in 
the blood or vessels. This concept relates to the included work in that hormone therapies 
work well in the dense fibroids because they do not have to enter the tumor, they only have 
to reach action sites upstream that influence the growth of the fibroids. Chances for success 
may be improved by designing carriers that only have to reach the tumor periphery to be 
effective. In this position, the therapy can still alter resources feeding tumor growth, change 
the tumor's environment, or recruit some of the body's natural defense mechanisms.
The most prevalent example of targeting the environment is through the use of antian- 
giogenic therapies to starve the tumor of needed resources. Further evidence for the idea
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of targeting the environment comes in a study using aromatase inhibitors in combination 
with a biophosphonate drug that inhibits bone loss and reduces the risk of metastasis in 
the bone [202]. The biophosphonate drug leads to bone or environment remodeling while 
the aromatase inhibitor starves the breast cancer cells of the estrogen needed for growth.
A physical attack such as hyperthermia can also modify the tumor environment. As 
an example, G. von Maltzahn et al. used one nanoparticle system to prepare the tumor 
environment for a second nanoparticle system [203]. They called this influence communica­
tion between the two nanoparticle systems. Essentially, they use one system to modify the 
tumor environment such that the second system can recognize it. They first confirmed that 
they can localize PEGylated gold nanorods to the tumor. They then used near infrared 
radiation to stimulate the gold nanoparticles and cause hypothermia and vascular damage in 
the tumor area. They were able to show tumor localization of nanoparticle by fluorescence 
and confirmed this using a temperature map showing hyperthermia only in the tumor area. 
They then showed that this vascular damage led to coagulation in the area of the tumor. 
They used staining to show increased levels of fibrinogen in heat treated tumors. The second 
nanoparticle system had receptors for fibrin or factor XIII. This communication between 
the nanoparticle systems increases accumulation in the tumor environment [203].
This method could also communicate with the immune system. Attacking the envi­
ronment has the potential to not only disrupt the normally supportive tumor ecology, but 
also attract the immune system. Furthermore, damage done in the environment will also 
produce some damage-associated molecular pattern (DAMP) molecules. These DAMPs are 
cytokines that can help trigger an immune response. Activation of platelets, the coagulation 
cascade, and the complement cascade can respectively lead to cytokine release, fibrin, and 
both C3a and C5a, which all play a role in recruiting the immune system [204]. Inflammation 
and scarring through a foreign body response can prevent cancer in some situations [205].
From one perspective, it is considered a failure when intravenous injections of a thera­
peutic agent do not reach the entirety of the tumor and only accumulate at the periphery. 
However, from another perspective, this localization at the periphery of the tumor is the 
perfect location to attract the immune system to the tumor. It may be possible to cause 
a chain of events that will make it easier for the immune system to be able to detect and 
follow the trail that leads it to attack the cancer.
4.3.2 A ctivate th e  im m une system
Inanimate carriers of drug are unreliable when they rely on passive delivery. They are at 
the whim of the forces that act upon them and cannot truly home in on tumor targets. The
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most representative magic bullet is found in the body’s own immune system. Paul Ehrlich 
himself stated that cancer would be more prevalent if not for the immune system [206]. 
It has both mobility and specificity. Immune cells can follow chemical gradients and have 
specificity with antibodies and cell receptors.
The immune system is a revolution in the fight against cancer, a leap forward in technol­
ogy, and a highly evolved weapon for pathogen rejection. It is important to have a therapy 
incorporate the natural and robust immune defenses of the body as they are specialized 
yet versatile. Furthermore, it will take many years before a nanoparticle synthesized in the 
laboratory equals the sophistication of a lymphocyte. Lymphocytes are able to multiply, 
migrate into tissues, produce their own toxic agents, and have other qualities that make 
them superior to nanoparticles in killing cancer cells. Even when cancer has been able to 
escape the immune system, therapies that intervene and boost the immune system have 
had success in causing tumor rejection.
One of the hallmarks of tumor escape from the immune system is its ability to supress 
the immune system. CD25 positive regulatory T cells can be reprogrammed to create 
tolerance for cancer, thereby allowing tumor growth. IL-2 has been shown to stop Treg 
immunosuppression and leads to cancer rejection [207]. Onizuka et al. showed that ad­
ministration and binding of monoclonal antibodies to the IL-2 receptor a  on these cells 
would prevent clonal expansion and reduce the number of regulatory T cells that support 
the cancer growth [208]. They found there was a time frame within which the monoclonal 
antibody had to be administered to result in tumor rejection by the immune system. They 
also performed controls by checking the effects of monoclonal antibodies for CD4+ and 
CD8+ T cells. When the CD8+ T cells were also prevented from expanding, the tumors 
were not rejected. They also tested the secondary response of treated mice. After successful 
immune rejection of the tumor following anti-CD25 monoclonal antibody administration, 
they transplanted more cancer cells and saw that they had acquired cancer resistance [208].
Immunobioengineering is a relatively new term to describe the engineering of bioma­
terials to interact with the immune system. Initially, biomaterials started out as simply 
the medical application of metals and other materials that were not designed to go into 
the body. It evolved to a need for biocompatibility to where the material is designed to 
be inert so it will have an acceptable host response and still be able to function. This is 
done by carefully selecting the material and by changing the bulk chemistry and surface 
properties at the interface with the body. It is now evolving to where the material should 
no longer be inert but interact with the biology and should cause a beneficial response to
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boost function [209]. Drug therapies have undergone a similar evolution. As mentioned in 
Chapter 1, Cremephor EL is an unsophisticated drug excipient used to solubilize paclitaxel 
that often results in unacceptable host responses. To address that issue, many drug carriers 
have been designed to offer stealth delivery of the drug. With recent progress, there are 
also carrier therapies that interact with the immune system and cause a beneficial response 
rather than trying to hide from the body [210].
Looking at the success of Keytruda, Opdivo, and Yervoy shows we can directly interact 
with the immune cells to promote tumor rejection. The difference between CTLA-4 and 
PD-1 antibodies is that the CTLA-4 blockade activates proliferation of T cells while PD-1 
primarily blocks the adaptive immune resistance developed by the tumor [211,212]. Thus, 
PD-1 antibodies make the T cells more effective in the intratumoral environment rather 
than boosting general T cell proliferation and antigen-specific immunity. PD-1 also results 
in higher response rates and reduced toxicity [213]. These antibody therapies work so well 
because they do not have to physically distribute into the tumor mass, but they act on 
immune cells that can migrate.
Beyond antibodies (a major component of the immune system), it has been shown 
that polymers can interact with the immune response when present in the tumor environ­
ment [214]. N-(2-Hydroxypropyl)methacrylamide (HPMA) can cause immunostimulation 
to the point of reaching cancer resistance. Mrkvan et al. treated mice with tumors using 
HPMA-doxorubicin conjugates. Any mice that survived were saved and showed resistance to 
another inoculation of cancer cells that would otherwise be lethal [215]. Polymers have also 
been expressly designed to interact with dendritic cells to aid in activating T cells [216]. 
Nanoparticles and polymers can prime the immune system as they interact with it by 
containing Tumor Associated Antigens (TAAs) [217-219]. By involving the immune system 
in fighting the tumor, it brings a component capable of adapting and seeking after evasive 
cancer cells. However, care must be taken to thoroughly analyze the interactions with the 
immune system to avoid unintended immunosuppressive effects that have been shown to 
actually promote tumor growth [220-223].
4.3 .3  C hallenges
To achieve tumor rejection by focusing treatment on the environment and immune 
system, there are certain challenges this approach must test. There must be a change 
in the environment by physical placement of therapeutics or by actions that cause a host 
response. There must be a recruitment of cellular components of the immune system and a 
reversal of immunosuppression. This tumor rejection must occur in an immunocompetent
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model where the tumor has been immunoedited.
The perception of a patient's quality of life has changed over the decades with advanced 
treatments, but toleration still requires mustered courage [224,225]. Sometimes, cancer 
drugs can only temporarily relieve the pain and other symptoms of the tumor and do 
so at the cost of other side effects (including pain). Current anticancer treatments are 
used because it balances the risk to benefit ratio. A minimally effective treatment is 
allowed because it does not increase the likelihood of death. In this perspective, some 
chemotherapies could be reminiscent of the abandoned neurological procedure of lobotomies: 
the body is damaged in an attempt to destroy the disease.
However, immunotherapy has the same challenge of balancing the risk to benefit ratio. 
Immunotherapy (such as CAR T cell therapy) can have impressive clinical outcomes, but 
that potency carries over to cases of severe toxicity [226,227]. Thus, it may be helpful to 
design fail-safe mechanisms into any type of immunotherapy [67].
Treatment focused on both the environment and immune system is a recommended 
paradigm shift. Some drug carrier technologies have been found to cause biocompatibility 
problems that could be beneficial if controlled and localized in the tumor environment. 
Furthermore, most chemotherapeutic drugs reduce the white blood cell count when it would 
be more beneficial to boost the activity of the immune system against the cancer (and also 
prevent any other opportunistic disease).
4.4 Conclusion
This project uses new tools to explore the role of the tumor environment in drug 
distribution. The environment may block or divert different doses of drug particles to 
limited areas of the tumor. Understanding these transport barriers is crucial to translating 
targeted therapies from the research bench to the patient—new models will need to be 
developed to make up for the shortcomings of the mouse model. The uterine fibroid model 
provides a challenging model for drug delivery and can be helpful in investigating the barriers 
to drug transport in solid tumors. There is risk for failure in developing new models, but 
the potential reward is substantial as it might change the way cancer medicines are vetted 
before entering clinical trials. The spatiotemporal analysis brings additional information by 
including two more dimensions: the third axis in space and the dimension of time. While 
this research builds upon previous work investigating drug transport in tumors, it brings 
a new perspective looking at dynamics between multiple doses. If some of the barriers 
cannot be fully overcome, better characterizing the factors that influence distribution will 
be helpful for predicting successful drug delivery for certain tumor types. Furthermore,
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we may be able to adapt and have more success hitting peripheral targets that can have 
downstream effects on cancer.
APPENDIX
CHALLENGES IN TRANSLATION
D. L. Stirland, J. W. Nichols, S. Miura, and Y. H. Bae, Mind the gap: A survey of how cancer 
drug carriers are susceptible to the gap between research and practice, J. Control. Release, 
vol. 172, no. 3, pp. 10451064, 2013. http://dx.doi.org/10.1016Zj.jconrel.2013.09.026. 
Included with kind permission of Elsevier and the coauthors.
A.1 Preamble
To better understand the translational difficulties of these drug carriers, a small selection 
of drug carriers designed to improve drug delivery is surveyed in the included article. These 
carriers do not represent the latest advances in technology. Older or established carriers were 
chosen because it often takes years for clinical data to be released [228]. While limited in 
scope, it shows some of the challenges that drug carriers face when trying to achieve active 
targeting. It also shows that antibody therapeutics are not immune to these challenges. 
The safety and efficacy data from preclinical studies are explored and compared with any 
available clinical data in an attempt to determine what may influence successful treatment 
of clinical tumors.
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A B S T R A C T
With countless research papers using preclinical models and showing the superiority of nanoparticle design over 
current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug 
carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for 
Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01.While not compre­
hensive, itcovers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemother­
apy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and 
efficacy between the animal and human studies. Discussion is provided to suggest w hat might be causing the gap. 
Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
© 2013 Elsevier B.V. All rights reserved.
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1. Introduction
Nanotechnology is a remarkable example of human achievement. In 
only a few decades of concerted effort, our knowledge of the laws of 
physics and chemistry has expanded to the point that we are able to ma­
nipulate matter at nearly the atomic scale to create complex structures 
with unique and potentially revolutionary functions. Nanotechnology 
describes the ability to manipulate matter at the scale of 1-100 nm in 
order to create and use structures with new, unique and useful proper­
ties [1]. This technology has far-reaching implications for improving 
the human condition, including more compact and powerful microchips 
and processors, more robust agriculture, cleaner, more efficient fuels, 
and better health. With this promise in mind, billions of dollars have 
been invested in nanotechnology research, and in some fields the return 
of that investment is starting to be realized [2]. However, as with most 
new technologies, progress has been uneven and the nature of future ad­
vancements uncertain.
Nanomedicine is the application of nanotechnology to improve the 
health ofindividuals through better diagnoses and treatments. However, 
nanomedicine is a very broad term, including applications in sensors, tis­
sue engineering, imaging agents and other diagnostics, lab-on-a-chip de­
vices, therapeutic agents, and drug carriers. Its usefulness has been 
diluted by a degree of irrational exuberance that has permeated the dis­
cussion of nanotechnology over the last few decades [2-12]. Further­
more, certain technologies such as liposomes, polymer therapeutics, 
and protein therapeutics have existed long before "nanotechnology” 
was introduced. Thus, when considering drug delivery technology, 
particularly for anti-cancer therapeutics, it may be useful to abandon 
the term  nanomedicine and instead adopt less loaded descriptors. This 
review will refer to these technologies as nano-sized drug carriers or 
simply drug carriers which are injectable into the blood stream, and 
focus on those drug carriers which were designed to provide better 
efficacy and lower toxicity for cancer therapeutics. The impact of drug 
carriers has in some ways been difficult to judge; they can be quite ver­
satile, allowing researchers the flexibility to design delivery strategies 
specific to environmental challenges posed by the body. On the other 
hand, the more complex designs have thus far had little impact on 
clinical therapies beyond merely adding the rhetoric of targeted drug 
delivery to somewhat conventional therapies.
Cancer has been an area of particular interest for nano-sized drug 
carriers due to the enhanced permeability and retention (EPR) effect 
which is thought to provide them  w ith significant therapeutic advan­
tages over small molecule chemotherapy drugs [13,14]. EPR refers to 
the tendency for nanoparticles and macromolecules to accumulate in 
tumors more, in comparison with the control solution formulations, 
due to the disorganized and ill-formed blood vessels that contain 
large fenestrae through which these large molecules can pass. Retention 
is increased by the dysfunctional lymph vessels which significantly hin­
der drainage from the tum or interstitial space. EPR was first discovered 
in the 1980s by Dr. Hiroshi Maeda and has subsequently become a key
concept in the field of cancer drug delivery [15,16]. According to the EPR 
hypothesis, nano-sized drug carriers should enjoy a natural advantage 
over traditional therapies as the increased drug concentration within 
a tum or should provide improved efficacy, and shielding of the drug 
from the rest of the body can provide reduced toxicity. This has gener­
ally been the case in the animal models used for preclinical studies 
[17-20], but the improved efficacy promised by the EPR effect has 
often failed to materialize in clinical settings [21,22].
The apparent gap between preclinical animal models and the clinical 
tumors encountered by clinicians is of great interest if drug carriers are to 
make a significant impact at the core of cancer therapy rather than just at 
the margins. Oncology drugs (including drug carrier technologies) suffer 
a 95% failure rate after entering human trials. Most of these failures occur 
in the efficacy phases and can cost hundreds of millions of dollars. A bet­
ter understanding of the shortcomings of commonly used models could 
thus potentially save billions of dollars in wasted effort.
This review presents a cross section of some of the most important 
formulation strategies being pursued by researchers including liposomal 
formulations, micelles, linear polymers and protein carriers. Each of 
these formulations is unique in the way it changes the interactions be­
tween the drug and body. Some are designed with a half-life of several 
days, leaving a portion to circulate for weeks in the blood, with the intent 
to slowly accumulate in the tumor via EPR. Others simply attem pt to im­
prove the solubility of the drug cargo without harmful effects. Still others 
seek to actively target tumors by attaching groups that participate in li­
gand binding events with either cancer cell surface proteins or other 
targets of interest. Most of these formulations drastically impact how 
the drug and body interact, including starkly different pharmacokinetic 
parameters such as half-life, area under the curve, distribution, and clear­
ance. Curiously, however, the impact of these formulations on efficacy is 
rarely significant outside the laboratory ( Fig. 1).
Fig. 1. Summary of phase III perform ance of selected drug carrier therapies com pared to 
standard treatm ent. PFS: progression free survival; OS: overall survival; ORR: overall re­
sponse rate. Data gathered from  phase III trials [21,22,69,106,119,122,183-185].
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Comparing human tumors to animal models can be a difficult game. 
In addition to the obvious differences in size, lifespan, physiology and 
metabolism between humans and mice which most commonly serve 
as models, the cancers themselves are significantly different from their 
naturally derived counterparts. Model cancers are grown artificially, 
from single cell lines, and in a matter of weeks, whereas human tumors 
emerge from complex tissues under immune surveillance over years. To 
make matters worse, preclinical and clinical studies rarely use the same 
benchmarks or endpoints. Preclinical studies often make use of mea­
surements not available to the clinician, such as tumor diameter. 
Phase III efficacy studies generally use the best available therapy as a 
comparator, which often includes combinational therapies. Preclinical 
studies, on the other hand, do not always use the best available thera­
pies as comparators but rather single compound formulations of the 
same drug contained in the carrier.
Given these differences, it may be reasonable to ask what can realisti­
cally be expected from human trials after successful animal trials, and are 
new drug formulations to treat human patients or mice being designed? 
Some of these discrepancies are beyond our control, but others can be 
ameliorated by concerted effort and greater global communication be­
tween the research and clinical communities as well as relevant regulato­
ry agencies. Following the history of these drugs from the benchtop to the 
bedside provides some insight into where the shortcomings are, whether 
in the models used or in the discussions about them.
2. Doxorubicin
Doxorubicin is an anthracycline topoisomerase inhibitor. It was first 
isolated from culture medium of Streptomycespeucetius var. caesius by F. 
Arcamone from Farmitalia Research Laboratories in 1967 [23]. The anti­
cancer activity of doxorubicin is given by multiple mechanisms [24,25]. 
Doxorubicin intercalates between base pairs in the DNA helix, and 
inhibits the binding of DNA and RNA polymerase, resulting in the 
prevention of DNA replication and protein synthesis. Specifically, DNA 
intercalated with doxorubicin stabilizes the topoisomerase II-DNA 
complex during DNA replication, and prevents the ligation of the 
nucleotide strand after double-strand breakage. Since its approval, doxo­
rubicin has been widely used to treat various malignancies (acute 
lymphoblastic leukemia, acute myelogenous leukemia, breast cancer, gas­
tric cancer, Hodgkin's lymphoma, neuroblastoma, non-Hodgkin's lym­
phoma, ovarian cancer, small cell lung cancer, soft tissue and bone 
sarcomas, thyroid cancer, transitional cell bladder cancer, Wilms' tumor 
and others) [26-28]. However, the use of doxorubicin has been limited 
by toxicities such as hematopoietic suppression, nausea, vomiting, apo­
plexy, alopecia and especially cardiotoxicity, which is a fatal adverse ef­
fect. Cardiotoxicity is characterized by a broad spectrum of symptoms 
ranging from asymptomatic electrocardiography (ECG)-changes, to 
pericarditis and decompensated cardiomyopathy. The probability of 
developing cardiotoxicity is largely dose-dependent. The usual dosage 
of doxorubicin is 60-75 mg/m2 every 3 weeks. Cardiomyopathy and 
congestive heart failure occur most frequently above a cumulative 
dose of 450-550 mg/m2 doxorubicin [29]. The most common cause of 
doxorubicin-related cardiotoxicity is oxidative stress. Doxorubicin 
produces oxygen free radical resulting in lipid peroxidation of cell 
membrane lipids [30-33]. The specificity of the oxidative stress to the 
cardiac cells could be due to relatively low levels of antioxidant en­
zymes in heart [34].
2.1. Doxil®/Caelyx®
Doxil® [US], or Caelyx® [outside US], was the first FDA-approved 
nano-sized drug carrier formulation [35].A sseen in ( Fig. 2 ), the doxoru­
bicin molecules are encapsulated in a bilayer vesicle oflipids known as a 
liposome. This liposome is coated by a layer of poly(ethylene glycol) 
(PEG) to limit uptake by the mononuclear phagocyte system (MPS). 
Doxil® was developed as pegylated liposomal doxorubicin (PLD) to
PEG coating
Aqueous core with 
entrapped doxorubicin HCI
Liposomal bilayer
Fig. 2. Pegylated liposomal doxorubicin (Doxil®/Caelyx®). Particle size is 80-90  nm. 
Developed by Johnson and Johnson and approved in 1995 for treating AIDS-related 
Kaposi's sarcoma. So far, th e  indications have been extended to ovarian cancer and m ulti­
ple myeloma. Illustration m odified from FDA label.
enhance efficacy and decrease toxicity of doxorubicin by virtue of its 
size (80-90 nm), pegylated surface, and stability in the blood, which 
allow prolonged blood circulation time considered necessary for high 
accumulation of doxorubicin in tumors [36].
2.1.1. Preclinical studies
Doxorubicin shows biphasic curves ofplasma concentration after in­
travenous (i.v.) injection. First phase accounts for rapid distribution 
with a half-life of 5-10 min and second phase is an elimination with a 
half-life of 30 ±  8 h [37]. In contrast to the rapid elimination of free 
doxorubicin from blood circulation, Doxil maintains a significantly 
higher blood concentration than free doxorubicin for several days in 
various animals (rabbit, rat, and dog) [38-42]. The area under the 
plasma concentration-time curve (AUC) of doxorubicin in animals 
treated with Doxil is at least 60 times greater than that treated with 
free doxorubicin. The distribution volume of Doxil is close to the blood 
volume in the body. Clearance curves of total doxorubicin and doxoru­
bicin entrapped in pegylated liposomes are superimposable [38,43]. 
This indicates that the leakage ofdoxorubicin from pegylated liposomes 
while circulating is negligibly small.
A number of studies have investigated the tissue distribution of doxo­
rubicin after i.v. injection of Doxil. Doxil treatment shows more 
accumulation of doxorubicin in various xenograft tumors (e.g., J6456 lym­
phoma [44], PC-3 human prostate adenocarcinoma [45], A375 human 
melanoma [46], N87 human gastric carcinoma [46], and C26 murine 
colon carcinoma [38]) than free doxorubicin treatment. Doxorubicin ac­
cumulation in the liver and spleen by Doxil is also increased [45,46].
The most important advantage of PLD is that doxorubicin accumula­
tion in the heart was drastically reduced compared to free doxorubicin 
[47]. Comparative studies in rats, rabbits and dogs demonstrated the 
decrease in cardiotoxicity [37,48].
Several efficacy studies using various tum or xenograft mice ( e.g., 
C-26 m urine colon carcinoma [49], PC-3 hum an prostate carcinoma 
[45], AsPC-1 hum an pancreatic carcinoma [50], HEY Human Ovarian 
Carcinoma [51], 3LL Human Lewis lung, carcinoma, [52], BT474 
breast carcinoma [52] and MCF-7 breast adenocarcinoma [52])revealed 
significant efficacy gains of Doxil over free doxorubicin [53,54]. Studies 
using Lewis lung xenografts and breast cancer xenografts showed that 
the efficacy of Doxil at 2 mg/kg was approximately equivalent to that 
of doxorubicin at 4 -9  mg/kg [52], indicating a 2 to 4.5-fold increase in 
potency of Doxil compared w ith free doxorubicin.
2.1.2. Clinical studies
The first clinical trial of Doxil in patients with broad types of cancer 
(breast cancer, non-small cell lung cancer, ovarian cancer, mesothelio­
ma, soft tissue sarcoma, and pancreatic cancer) was conducted from 
1991 to 1994 in Jerusalem, and showed first proof of passive targeting 
based on the EPR effect in humans after intravenous administration 
[55]. Since then, a huge number of clinical studies have been conducted 
in various cancers: mainly AIDS-related Kaposi's sarcoma (ARKS), ovar­
ian cancer, breast cancer, multiple myeloma and soft tissue sarcoma.
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Pharmacokinetic results are summarized in a review article by 
Gabizon et al. [39]. Doxil has significantly longer half-life than that of 
free doxorubicin. Surprisingly, the half-life found in clinical studies of 
~45 h is even longer than that found in rodents and dogs of ~20 h and 
~30 h, respectively.
Tissue distribution has also been studied from the first clinical trials. 
All results reveal that Doxil had a higher accumulation in the tumor 
compared to the adjacent, normal tissues as well as the tum or treated 
with free doxorubicin [55-58]. There is a tissue distribution study 
based on the use of 111In-DTPA labeled, drug free, pegylated liposomes 
of identical lipid composition to Doxil [36]. Tumors were visualized in 
fifteen of seventeen patients with breast, head and neck, bronchus, gli­
oma and cervix cancer by gamma camera. Various normalized levels of 
accumulation (33% of injected dose/kg (ID/kg) in head and neck cancer, 
18.3% ID/kg in lung cancer and 5.3% ID/kg in breast cancer) were detect­
ed. However, less than 5% ID was in a tum or as a whole due to small 
sizes of the solid tumors while a significant accumulation in other 
organs (liver, spleen and bone marrow) was detected.
Doxil shows a vastly different adverse-effect profile from that of free 
doxorubicin. These profiles are well summarized in review articles 
[59,60]. While many toxicities induced by doxorubicin, as represented 
by cardiotoxicity, were dramatically decreased [61,62], overall mucocu­
taneous toxicity was increased. Palmer-planter erythrodysesthesia 
(PPE) is particularly recognized as dose limiting toxicity.
The efficacy of Doxil has been extensively summarized in many arti­
cles and book chapters [63,64]. Doxil showed better efficacy than conven­
tional single or combinatory therapies in several cancers: bleomycin and 
vincristine [65,66], paclitaxel [67] and highly active antiretroviral therapy 
[68] in ARKS, as well as topotecan in recurrent ovarian cancer [69,70]. On 
the other hand, Doxil showed equivalent efficacy with reduced toxicity to 
free doxorubicin in metastatic breast cancer [22] and multiple myeloma 
[71], despite prolonged blood circulating time and improved accumula­
tion in tumors (see Table 1).
In summary, Doxil improved the toxicity profile owing to its different 
pharmacokinetics and biodistribution from those of free doxorubicin; 
however, Doxil introduced other toxicities like PPE. Unlike preclinical re­
sults, Doxil has yet to show improvement in efficacy when compared 
with free doxorubicin. For the patient, Doxil absolutely has an advantage 
compared with conventional therapy due to reduced toxicity. Still, there 
seems to be an unknown gap in efficacy between preclinical and clinical 
studies.
2.2. PK1/FCE 28068
PK1 (FCE 28068) (Fig. 3) was the first drug-polymer conjugate to 
enter clinical trials. Doxorubicin is conjugated with a synthetic N-(2-
Fig. 3. PK1/FCE 28068. a =  96.1%, b =  3.9%. Particle size is around 8 nm. Developed by 
Pharmacia w hich m erged w ith  Pfizer [88].
hydroxypropyl)methacrylamide (HPMA) copolymer via Gly-Phe-Leu- 
Gly peptidyl linker designed to degrade by thiol-dependent lysosomal 
protease [72,73] and forms a unimolecular micelle in aqueous solution
Table 1
Summary of clinical efficacy.






Characteristics PLD1 BV PLD1 BV PLD1 PTX PLD1 HAART PLD2 TPN PLD2 DOX DVd VAd
No. of patients 121 120 133 125 37 36 13 15 239 235 254 255 97 95
CR (%) 6.0 1.0 1.0 0.0 5.0 8.0 31.0 13.0 3.8 4.7 - - 3.1 0.0
PR (%) 53.0 22.0 45.0 25.0 41.0 47.0 46.0 7.0 15.9 12.3 - - 41.3 41.1
OR (CR +  PR, %) 59.0 23.0 46.0 25.0 46.0 55.0 - - 19.7 17.0 33.0 38.0 44.4 41.1
Stable (%) 38.0 68.0 53.0 67.0 32.0 25.0 - - 32.2 40.4 25.0 25.0 39.2 48.4
Progressive (%) 0.0 4.0 2.0 8.0 3.0 3.0 - - 48.1 42.6 18.0 11.0 2.1 0.0
Not assessable (%) 3.0 5.0 0.0 0.0 24.0 17.0 - - - - 18.0 21.0 14.4 10.5
PFS (m onths) - - - - 12.2 17.5 - - 3.8 4.0 6.9 7.8 78%* 76%*
OS (m onths) 5.3 5.3 - - - 53.6 - - 14.0 13.2 21.0 22.0 88%* 85%*
Ref. [64] [63] [65] [66] [67] [20] [69]
CR: Complete response; PR: Partial response; OR: Overall response; PFS: Progression free survival; OS: Overall survival; ARKS: AIDS-related Kaposi's sarcoma; PLD1: Pegylated liposomal 
doxorubicin (20 m g/m 2); PLD2: Pegylated liposomal doxorubicin (50 m g/m 2); BV: bleomycin (15 IU/m2) and vincristine (2 m g); ABV: doxorubicin (20 m g/m 2), bleomycin (10 m g/m 2) 
and vincristine (1 mg); PTX: Paclitaxel (100 m g/m 2); HAART: highly active antiretroviral therapy; TPN: Topotecan (1.5 m g/m 2); DOX: Doxorubicin (60 m g/m 2); DVd: pegylated liposo­
mal doxorubicin (40 m g/m 2), vincristine (1.4 m g/m 2; maximum, 2.0 mg) and reduced-dose dexam ethasone (40 mg); VAd: vincristine (0.4 mg) doxorubicin (9 m g/m 2) and reduced- 
dose dexam ethasone (40 mg); ‘- 'n o t  available; ‘*' 1 year PFS o r OS ra te [22,65-69,71].
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with a diameter of around 8 nm [74,75]. HPMA is non-biodegradable 
and essentially nontoxic in the rat, even a t doses of 30 g/kg [72]. Its 
hydrophobicitylimits MPS sequestration and its relatively high molecu- 
larw eight (~20-30 kDa) allows it to avoid renal elimination [74]. These 
features allow prolonged blood circulation time resulting in high accu­
mulation in tumors. Furthermore, the high molecular w eight prevents 
diffusion across the membrane, restricting cellular uptake to endocytic 
pathways and facilitates the cleavage of the linker and the release of 
doxorubicin in endosomes. Additionally, PK1 has been developed to 
overcome the resistance due to P-glycoprotein overexpression based 
on contributions of the endocytic (pinocytic) cellular uptake and the 
controlled release in the endosome. The in vitro results using A2780 
resistant hum an ovarian carcinoma cell line showed no induction of 
MDR1 gene by PK1 and indicates th a t PK1 can avoid excretion by 
P-glycoprotein [76-78].
22.1. Preclinical studies
Since doxorubicin is conjugated w ith HPMA, free doxorubicin is not 
detected in plasma and tissues after administration ofPK1.The pharma­
cokinetics study of PK1 using mice showed the half-life of PK1 was ap­
proximately 15 times longer than that of the free drug in mice [79].
Consistent with prolonged blood circulation time, several studies re­
veal relatively high accumulation of PK1 in xenograft tumors in mice 
[80-85]. PK1 showed 17-77 times higher accumulation in B16FIO mela­
nomas in mice compared w ith free doxorubicin [80]. The correlation be­
tween molecular weight of HPMA and tumor accumulation was studied 
as well [82,83]. Higher molecular weight allows longer blood circulating 
time and higher accumulation in the tumor, liver and spleen. The molec­
ular weight of PK1 is correlated with high tumor accumulation and low 
accumulation in other tissues. In a study using A2780 human ovarian car­
cinoma in mice, PK1 showed 45-250 times higher accumulation in the 
tumor than that in the other tissues (liver, kidney, lung, spleen, and 
heart) [81]. Remarkably, the accumulation of PK1 in normal tissues was 
6-50 times lower than that of free doxorubicin over 30 days.
Due to decreased distribution ofPK1 in normal tissues, PK1 signifi­
cantly improves the doxorubicin toxicity profile [85,86]. Regarding 
cardiotoxicity, ra t models given free doxorubicin or the mixture of free 
doxorubicin and HPMA showed decreased cardiac output and heart 
rate, while rats given PK1 showed no significant change even in histo­
logical examination [85].
The efficacy studies of PK1 have been conducted using various ascites 
tumor models: (L1210 murine lymphocytic leukemia, B16F10 murine 
melanoma, Walker sarcoma, P388 murine leukemia, M5076 murine 
reticulum cell sarcoma, LS174T human colon adenocarcinoma, and 
A2780 multidrug resistant human ovarian carcinoma [19,72,81,84]). In 
all models, PK1 demonstrated greater efficacy compared to free doxorubi­
cin. Moreover, PK1 was effective in both the sensitive and drug resistant 
A2780 xenograft models, decreasing the tumor size to 3.5 and 5.6% of 
the initial size, whereas free doxorubicin was effective in only the 
sensitive model and decreased tumor size by about 33.3% [81,84]. In addi­
tion to avoiding excretion by P-glycoprotein, the result was partially 
accounted for by decreasing the permeability ofblood vessels and creating 
a more homogeneous drug distribution. Generally, doxorubicin increases 
the permeability of blood vessels by up-regulation of the VEGF gene and 
enhances the accumulation in the same location. This results in heteroge­
neous distribution of doxorubicin in a tumor. In contrast, PK1 decreases 
the permeability of blood vessels by down-regulation of VEGF gene and 
prevents excess accumulation in dead cells. This resulted in a more homo­
geneous distribution of nanoparticles in murine tumors [81,84].
22.2. Clinical studies
Phase I and II clinical studies w ere conducted in thirty-six and sixty- 
two patients w ith non-small cell lung cancer (NSCLC), colorectal cancer, 
and breast cancer in the United Kingdom [87,88].
Pharmacokinetic results showed a profile similar to that of preclini- 
cal studies. Blood circulating time was prolonged in PK1; the
distribution half-life was 1.8-3.0 h while free doxorubicin was only sev­
eral minutes.
Tissue distribution was also examined using the 131I-labeled analog 
for gamma camera imaging. Minimal accumulation of PK1 in the liver, 
kidney, and tum or w as observed after 24 h. Only six patients showed 
accumulation in the tum or in phase I studies [87] and there was no 
evidence of tumor accumulation in phase II studies [88].
PK1 showed no polymer-related toxicity and a significant decrease 
in dose-limiting toxicity caused by doxorubicin. Cardiotoxicity was not 
observed even w hen a cumulative dose of PK1 reached 1680 mg/m2 
(doxorubicin equivalent), despite a cumulative dose of doxorubicin 
which m ost frequently causes cardiotoxicity is 450-550 mg/m2 [87].
Regarding efficacy, PK1 demonstrated only two partial and two minor 
responses in thirty-six patients w ith NSCLC, colorectal cancer and breast 
cancer in phase I studies [87]. However, it is notable that PK1 showed 
activity in the cancer considered resistant/refractory to conventional 
chemotherapy and can be interpreted as a proof of concept that drug- 
polymer conjugations may be advantageous in resistant cancers. In con­
trast, PK1 demonstrated 6 partial responses in forty patients with NSCLC 
or breast cancer in Phase II studies, but all patients that responded were 
anthracycline-naive or chemotherapy-naive patients [88]. Moreover, 
PK1 showed no activity in patients with colorectal cancer.
The pharmacokinetic results ofPK1 of preclinical and clinical studies 
correlated. However, there seems to be a gap between preclinical and 
clinical studies on tissue distribution and efficacy.
3. Paclitaxel
Taxanes were discovered in the early 1960's as part of an NCI initia­
tive to screen synthetic and natural compounds for anti-cancer activity. 
It was initially collected from the bark of the rare and highly noxious Pa­
cific yew tree [89]. The clinical utility of the drug w as limited until the 
1990's due to both environmental concerns and the difficulty in formu­
lating the highly insoluble compounds [90]. However, by the late 80's 
clinical trials for paclitaxel and a slightly more soluble taxane, docetaxel, 
were being conducted in earnest, and new methods for synthesizing the 
drug from the more common varieties of the yew plant brought the 
drug into common use [91]. Once brought to the market, taxanes had 
a significant impact on clinical therapies and were used as a first or sec­
ond line therapy for numerous cancer types including lung, breast and 
ovarian cancers.
These drugs work by binding the beta-tubulin subunit and stabilizing 
the microtubules within the cell cytoplasm [92]. This prevents the micro­
tubules from disassembling, even in the presence of signals normally 
causing catastrophe. The stabilized microtubules are unable to separate 
from the centromeres during mitosis which arrests the cell cycle and trig­
gers apoptosis. Microtubules are capable of polymerizing stable microtu­
bules even in the absence of guanosine triphosphate (GTP) [92].
Formulating paclitaxel and its counterpart for systemic administra­
tion proved to be a very difficult challenge. The drug contains a high 
number of fused rings and is very hydrophobic. To solubilize the drug, 
researchers turned to Cremophor® EL, an emulsifying compound close­
ly related to Castor oil [93]. This formulation is marketed as Taxol®. 
Taxol sufficiently solubilized paclitaxel for systemic delivery and finally 
allowed paclitaxel to come to the market and provide a new  standard of 
care for many cancer patients. This solubilizing agent, however, could be 
highly toxic causing m any patients to have acute hypersensitivity reac­
tions and limiting the allowable dosage for the patient [94]. Acute toxic- 
ities associated with the Cremophor EL formulation are managed by 
premedication in current practice. The limiting toxicity for paclitaxel 
therapies is generally neutropenia, which is managed by giving the pa­
tient granulocyte stimulating factor before treatm ent in an effort to pre­
vent crashing neutrophil levels [95]. Docetaxel is a slightly more soluble 
m ember of the taxane family and has been somewhat useful in reducing 
this toxicity [96,97].
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The current standard formulation of paclitaxel using Cremophor EL 
provides a low-hanging fruit for drug carrier technologies. Reformulating 
the drug in a less toxic carrier allows more of the drug to be used with 
less risk to the patient and improve outcomes without relying on EPR, 
targeted delivery or other characteristics of cancer drug delivery.
3.1. Abraxane®
Among the most successful second generation paclitaxel formula­
tions is Abraxane®. Abraxane (Fig. 4 ) is indicated for metastatic breast 
cancer, non-small cell lung cancer, and has recently shown promise as 
a tool against pancreatic cancer [98-100]. It generated $385.9 million 
in 2011, which is expected to rise to $2 billion if Abraxane becomes 
standard care for pancreatic cancer [101]. Tens of thousands of patients 
have been treated with this formulation.
3.1.1. Preclinical studies
Preclinical evidence has suggested that albumin accumulates prefer­
entially in tumors in comparison with surrounding tissue [102]. Multiple 
potential mechanisms have been invoked to explain the phenomena, in­
cluding EPR and tumor protein targeting. However, the extent of albu­
min accumulation in clinical practice is still unknown and may or may 
not contribute to enhanced drug efficacy.
Fig. 5 shows the comparison of Abraxane and Taxol treatments in an­
imal models [103]. For xenograft ovarian and breast tumors, the differ­
ence between the two is indeed remarkable, showing p-values of 0.004 
and 0.0001, respectively, with impressive numbers of mice surviving 
tumor free for the duration of the study. The pharmacokinetic advan­
tages were also significant though not dramatic compared with the phar­
macokinetic changes in other drugs. The Abraxane formulation shows an 
approximately 50% reduction in AUC and a dramatic drop in maximum 
concentration (Cmax). Interestingly, the volume of distribution and clear­
ance rate significantly increased, indicating that Abraxane behaves more 
like a small molecule drug than Taxol [104].
3.1.2. Clinical studies
Abraxane utilizes the serum protein albumin to solubilize and carry 
the drug in circulation, the formulation is Cremophor free and clinical 
trials indeed indicated a reduction in acute toxicity in patients
(Table 2) [98,105]. The reduction in toxicity allows Abraxane to be 
more aggressively dosed than Taxol. The recommended paclitaxel dos­
ing for Taxol is 175 mg/m2, compared to 260 mg/m2 for Abraxane, 
though this leads to a total exposure AUC only 17% higher than Taxol
Fig. 4. Albumin-bound paclitaxel (Abraxane). Purple represents hydrophobic regions. Particle 
size 7 nm  or 67 kDa (size of albumin protein). FDA approval 2005 for treating advanced met­
astatic breast cancer. Recommended dose is 260 mg/m2 every 3 weeks while tolerated [186].
Fig. 5. Tumor volume and Kaplan-M eier analysis of tum ors in two xenograft m ouse tum or 
models trea ted  w ith  Abraxane (closed circles), Taxol (open circles), and untreated con­
trols (closed diam onds). A & B MX-1 (breast tum or xenograft); C & D SK-OV (ovarian 
tum or xenograft).
Reprinted w ith permission from Desai et al:  Increased antitum or activity, intratum or pacli- 
taxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound pac- 
litaxel, ABI-007, compared w ith cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324, 
2006. Copyright 2006 by the American Association for Cancer Research [103].
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Table 2


















N eutropenia 82 22 80 9 91 65 21 14 71 46
Anemia - - 33 1 54 12 17 5 19 3
Platelet 3 1 2 1 28 0 7 2 2 0
Nausea 22 1 30 3 28 0 33 4 70 3
Vomiting 10 1 18 4 - - 19 2 52 3
Diarrhea 15 1 26 1 23 0 16 1 25 2
Fatigue 39 3 47 8 58 4 27 6 7 3
Arthralgia 49 4 44 8 46 2 12 <1 29 7
Myalgia 49 4 44 8 60 0 - - 54 6
Neuropathy 56 2 71 10 65 2 50 19 71 13
Alopecia 94 N/A 90 N/A 88 N/A 9 N/A 81 N/A
AST 32 N/A 36 N/A 32 N/A - - - -
Hypersensitivity 12 2 4 0 - - - - 7 4
[106]. Directly comparing these numbers can be difficult, however, be­
cause the ratio of free to bound paclitaxel will be different for each
0 16 32 48 64 80  96 112 128 144 
Week
0 16 32 48 64 80  96 112 128 144 
Week
Fig. 6. (A) Patient survival over time. (B) Patient survival over time in patients w ho re­
ceived second-line or greater therapy. P values from log-rank test. Survival indicates 
time from first dose of study drug to date of death.
R eprin ted  w ith  perm ission. © 2005 A m erican Society of Clinical Oncology. All rights 
reserved. G radishar, W. et al: J Clin Oncol 23 (31) 2005: 7794-7803.
formulation. Lower toxicity also allows Abraxane to be administered 
in a fraction of the time that Taxol is (30 min vs. 3 h) and without 
premedication to mitigate acute side effects [105].
Abraxane does seem to have clear efficacy gains compared to Taxol. 
On average, the median time to disease progression was approximately 
five weeks longer for Abraxane treatm ent than Taxol (p =  0.006), 
while quality of life (QOL) measurements were basically steady. Overall 
survival did not differ significantly between Taxol and Abraxane (Fig. 1) 
as a front line therapy, though as a second line therapy Abraxane 
appeared to extend life by nearly ten weeks (p =  0.024) [106]. Toxicity 
also did not differ significantly (Table 2).
While extending life five to ten weeks may seem paltry in terms of the 
overall tragedy of cancer, seeing any improvement over standard care 
does provide hope. It cannot be construed, however, as anything more 
than an incremental gain or as a revolutionary technology. Especially in 
light of the tremendous promise Abraxane showed in preclinical studies.
Clinical and preclinical studies both indicate that albumin- 
conjugated paclitaxel enjoys an efficacy advantage over the Taxol for­
mulation (see Figs. 5 and 6). This improvement is credited both to the 
higher dosage allowed by the elimination of the highly toxic Cremophor 
EL solubilizing agent and to tum or specific targeting via EPR and 
receptor-ligand targeting [107]. SPARC (secreted protein acidic and 
rich in cysteine) is a protein that appears to be up-regulated in many tu ­
mors. It is capable of interacting with albumin and potentially capable of 
increasing the retention of albumin bound drugs in the tum or [102]. 
Combined with EPR from a tumor's pathological vasculature, SPARC 
binding may help explain some of the improved efficacy of Abraxane, 
especially in preclinical studies. However, the relatively minor efficacy 
improvement in human patients may not require any more explanation 
than the increased paclitaxel dosage and availability compared to Taxol. 
Still, Abraxane showed greater efficacy gains than any other drug carrier 
for which phase III were available. Interestingly, paclitaxel would likely 
be bound to albumin when administered as a free drug. The Cremophor 
EL emulsion that is used in Taxol, however, may act as a micelle 
nanocarrier that can significantly alter the drug concentration com­
pared to a non-formulated state [108,109]. Thus the improved efficacy 
of the Abraxane formulation over the Taxol in humans may be a result 
of Abraxane more closely approximating the free drug state than Taxol.
32. NK105
NK105 (Fig. 7) is a micellar formulation of paclitaxel currently making 
its way through clinical trials in the United States. The micelles are formed 
using a diblock copolymer of PEG (hydrophilic) and polyaspartate 
(hydrophobic) modified to convert half the carboxylic groups to 
phenyl-1-butanol to create a more stable, hydrophobic core. Paclitaxel
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Fig. 7. NK105, micellar paclitaxel. Size range 20-430 nm, average size 85 nm. Not FDA 
approved but previously tested  for use as second-line therapy for recurren t m etastatic 
gastric cancer. Recommended dose is 150 m g/m 2.
loads into the core by hydrophobic interactions. The process is well 
controlled and creates micelles with an average diameter of 85 nm [110].
3.2.1. Preclinical studies
The PEG coating of the NK105 micelle radically alters the pharmaco­
kinetics of the drug cargo. Preclinical studies indicated the paclitaxel AUC 
was 25 times higher for NK105 than for paclitaxel, with 4 -6  times longer 
half-life and 3 times higher maximum concentration. Perhaps most im­
pressive were the differences in intratumoral concentrations which 
were more than 100 times greater than paclitaxel after 72 h [110].
Preclinical trials showed remarkable promise for the NK105 paclitax­
el formulation. In a one month study performed by Hamaguchi et al., es­
calating equivalent paclitaxel doses were administered using the NK105 
and Taxol formulations. At every dose point tested, NK105 performed 
significantly better than free paclitaxel and at doses above 100 mg/kg, 
all mouse models receiving NK105 were completely cured (Fig. 8). Tox­
icity indicators did not appear significantly different between the two 
treatments, though neurotoxicity as measured by demyelination of 
nerve fibers was significantly less (p < 0.001) [110].
3.2.2. Clinical studies
Clinical trials indicated a ninefold increase in the AUC though a lower 
paclitaxel dose was used (150 mg/kg vs. 210 mg/kg) [111]. In spite of
Fig. 8. Relative changes in HT-29 tum or growth rates in nude mice. (A) Effects of PTX (open 
symbols) and NK105 (closed symbols). PTX and NK105 w ere injected i.v. once weekly for 
3 weeks at PTX-equivalent doses of 25 mg/kg (squares), 50 mg/kg (triangles), and 
100 mg/kg (circles), respectively. Saline was injected to control animals (shaded circles). 
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: 
British Journal of Cancer [110], copyright 2005.
the large increase in overall drug exposure as measured by the AUC, 
neutropenia, the primary toxicity of paclitaxel, was slightly changed 
from the Taxol formulation. Other hematological toxicities also changed 
little from Taxol. Hypersensitivity reactions were markedly reduced as 
well.
At the time of writing, NK105 was being recruited for phase III trials, 
leaving only limited clinical efficacy data from the phase II trial. In the 
phase II study for NK105, as a second-line therapy for gastric cancer, 
the overall response rate (ORR) was 25% with the 95% confidence inter­
vals between 14.4% and 38.4%. Other indicators were progression-free 
survival (PFS) and overall survival (OS) which came in at 3.0 months 
and 14.4 months, respectively. Though the phase II study did not use a 
comparator, we may consider trials of other drugs and drug combina­
tions to give a rough idea of how these values compare to existing treat­
ments. Other trials using paclitaxel alone have yielded ORRs of 17-23% 
[112]. The recommended frontline treatm ent for gastric cancer is a com­
binational therapy using epirubicin, cisplatin and continuous infusion of 
5-FU (ECF) [112]. Studies of previously untreated advanced gastric 
cancers have yielded ORRs as high as 71%, but generally above 40% 
[113-115]. If frontline treatm ent fails there are still numerous other 
combinational therapies from which to choose to treat the recurrent 
cancer [112,116].
While upcoming phase III trials may show greater efficacy gains of 
NK105 over paclitaxel or currently available combinatory therapies 
against recurrent cancer, early evidence indicates that the ORR of 
the drug is unrelated to the orders-of-magnitude improvement in 
intratumoral drug accumulation seen in preclinical studies.
3.3. Genexol-PM®
Genexol-PM® is a polymeric micelle composed of a diblock 
copolymer of monomethoxy PEG-bfocfc-poly(D,L-lactide) (mPEG-PDLLA) 
(Fig. 9). The micelles are formed by the solid dispersion technique and 
form stable structures ranging from 20 to 50 nm in diameter [117]. The 
formulation is in numerous clinical trials including a phase IV trial for 
metastatic breast cancer.
3.3.1. Preclinical studies
Preclinical pharmacokinetic studies showed a unique drug distribu­
tion pattern. In a preclinical study, the paclitaxel dosage for the 
Cremophor EL formulation was 20 mg/kg and the micelle formulation
Hydrophilic mPEG Hydrophobic PDLLA 
*  Paclitaxel
Fig. 9. Genexol-PM. Size range 2 0 -50  nm. In phase III trials as second-line therapy for re­
current m etastatic breast cancer. Recommended dose 300 m g/m 2 paclitaxel equivalent.
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was dosed at 50 mg/kg. In spite of the lower dosage of the Taxol and the 
pegylation of the micelle, the AUC of the Genexol-PM formulation was 
nearly 30% lower than Taxol. In spite of the lower AUC, the drug accu­
mulation was higher in all sampled tissues including a nearly 100% in­
crease in tumor accumulation. At equivalent doses the AUC could be 
an order of magnitude lower yet still more than double tissue concen­
trations [117]. The unique pharmacokinetics of the Genexol PM formu­
lation may simply be a result of the relatively unstable nature of the 
mPEG-b-PDLLA copolymer micelle, which appears to substantially re­
lease the drug into the bloodstream very soon after administration. 
This allows the drug to be cleared much more rapidly, but the higher 
overall dose allowed for greater tissue accumulation. When equivalent 
paclitaxel doses were administered, the tissue exposure remained the 
same in spite of the fact that the AUC of the Genexol-PM formulation 
was an order of magnitude lower.
Preclinical studies proved Genexol-PM to be remarkably capable at 
producing complete tum or remission in mouse models. One study 
done on athymic mice bearing MX-1 human breast tumor xenograft 
showed Genexol-PM administered at the maximum tolerated dose 
(MTD) of 60 mg/kg was able to produce complete remission in all tu ­
mors while Taxol at 20 mg/kg was only able to delay tumor growth 
for approximately 14 days, after which growth resumed as quickly as 
without treatment. The authors indicated that the increased efficacy is 
likely due to the significantly lower toxicity, allowing a dose three 
times higher than could be achieved with Taxol. A similar protocol 
with a SKOV-3 human ovarian cell line xenograft tumor also showed a 
marked improvement over Taxol. While Taxol was only able to slow 
tumor growth, Genexol-PM significantly reduced the tum or mass and 
caused complete remission in some mice, giving an overall delay in 
tumor progression of nearly six weeks (Fig. 10) [117].
3.3.2. Clinical studies
As in the preclinical trials, early clinical studies showed that the AUC 
of Genexol-PM was consistently lower than Taxol. Reduced toxicity 
allowed a much higher dose of paclitaxel to be administered than was 
possible for Taxol (300 mg/m2). In clinical studies the AUC and plasma 
half-life of Genexol PM remained well below that ofTaxol [118]. This 
can be explained by the instability of the PEG-PDLLA micelles, which 
can break up soon after administration, allowing the paclitaxel to be car­
ried in the blood as a small molecule drug.
Days following treatment
Fig. 10. Antitumor efficacy of Genexol®-PM and Taxol® on Tac:Cr:(NCr)-nu athymic mice bear­
ing MX-1 human breast tum or xenograft. Tumors were allowed to establish and mice were 
treated on 3 consecutive days with saline (•), Taxol® vehicle (■), Genexol®-PM vehicle (▲), 
Taxol® 20 mg/l<g (▼) or Genexol®-PM 60 mg/l<g (♦). Each point represents a mean ±  S.D. 
ReprintedfTomJ. Control. Release 72( 1 -3 )S. W. C. Kim, D. W. Kim, Y. H. Shim, J. S. Bang, H. S. Oh 
and M. H. Seo, In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and ef­
ficacy, 191-202, Copyright 2001 with permission from Elsevier.
Samyang has conducted or is currently conducting numerous clinical 
trials for Genexol-PM covering multiple indications and often in combi­
nation with small molecule drugs. The toxicity profile of the drug from 
phase II studies is generally in line with the paclitaxel formulations pre­
viously discussed, though at a much higher dose (Table 2 ). A phase IIb 
study of Genexol-PM in combination with cisplatin to treat non-small- 
cell lung cancer was able to show only non-inferiority providing progres­
sion free survival and overall survival curves that were nearly identical to 
the paclitaxel +  cisplatin controls (Fig. 11). Toxicity was also substan­
tially similar for both treatments, though neutropenia was greater in 
the Genexol-PM +  paclitaxel formulation. Progression free survival for 
the Genexol PM +  cisplatin formulation was 5.4 months compared to 
5.5 months for free paclitaxel +  cisplatin and overall survival was one 
month longer for the former [119].
Genexol-PM seems to provide another case of a seemingly revolu­
tionary drug becoming rather ordinary during clinical trials. The formu­
lation allows a much higher paclitaxel dose to be administered without 
increasing the toxicity, but the higher dose apparently fails to provide 
greater efficacy. Samyang is still pursuing FDA approval for the drug, 
which may be granted on the same basis as Doxil, based on an altered 
toxicity profile making it more suitable for a subset of patients.
3.4. Xyotax™
Xyotax™ (Fig. 12), paclitaxel poliglumex (PPX) was am ong the 
m ost promising of the second generation paclitaxel formulations. 
The formulation grafts paclitaxel in a comb-like pattern  to a linear 
polymer of L-glutamic acid using a degradable linker. The link between 
the paclitaxel and the polymer backbone effectively disables the active 
site of the taxane drug rendering it inert until it is released from the con­
jugate. Because the link is relatively stable, drug release tends to happen 
slowly. The total size of the conjugated system is approximately 48 kDa, 
of which more than a third is the paclitaxel drug.
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Fig.11. PFS and OS among the study patients. (A) Kaplan-Meier curves for PFS in the Intent- 
to-Treat (ITT) Population (2P =  .70). (B) OS in the ITT Population (2P =  .83). Blue repre­
sents Genexol-PM +  cisplatin and red represents paclitaxel +  cisplatin. 
ReprintedfromClin. Lung Cancer 14(3), S. Y. Lee, H. S. Park, K. H. K. Y. Lee, H. J. Kim, Y. J. Jeon, T. 
W. Jang, Y. C. Kim, K. S. Kim, I. J. Oh, and S. Y. Kim, Paclitaxel-loaded polymeric micelle (230 
m g/m(2)) and cisplatin (60 m g/m(2)) vs. paclitaxel (175 m g/m(2)) and cisplatin (60 mg/ 
m (2)) in advanced non-small-cell lung cancer: a multicenter randomized phase IIB trial, 275­
282, Copyright 2013, w ith permission from Elsevier. (For interpretation of the references to 
color in this figure legend, the reader is referred to the w eb version of this article.)
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Fig. 12. Paclitaxel poliglumex (PPX; Xyotax). Size range 4 0 -5 0  kDa. Not FDA approved. 
Under investigation to trea t NSCLC. Recommended dose 210 m g/m 2 paclitaxel equivalent
3.4.1. Preclinical studies
As with other drug carriers, the poliglumex formulation can drasti­
cally alter the pharmacokinetic profile of the drug. Due to the stable 
binding of paclitaxel to the polymer backbone, the patient exposure to 
the bioactive drug can be quite low even when the total paclitaxel 
dose becomes very high. Preclinical pharmacokinetic studies using 
equivalent paclitaxel doses in mice showed that even with a twelvefold 
increase in total AUC for poliglumex in comparison with Taxol (due to 
slower clearance), the plasma exposure to active taxane was more 
than sixteenfold less. Intratumoral exposure to active drug, on the 
other hand, was nearly double that of the Taxol formulation. On the 
surface, this result shows great potential for improving efficacy while 
drastically reducing systemic drug exposure and toxicity, but the slow 
release of the drug into surrounding tissue could drive high drug con­
centrations in tissues other than the tumor by a similar mechanism.
Early preclinical studies showed great promise for the PPX formula­
tion to improve anti-tumor efficacy of paclitaxel for some cell lines. In 
one study by Li et al., PPX at a dose of 40 mg/kg effected complete regres­
sion in OCA-1 ovarian and 13762F breast cancer tumors in mice, whereas 
free paclitaxel was only able to suppress growth for approximately ten 
days after which growth resumed [120]. The formulation did not appear 
to be so successful in all cell lines. HCa-1 hepatocarcinoma tumors were 
only marginally slowed by PPX at a dose of 80 mg/kg, though a statisti­
cally significant gain was seen over free paclitaxel administered at 
800 mg/kg. Efficacy gains against FSa-II fibrosarcoma tumors were simi­
larly modest [121].
3.4.2. Clinical studies
Phase I clinical studies determined the MTD for PPX to be 233 mg/m2 
given in three week doses. At that level, the AUC of bound taxane was 
1583 mg-h/L with a half-life of approximately 120 h. Exposure to free 
paclitaxel was significantly less, only 27.8 mg-h/L, a nearly sixtyfold de­
crease between total dose and available paclitaxel. This result proved 
similar to the preclinical results which also showed a large increase in 
total AUC, even while exposure to the active drug declined.
The success of PPX in eradicating some types of tumors in preclinical 
studies helped fuel a large number of clinical trials, many of which 
progressed to phase III [21,122-125]. Xyotax generally shows less toxic­
ity than other paclitaxel formulations; neutropenia and alopecia, in par­
ticular, showed marked improvement with the poliglumex formulation.
Neuropathy on the other hand, was increased in comparison with the 
docetaxel standard used in the study [21].
At least six phase III clinical trials were launched with Xyotax, based 
on enthusiasm from preclinical and early clinical results. A few trials 
were based on administering PPX alone, and several others tested PPX 
in combination with other drugs. A large portion of these studies were 
completed in 2008 leaving a wealth of efficacy data. Almost all of this 
data indicates that PPX is no more efficacious than the comparative 
treatment. A phase III study comparing either PPX or paclitaxel in com­
bination with carboplatin against NSCLC. This study failed to show any 
benefit of PPX over paclitaxel; overall median survival for the PPX 
group was 7.9 months and 8 months for the paclitaxel group, similarly 
the time to progression was 3.9 months and 4.6 months, respectively. 
Neither of these differences was statistically significant. Toxicities dif­
fered somewhat between the two treatments, with patients receiving 
PPX experiencing less cardiac toxicity, alopecia and muscle toxicity, 
but more nausea and vomiting [124].
Another trial for treating NSCLC using PPX alone and comparing 
with single agent docetaxel yielded similar results, the docetaxel treat­
m ent is ostensibly better than the PPX. Overall median survival for both 
was 6.9 months, though median time to progression was 2.6 months 
for docetaxel and 2.0 months for PPX. Again, toxicities differed only 
slightly w ith neutropenia being more common in patients receiving 
docetaxel and neuropathy being more common in patients receiving 
PPX [21]. A third trial published in 2008 comparing single agent PPX 
with single agent control (gemcitabine or vinorelbine) for treating 
NSCLC yet again tells the same story. The study showed similar overall 
median survival times between the experimental and control groups 
(7.3 months vs. 6.6 months), similar time to progression (2.9 months 
vs. 3.6 months), and slightly different toxicities (improved hematologi­
cal and gastrointestinal effects but worsened neuropathy) [122].
Xyotax is a fairly simple drug carrier that packages paclitaxel in a 
slow releasing formulation. The goal is to allow the nanoparticle form 
of the drug to accumulate in a tumor via EPR then slowly release the 
drug in the tumor while sparing the rest of the body drug exposure. 
The approach was largely successful in preclinical trials, causing com­
plete remission of some tumors in mice, though success was limited in 
other cell lines. As with other drug formulations, clinical trials did not 
bear out the promise of preclinical studies. All three clinical trials report­
ed show no significant difference in efficacy, in spite of the radically dif­
ferent pharmacokinetic profile of the formulation.
4. Cisplatin
Cisplatin, cis-diamminedichloroplatinum (II), cis-[PtCl2(NH3)2] 
(CDDP) is the first anti-cancer drug containing inorganic platinum and 
one of the most widely used anti-cancer drugs. In the 1960s, Barnett 
Rosenberg unexpectedly discovered the inhibition of cell division by 
platinum salts from "inert” platinum electrodes [126-128] and its po­
tent anti-cancer activity was revealed in sarcoma 180 and leukemia 
L1210 in mice [129,130].
The anti-cancer activity of cisplatin is given by crosslinking DNA 
[131]. Cisplatin forms highly reactive and charged platinum complexes 
which bind to nucleophilic groups, such as guanine and cytosine in DNA 
and form intrastrand and interstrand DNA cross-links, as well as DNA- 
protein crosslinks. These cross-links result in apoptosis and cell growth 
inhibition. Since approved for use in testicular and ovarian cancers by 
the FDA in 1978, cisplatin is widely used to treat various malignancies 
(bladder cancer, cervical cancer, malignant mesothelioma, non-small 
cell lung cancer, ovarian cancer, squamous cell carcinoma of the head 
and neck, and testicular cancer) [132]. However, the major toxicity of 
cisplatin therapy is irreversible nephrotoxicity, which has been recog­
nized in rats as early as 1971 [133]. Cisplatin accumulates in proximal 
tubular epithelial cells by both active and passive uptake. The active up­
take is mediated by organic cation transporter (OCT2) and is especially 
recognized as a critical pathway for accumulation in proximal tubules
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[134]. Nephrotoxicity was a serious obstacle during clinical trials and re­
mains a major dose-limiting toxicity. To reduce nephrotoxicity, patients 
are hydrated excessively pre- and post-treatm ent and associated incon­
veniences can decreases their quality of life (QOL) [135]. Cisplatin ther­
apy also causes neurotoxicity, gastrointestinal toxicity (nausea and 
vomiting), hematological toxicity and ototoxicity [136]. Ototoxicity is 
usually bilateral, irreversible, and cumulative. Audiological studies 
have indicated that up to 90% of the patients treated with cisplatin ex­
perience significant hearing loss, especially at high frequencies 
[137,138]. Various types of cisplatin analogs (carboplatin, oxaliplatin, 
satraplatin, and picoplatin) have been developed to reduce these 
toxicities [139-141]. Furthermore, its anti-tum or activity is limited by 
various types of resistance such as increased efflux, inactivation by sulf- 
hydryl molecules (e.g., glutathione), and increased DNA repair [142].
4.1.NC-6004
As early as 1996, cisplatin-incorporated polymeric micelles using 
PEG-poly amino acid block copolymer has been developed to decrease 
cisplatin's toxicity [143-146]. NC-6004 (Fig. 13) was first introduced 
in 2003 [147] and is currently undergoing phase II clinical trials. NC- 
6004 consists of the block copolymer, PEG which constitutes the outer 
shell and poly(glutamic acid) which constitutes the inner core. The cis­
platin drug forms a complex with the carboxyl group of poly(glutamic 
acid) in this formulation. NC-6004 is clearly distinguished from typical 
micelles consisting of an amphiphilic polymer. The micelle formation 
is driven by the ligand substitution of platinum (II) from chloride to car­
boxyl groups of glutamine. The molar ratio of cisplatin to the carboxyl 
groups in the copolymers was 0.71. The size is around 30 nm with a nar­
row distribution. NC-6004 is remarkably stable in distilled water and it 
dissociates into unimers accompanied by cisplatin release in chloride- 
rich solutions. The high stability is assumed to be allowed by the rigid 
structure stabilized by interpolymer cross-linking by Pt(II) atom.
4.1.1. Preclinical studies
NC-6004 shows significantly prolonged blood circulating time com­
pared with cisplatin in rats [148,149]. Using frameless atomic absorp­
tion spectrophotometer (FAAS) to detect elemental platinum, it was 
found that free cisplatin was detected in plasma only up to 4 h after 
i.v. injection while cisplatin delivered by NC-6004 was detected up to
48 h after i.v. injection. The AUC and Cmax of elemental platinum in 
the rat treated with NC-6004 are 65 times and 8 times greater, respec­
tively, compared with cisplatin treatment. Furthermore, total body
clearance and volume at steady state of NC-6004 are significantly 
lower than that of cisplatin. These findings are accounted for by the 
"stealth effect” seen in pegylated nanoparticles.
As mentioned in the introduction of cisplatin, it accumulates in the 
kidney within 1 h after i.v. injection in the rat. In contrast, NC-6004 
shows relatively high accumulation in the liver and the spleen instead 
of the kidney, and highest accumulation is seen at 48 h after i.v. injec­
tion [148,149]. The maximum concentration of platinum in the kidney 
is 3.8-fold lower for NC-6004 than for cisplatin. Tumor accumulation 
was examined using a xenograft model of MKN-45 human gastric carci­
noma in mice. Although Cmax is observed 10 min after i.v. injection of 
cisplatin, NC-6004 shows 3.6 fold higher Cmax than cisplatin at 48 h 
after i.v. injection. These results are consistent with the prolonged 
blood circulating time in pharmacokinetics results.
Nephrotoxicity (dose limiting toxicity) and neurotoxicity were 
mainly studied using rats [148-150]. Seven days after injection of cis­
platin or NC-6004, the concentration of blood urea nitrogen (BUN) 
and creatinine, assessors of kidney function, was increased only in rats 
treated with cisplatin. Moreover, 4 of 12 rats treated with cisplatin 
died while no deaths were observed in the rats treated with NC-6004. 
Histological studies using TUNEL assay also revealed the significant de­
crease of nephrotoxicity of NC-6004 compared with cisplatin [150].
Neurotoxicity was examined by electrophysiological methods. There 
was no delay of sensory nerve conduction velocities observed in the rats 
treated w ith NC-6004 although a significant delay was observed in the 
rats treated with cisplatin. Additionally, NC-6004 shows significantly
Fig. 13. Cisplatin incorporated polymeric micelle (NC-6004). Particle size is around 50 nm. 
Developed by Nanocarrier. Yasuhiro M atsumura, Polymeric Micellar Delivery Systems in 
Oncology, Japanese Journal of Clinical Oncology, 2008, 38 ,12 , 793-802, by permission of 
Oxford University Press [187].
Fig. 14. Relative changes in MKN-45 tum or grow th rates in nude mice. (A) Cisplatin and 
NC-6004 w ere injected i.v. every 3 days, th ree adm inistrations in total, a t  CDDP- 
equivalent doses of 0.5 m g/kg ( • ,  0 ) ,2 .5  m g/kg (▲, A ) ,a n d 5  m g/kg (■ , □ ), respectively. 
Glucose (5%) was injected in the control mice (x). (B) Changes in relative body weight. 
Data w ere derived from  the sam e mice as those used in the present study. Values are 
expressed as the m ean ±  S.E.
Reprinted by permission from Macmillan Publishers Ltd on behalf o f Cancer Research UK: 
British Journal of Cancer [148], copyright (2005).
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lower accumulation of platinum in the sciatic nerve compared with 
cisplatin in histological examination. These results clearly revealed 
NC-6004's improved toxicity compared to cisplatin.
Recently another serious toxicity, ototoxicity, was studied in guinea 
pigs [151]. Auditory brainstem responses to sound stimulation of 
various frequencies were examined before and after treatm ent with 
NC-6004 or cisplatin. Although cisplatin induced a threshold shift of au­
ditory brainstem response, particularly at high frequency, NC-6004 
showed no apparent threshold shifts.
NC-6004 significantly inhibits the xenograft tumor growth of MKN-45 
human gastric carcinoma in mice [148] and OSC-19 oral squamous cell 
carcinoma in mice [150], but there was no significant difference from 
the cisplatin at the same dosage. Additionally, significant weight loss 
was observed in the mice treated with cisplatin. On the other hand, the 
mice treated with NC-6004 did not show as much weight loss as the 
mice treated with cisplatin which is accounted for by the difference of 
toxicity profile between the two formulations (Fig. 14).
4.1.2. Clinical studies
A phase I study was conducted with seventeen patients that had var­
ious advanced solid tumors (lung, colon, hepatic cell, mesothelioma, 
esophagus, pancreas, melanoma, and renal cell) in the UK starting in 
the year 2000 [152]. NC-6004 was administered intravenously every 
3  weeks. The dose escalation started at 10 mg/m2 and reached 
120 mg/m2.
The pharmacokinetics was examined at 120 mg/m2. The Cmax and 
AUC of total platinum in plasma were 11-fold higher than those of cis- 
platin, and 88% of those were due to intact micelle form. Therefore, 
Cmax and AUC of active species of platinum in plasma are 35-fold smaller 
and 8.5-fold larger compared with the values of cisplatin from other 
clinical trials [153]. Consistent with these results, NC-6004 generally 
shows less severe and less frequent toxicities compared with cisplatin. 
No significant myelosuppression, ototoxicity, emesis, or neurotoxicity 
was observed. Although nephrotoxicity was mitigated, it was still ob­
served in patients who received 120 mg/m2 even with a pre- and 
post-treatm ent hydration regimen. Cisplatin therapy generally requires
8 h of hydration both before and after the cisplatin treatm ent to reduce 
nephrotoxicity. Therefore, low nephrotoxicity of NC-6004 is clearly ad­
vantageous over cisplatin due to increased QOL. On the other hand, un ­
anticipated hypersensitivity was frequently observed and was related to 
all dose interruptions. The mechanism of hypersensitivity has not been 
determined yet. As for efficacy, seven out of seventeen patients showed 
stable disease status and the median progression free survival time was
49 days. However, neither complete nor partial responses were seen.
Remarkably, these clinical results generally correspond to preclinical 
results despite unpredicted toxicities such as hypersensitivity. It could 
be accounted for by the sustained release of platinum from NC-6004 
which is promoted by chloride replacement unlike the designs of 
other drug carriers. It might prevent a significant increase of plasma 
concentration of active platinum that in turn decreases the toxicity. 
Still, released free active platinum in plasma could be functioning in 
the same manner as cisplatin.
5. Targeting moieties
One of the ways that drug carriers may improve cancer therapy is by 
targeted therapy. While many drug carriers claim targeting based on im­
proved distribution profiles, this section will focus on drug carriers that 
have specific groups added to provide receptor-specific targeting func­
tionality. Obviously, these targeted therapies cannot sense their target 
from a distance nor do they have any control over their own trajectory. 
Drug carriers that are designed to be targeted must rely on circulation 
in the blood stream and must rely on access to the cancer cells. Given ac­
cess to the target, interactions between the drug and the cancer cell can 
be increased with targeting moieties. Targeting moieties present on the 
drug carrier can be antibodies that bind to a specific antigen or they
can be various biological molecules that have been shown to interact 
with receptors on certain cell types. Essentially, enabling receptor- 
ligand binding between the drug and the target increases the likelihood 
of thedrugbeing in thepresenceofthedesiredtarget. Themost common 
and m ost successful (in term s of FDA approval) m ethod of receptor- 
ligand binding involves the use of antibodies. Some of these antibodies 
act as a drug when binding their ligand (antigen), others are linked to a 
drug such as with antibody-drug conjugates. Antibodies are excellent 
tools for providing mechanisms of binding. They can be selected to 
have high specificity and affinity for their target ligand. However, care 
must be taken to select the correct ligand target. It is difficult to find 
binding targets that are unique to cancer cells. Often, therapies have 
to rely on overexpression of certain proteins by cancer cells. Care 
must also be taken in the selection of an appropriate linker to conjugate 
the drug to the drug carrier/targeting moiety. Beyond antibodies, there 
are numerous preclinical studies showing how adding targeting moie­
ties to drug carriers such as polymers, liposomes, micelles, etc. will im­
prove efficacy — many have even made it to clinical trials. However, 
they have yet to make a presence in the field of clinically approved 
drug carriers for targeted cancer treatment.
5.1. Mylotarg®
Mylotarg (Fig. 15) is the product name for gemtuzumab ozogamicin 
which is a humanized monoclonal antibody (hP67.6) against the CD33 
antigen that is linked to a derivative of calicheamicin, an antibiotic 
that is toxic due to its ability to damage DNA [154,155]. Approximately 
50% of the antibodies have about four to six drug molecules per anti­
body (the remainder of the antibodies are unconjugated). CD33 was 
chosen as a target because approximately 90% of AML patients have 
CD33+ leukemia cells and because it is internalized upon binding 
[156,157]. Following encouraging phase II trials, it gained accelerated 
approval to address an unm et medical need for relapsed AML [154,155].
5.1.1. Preclinical studies
In vitro and in vivo studies tested various linkers joining the P67.6 
antibody (not yet humanized for preclinical studies) with the 
calicheamicin drug derivative. The in vivo studies used HL-60 human
Fig. 15. M ylotarg/gem tuzum ab ozogamicin. Size range: 5 -2 0  nm  o r 151-153 kDa. Bind­
ing site: CD33. FDA approved in 2000 and w ithdraw n in 2010. Indicated for CD33 positive 
acute myeloid leukemia. Recom m ended dose is 9 m g/m 2 i.v. over 4  h and repeated in 
14 days. Company: Pfizer.
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Fig. 16. Complete cure rates in mice for various dose strengths o f Mylotarg.
Reprinted w ith permission from  Bioconjug. Chem. 13(1) Hamann P. e t  al. 47-58,
2002. Copyright 2002 American Chemical Society.
promyelocytic leukemia cells implanted subcutaneously into athymic 
mice and found a formulation that showed a complete inhibition of 
tumor growth but was only compared to a buffer control. Unfortunate­
ly, that formulation was abandoned due to an unexpected problem with 
sensitivity to periodate oxidation after humanizing the P67.6 antibody 
[158]. A new formulation with a bifunctional linker was chosen and 
named gemtuzumab ozogamicin. In vivo studies found the formulation 
to be effective w ith complete inhibition of HL-60 xenografts in mice 
when tested at various doses (Fig. 16) [159].
A summary of preclinical trials boasts selective in vitro activity 
against a CD33 +  cell line when treatm ent was compared in cells not ex­
pressing the CD33 antigen. W hen administering 6 weekly doses up to 
7.2 mg/m2 in mice and 22 mg/m2 in monkeys, myelotoxicity and toxic­
ity in the liver, kidney, and testes were present, though not lethal. Pre- 
clinical studies also showed that Mylotarg distributed preferentially to 
the liver and the major excretion pathway was biliary [154].
5.1.2. Clinical studies
Phase I trials used a dosing interval of 2 weeks, as the half-life of the 
drug is over 3 days. It was found that three biweekly doses caused 
myelosuppression, thus, most received only two doses. The major toxic­
ity found in phase I trials was myelosuppression (neutropenia and 
thrombocytopenia) because CD33 is expressed on myeloid progenitor 
cells [154]. The dose limiting toxicity was stated to be neutropenia. 
Other complications were fever, nausea, chills, leukopenia, vomiting, 
rash, and pain. Furthermore, some patients developed antibodies 
against Mylotarg after 2 -3  doses. While testing the safety of various 
doses in the phase I trial, two out of forty-one patients (one dosed at 
1 mg/m2 and the other at 4 mg/m2) achieved a complete response 
(CR) defined by transfusion independence and clearance of leukemic 
blasts as well as a recovery of hemoglobin, neutrophils, and platelets. 
Seven patients (dosed at 5, 6, and 9 mg/m2) had clearance of leukemic 
blasts but not a recovery of their platelet count and were designated 
as a partial response (PR). The approval summary for phase I trials states 
that the hepatobiliary excretion pathway was not included in the phar­
macokinetic studies and no mention was made of liver toxicity, despite 
evidence in preclinical studies. As only 50% of the antibodies are actually 
linked to the calicheamicin, the methods used to characterize the
Table 3














Adult samples 2 27 17 6 3 1
10 27 12 3 6 6
Pediatric samples 2 15 2 5 3 5
10 5 0 1 1 3
a Concentration of N-acetyl-gamma calicheamicin dim ethyl hydrazide. Antibody con­
centration is 40-fold greater.
pharmacokinetics of Mylotarg may be questionable. The data simply 
do not provide much information when the half-life of a 9 mg/m2 
dose of antibody varied greatly from 67 ±  37 h to 88 ±  58 h for the 
first and second doses, respectively. The AUCs for the antibody were 
also quite varied-ranging from 132 ±  136 to 243 ±  198 mg-h/L for 
the first and second doses. For comparison, the total calicheamicin 
half-life was found to be 39 ±  25 h for the first dose and 63 ±  63 h 
for the second dose. Finally, the AUC of total calicheamicin was 2.1 ±  
1.8 mg-h/L for the first dose and 4.7 ±  4.1 mg-h/L for the second 
dose. Following the Phase I trial, the recommended phase II dose was
9 mg/m2 i.v. over 2 h for two doses [154].
The phase II trials consisted of 142 patients between three study 
groups labeled 201, 202, and 203. They used the recommended dose 
of 9 mg/m2 and all 142 patients received at least one dose while 109 re­
ceived two doses and 5 received 3 doses. The phase II studies saw 16% 
with a CR and 13% with a PR. The CR and PR were summed to 30% and 
termed as the overall response (OR) rate. Among these responders, 
the CR group had a relapse-free survival (RFS) of 7.2 months and the 
PR group had a RFS of 4.4 months, thus averaging 6.8 months for the 
OR group. Treatment was generally well tolerated except for cases of in­
fusion related symptoms, fever, chills, hypotension, hypoxia, difficulty 
breathing, and bleeding. However, treatm ent caused tumor lysis syn­
drome in four cases with one resulting in death. Furthermore, in the 
phase II clinical trials the hepatotoxicity was evident with hepatic func­
tion abnormalities, bilirubin elevations, and transaminase elevations. 
Most cases were treatable, but one patient died of hepatic failure. How­
ever, by combining the CR and PR to form an impressive OR rate, there 
was enough evidence for efficacy and to gain a fast track approval [154].
5.1.3. Postmarketing data
The postmarketing data revealed some severe adverse events such as 
hypersensitivity reactions, pulmonary toxicity, and hepatotoxicity- 
especially veno-occlusive disease (VOD). A post-market phase III trial 
from 2004 to 2009 at the Southwest Oncology Group showed a poor re­
sponse rate and adverse effects of Mylotarg plus various chemotherapies 
compared to traditional chemotherapies alone [160]. Not long after, on 
June 21, 2010, there was a FDA news release announcing that Pfizer vol­
untarily withdrew Mylotarg from the U.S. market [161]. A recent study 
completed in Germany showed a similar lack of improved efficacy. The 
CR rate for gemtuzumab ozogamicin therapy was 31% while standard 
care had a CR rate of 32%. While there may be some slight advantage in 
the relapse free survival, due to the improvements in preventing relapse, 
there is very little difference between the overall survival percentages. 
Unfortunately, this study also showed serious toxicities associated with 
the gemtuzumab ozogamicin therapy. There were eight induction deaths 
in the gemtuzumab ozogamicin group and three in the standard care and 
two of the induction deaths from the GO group had severe VOD as an un­
derlying complication [162]. Another large randomized open-label trial in 
the UK produced results of lack of superiority in efficacy for those patients 
receiving gemtuzumab ozogamicin therapy. The survival percentage and 
relapse free survival percentages are shown in Fig. 17. It was only by sep­
arating patients with favorable cytogenics or prognostic index that bene­
fits could be seen [163]. The gap present could be a matter of choice for 
the target. Inconsistent expression is much more prevalent in clinical can­
cers with a varied human population. Prior results from ex vivo studies on 
inhibition of colony formation were less than impressive compared to the 
in vivo studies on tumor growth suppression in mice (Table 3) [159]. Fur­
thermore, liver toxicity was an issue and it is likely that Mylotarg was pas­
sively targeting the liver by targeting CD33 +  cells of myeloid lineage 
(leukemia and others) in the liver sinusoids [164].
5.2. PK2
PK2 is an HPMA drug-polymer conjugate very similar to PK1 except 
that it has a galactosamine moiety added to target the liver (Fig. 18). The 
galactosamine moiety is a biomimetic ligand for the asialoglycoprotein
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receptor found on differentiated hepatocytes; thus, this receptor is not 
uniquely expressed by hepatomas. Furthermore, depending on the 
state of differentiation of the cancer cells, expression can even exist at 
lower levels than healthy liver tissue [165]. Still, the hope was to induce 
more accumulation of the drug into the liver to treat hepatomas which
Fig. 17. An open-label trial involving 1113 patients th a t w ere randomly assigned w hether 
o r no t to include gem tuzum ab ozogamicin as part o f their induction therapy. Broadly, 
there w ere only slight differences in overall survival (A), relapse-free survival (B), cum u­
lative incidence of relapse (C), and cum ulative incidence of death (D).
Reprinted w ith permission. © 2011 American Society of Clinical Oncology. All rights reserved. 
Burnett, A. e t  al. J Clin Oncol 29(4) 2011 369-377.
is aided by the fact that liver physiology is conducive to accumulation of 
nanoparticles that rely on the EPR effect.
5.2.1. Preclinical studies
Preclinical studies in mice have shown drastically faster blood 
clearance and higher liver uptake in formulations containing higher ga- 
lactosamine content (4 mol% compared to 1 mol%). These studies 
showed formulations with greater than 80% of the 125I-labeled dose ac­
cumulated in the liver [166]. Another preclinical study grew human 
colon carcinomas in the livers of nude mice. As the colon carcinoma 
does not have asialoglycoprotein receptors, radio labeled HPMA 
copolymer-doxorubicin-galactosamine conjugates were absent in 
tum or areas in the liver as shown by Fig. 19 [167].
5.2.2. Clinical studies
In the preliminary clinical study where a formulation of 1.0 mol% of 
galactosamine for PK2 was chosen, only 30% of the dose accumulated in 
the liver when scanned at 24 h following administration [168]. In the 
phase I clinical study they chose 1.5 mol% galactosamine for the PK2 for­
mulation. However, this same study compared PK2 with PK1 (almost 
identical, save it has no galactosamine moiety) and planar gamma- 
camera imaging showed PK2 preferentially accumulating in the liver 
while PK1 was not [165]. Unfortunately, while it was accumulating in 
the liver, SPECT imaging showed it accumulating to a lesser degree in 
the cancerous regions of the liver likely lacking asialoglycoprotein re- 
ceptors—where the treatm ent needs to go—and possibly explains why 
no efficacy gains were reported in clinical studies.
The AUC (from 0 to 192 h) at 120 mg/m2 reached as high as 
296 mg-h/L when administered by a 24 h infusion [165,168]. The 
MTD was found to be 160 mg/m2 due to doxorubicin associated toxicity 
of myelosuppression, mucositis, and fatigue. The recommended dose for 
phase II trials was 120 mg/m2. For comparison, the MTD of PK1 was 
higher at 320 mg/m2 [87,165].
Some dated review articles state that PK1 is in phase I/II clinical tri­
als; however, it is notably absent in lists of more recent review articles 
and government databases of clinical trials [13,169-171]. It may be 
safe to assume it has "quietly disappeared” after not performing as 
well in clinical studies.
5.3. CALAA-01
Another example of a targeted drug carrier uses siRNA as the delivered 
drug. The product name is CALAA-01 (Fig. 20) and the nanoparticle is the 
delivery vehicle Rondel™. It is composed of a linear polycationic polymer 
containing cyclodextrin and imidazole groups [172]. The imidazole 
groups are added to enhance unpacking and delivery of siRNA [173]. 
The cyclodextrin groups form a complex with hydrophobic adamantane 
(Ad) groups where each are conjugated to PEG alone or with a human 
transferrin (Tf) protein for targeting. The PEG is to help stabilize and min­
imize unwanted interactions (such as aggregation, protein binding, or 
macrophage uptake). They conjecture that these nanoparticles are able 
to take advantage of the tumor physiology to aid in intended tissue 
targeting [172]. Additionally, the Tf groups bind to Tf receptors that are 
found in a wide variety of malignant tissues [174,175]. Using siRNA to in­
hibit the expression of RRM2 results in an antiproliferative effect that 
could potentially treat a wide range of tumors [176].
5.3.1. Preclinical studies
In non-human primate studies, they tested the safety of the 
nanoparticles at doses of 3, 9, and 27 mg siRNA/kg. There was concern 
about the possibility of the PEG component causing hypersensitivity re­
actions, activating complement, or accelerating clearance from the 
blood. The results showed that there was some antibody formation 
only at the highest dosage, but that it was formed against the Tf protein 
on the drug carrier. Regardless of the dose, the majority of nanoparticles 
and siRNA had been cleared from plasma within 2 h. While ELISA
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Fig. 18. PK2/FCE 28069. Size: about 27,100 Da. Binding site: Asialoglycoprotein receptor. 
Review articles state phase I/II FDA trials, though not currently found on clinicaltrials.gov. 
Indicated for hepatocellular carcinoma. The recom m ended dose is a 4  m g/kg loading dose 
w ith  2 mg/kg w eekly doses or an 8 mg/kg loading dose w ith  a 6 m g/kg dose every 
3 weeks. Developed by Pharmacia w hich m erged w ith Pfizer.
studies showed an increase in cytokine levels for IL-6, IL-12 and IFN- 
gamma, they saw no salient physiological signs of toxicity. However, 
the highest dose saw an increase in blood urea nitrogen and creatinine 
significant enough to indicate kidney toxicity. Researchers doubted the 
toxicity was due to siRNA; unfortunately, they did not test a formulation 
w ithout siRNA as a control. Still, they suggested there was a large ther­
apeutic index by reasoning that the equivalent effective dose found in 
mice was near 0.5-1.0 mg/kg and well below the 27 mg/kg that had 
some indicated toxicities [177].
!n vivo studies in mice using 64Cu-DOTA-siRNA delivered by Tf- 
targeted and non-targeted nanoparticles showed similar tissue distribu­
tion, blood clearance, and tumor accumulation. The authors state that 
their methodology does not differentiate between the different states 
of 64Cu-DOTA-siRNA [178].
The majority of the preclinical efficacy data focuses on protein ex­
pression levels and cell growth inhibition. A/J mice using siR2B +  5 
had the best results in blocking protein expression in vivo. Also, Fig. 21 
shows tumor volume progressed slower when treated w ith the targeted 
and pegylated nanoparticle formulation containing siR2B +  5 (which 
was eventually chosen for the CALAA-01 formulations) as well as an 
improvement in cumulative survival [179,180]. Unfortunately, an im­
provement of 20 days for cumulative survival in mice may not be pre­
dictive of how CALAA-01 will prolong life for humans. On the other 
hand, mathematical models were employed to elucidate the mecha­
nisms affecting the threshold and duration of the knockdown in order 
to improve treatm ent design [180].
5.3.2. Clinical studies
CALAA-01 is only in phase I of clinical trials. Thus, clinical data is lim­
ited for comparison against preclinical data. As the best performer in 
preclinical trials, siR2B +  5 was selected for the siRNA component of 
CALAA-01 to be used for clinical trials and is termed C05C. Research is 
ongoing, but a review article states that there is fast clearance and an 
acute elevation of cytokines as seen in preclinical trials [172].
Fifteen patients were enrolled where the average age was 62. Dosing 
was tested at escalating doses of 3, 9,18, 24, and 30 mg/m2 for 30 min 
i.v. on days 1, 3, 8, and 10 of 21 day cycles. There were no dosage
limiting toxicity issues and the most common adverse events were fa­
tigue, fever/chills, allergic reactions, constipation, and nausea/vomiting. 
One patient had anemia and two patients had thrombocytopenia. One 
patient had sinus bradycardia [181]. While the purpose of the phase I 
trial was safety, they reported on some aspects of efficacy. One patient 
a t the highest dose saw their metastatic melanoma change course and 
become stable for 4 months. Furthermore, a total of four patients with 
melanoma had biopsies that showed nanoparticles internalized in 
cells. At the highest dose, RRM2 knockdown had occurred at the 
mRNA and protein level [179,181].
Still, it remains to be seen w hat kind of response will be seen in the 
clinical setting. In the clinical trial report, the researchers saw no tumor 
responses in any of the patients. While the improvements of CALAA-01 
in tumor growth deceleration and cumulative survival rates in preclini- 
cal studies are promising, early reports from phase I trials indicate that it 
may not have as much efficacy in clinical tumors. The targeted binding 
site of CALAA-01, transferrin receptors, is also found on some normal 
tissues and could be a potential pitfall in its clinical progression [174]. 
However, delivery of a less toxic siRNA that is antiproliferative—rather 
than a toxic small molecule drug—could abrogate some of the dangers 
from lack of specificity in their chosen target.
5.4. Discussion—Targeted formulations
There are general factors that make some of the products from this 
section unfit for market approval. Some of these targeted drug carriers 
suffered from similar problems as non-targeted drug carriers: unaccept­
able toxicity and insufficient efficacy in the clinical setting (e.g., 
Mylotarg). Sometimes, targeted drug carriers appear to have issues 
due to their implementation of targeting and they may have performed 
better w ithout targeting (e.g., PK2). At times, the issues become appar­
ent only after conducting clinical trials. Essentially, the selection of ap­
propriate receptor-ligand binding is a key to its success in practice. 
There were two examples of how poorly chosen targeting groups likely 
caused problems in clinical trials and the third targets receptors known 
to be found on some normal tissues. Unfortunately, one of the difficul­
ties with cancer in the clinical setting is its inherent heterogeneity and 
similarity to ‘self', thus making it difficult to choose a ligand that will 
be universally expressed by cancer cells yet not expressed by healthy 
tissue. This is not as much of an issue in preclinical studies that use 
more homogeneous cancer cell lines and could explain the disparity in 
results when translating to the clinical setting.
The limited market success in drug carriers with targeting groups 
has occurred mostly with antibody therapies. A simple search on the 
FDA drug database, Drugs@FDA, for the suffix “mab” will return num er­
ous FDA approved antibodies (a considerable fraction is for cancer treat­
ment). Some are antibody-drug conjugates such as Adcetris® and
Anterior Anterior
Posterior Posterior
Fig. 19. SPECT and CT imaging of a patient treated with PK2 showing decreased accumulation 
of targeted nanoparticles in the tum or region. The SPECT shows accumulation of PK2 in the 
liver except in the central region. The tum or is visible in the CT image as the dark mass in 
the central region.
Reprinted w ith permission. © 2002 American Society of Clinical Oncology. All rights reserved. 
Seymour, L. e t al. J Clin Oncol 20(6) 2002 1668-1676.
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Fig. 20. CALAA-01. Size: about 70 nm. Binding site: Transferrin receptor. Currently in 
phase I o f FDA clinical trials. Seeking indication for solid tum ors. The recom m ended dose 
is 18-30  mg siRNA/m2. Developed by Calando Pharmaceuticals, Inc.
Kadcyla®, while others act as a drug simply by binding to the ligand, 
such as Herceptin® and Erbitux®. Antibodies are on the lower range 
of drug carrier sizes at approximately 5-20 nm in diameter (depending 
on the axis). They are made by cells resulting in uniform and biocompat­
ible products. However, variation does exist due to m etabolism / 
degradation, immune responses, organism of origin, drugs, and linkers. 
Still, there are more and more antibody therapies being approved by the 
FDA when compared to other targeted drug carriers such as polymers,
Fig. 21. The targeted and pegylated formulation containing the RRM2 sequence denoted as 
siR2B +  5 perform ed the best in tum or grow th inhibition. (A) Tumor grow th rates and 
(B) Kaplan-M eier survival curves.
From Derek W. Bartlett,Mark E. Davis, Biotechnology & B ioengineering [180] Copyright© 
2000 by John W iley Sons, Inc. Reprinted by permission of John W iley & Sons, Inc.
colloids, or microemulsions. Preclinical studies are replete with poly­
mers, micelles, liposomes, etc., that contain multifunctional aspects, be­
yond just targeting moieties, that provide preferential treatm ent to the 
target tissue; however, it seems relatively few of these enter clinical 
trials and they have yet to successfully navigate through clinical trials 
to market approval. Apparently, the simplest designs have the best 
hope for causing positive effects in the complex clinical cancer setting.
6. Conclusion
This survey is meant to be a broad, though not comprehensive, review 
of intravenously injectable cancer drug carriers that have undergone 
some clinical testing. The formulation strategies used vary widely from 
compound to compound. Drugs can be covalently bonded to proteins or 
polymers, loaded into micellar or liposomal structures by hydrophobic in­
teractions, bound to the nanoparticle surface by ionic bonds, or sterically 
trapped within a structure. The drug carriers have a drastic effect on the 
dosing of the drug either by frequency or MTD. Comparable doses ranged 
from slightly lower to many-fold higher drug equivalents than their free- 
drug counterparts. Pharmacokinetic properties were also substantially al­
tered with circulation half-life in some cases extended from hours to days 
or even weeks; drug exposure as measured by the AUC often increased as 
well. In some of these cases, these increases in half-life and AUC compared 
to the free drug occurred in both preclinical and clinical trials. Unfortu­
nately, these improvements in dosing or pharmacokinetics and this 
focus on comparing against a free drug do not coincide with the gap be­
tween preclinical and clinical results. Comparing the half-life, AUC, Cmax, 
and other pharmacokinetic values between preclinical and clinical data 
is often not possible for the drug carriers as they are either not compara­
ble or missing from the literature.
The efficacy in preclinical studies can be incredible; an HPMA-drug 
conjugate [81], Abraxane [103], NK105 [110], Genexol-PM [117], Xyotax 
[120], and gemtuzumab ozogamicin [159] were able to completely cure 
all mice of specific tumors (i.e., show tumor regression and complete 
growth inhibition for the remainder of the study). In spite of the tremen­
dous advantages in efficacy the drug carriers seem to enjoy in preclinical 
studies, the difference seems to collapse to nearly zero in human tumors. 
The question of why the nanoparticle should perform in clinical trials, 
essentially the same as the free drug, may be an important one for under­
standing how to best proceed with new drug carrier therapies. Further­
more, one must understand the differences that are present in the 
preclinical and clinical studies. Some of the differences are obvious and 
the known shortcomings in using animal models for human cancer ther­
apy testing are accepted because the murine model is the most widely 
used model in preclinical studies and has been invaluable in providing 
information and saving human lives. Still we must acknowledge the 
differences with regard to immunocompetency, metabolism, biological 
rhythms, hormone cycles, and heterogeneity-among others-and how 
these can affect the rate and nature of tumor growth.
The clinical environment also differs in attitudes, goals, training, pro­
tocols, and sample population characteristics. Due to an increased level 
of complexity, successful clinical trials are highly dependent on the 
proper design of the experiments. There is heterogeneity not only 
from patient to patient, but clinical tumors are more heterogeneous in 
terms of environmental and cellular composition. Depending on the na­
ture of the cancer and the patient, the results can be drastically different. 
It is not suggested that chaos theory rules supreme in clinical trials, but 
it does help to explain the difficulty in reproducing results. The butterfly 
effect suggests the importance of consistency in initial conditions. For 
example, a ball may come to rest in entirely different locations at the 
bottom of a hill based on where it is placed at the crest. Imagine now, 
the topography of that hill can change as cancer is different from patient 
from patient and the resulting path of treatm ent can be different. In re­
ality, heterogeneity in clinical cancers (including genetic, epigenetic, 
and environmental differences) is considered to play a major role in 
failed treatments.
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There are some promising strategies to navigate and bridge the gap 
between research and clinical practice. These include advancements in 
personalized medicine and theranostics which would both address the 
issue of adapting to the unique circumstances of an individual patient. 
There are also increased efforts in modifying the tum or environment, 
which could perhaps serve as a way to make the disease population 
more uniform and treatable. As a means of stimulating discussion and 
creativity in bridging the gap, a short list of suggestions is being submit­
ted that might help. Initially, consistent protocols for specific experi­
m ents could be developed that would serve as a prerequisite for 
clinical trials. Similar experiments would then be required, and must 
be reported on, in clinical trials. This would, hopefully, improve repro­
ducibility and allow for comparisons to be made between preclinical 
and clinical trials. This could be an opportunity to provide more trans­
parent reporting of pharmacokinetic and efficacy results, even if the re­
sults are negative. As reporting negative results is perceivably not as 
rewarding, they are a lot more difficult to find in publications and some­
times get summarized in conference meetings. However, the Declara­
tion of Helsinki states that authors have an ethical duty to publish all 
results from clinical trials-whether positive, negative, or inconclusive 
[182]. While there are provisions in section 801 of the Food and Drug 
Administration Amendments Act that require a summary of results, 
there seem to be loopholes in the system that allow for some negative 
results from clinical trials to avoid being published. If made publicly 
available, the negative data could be extremely useful to understand 
the faults of the drug, model, or protocols and to learn from such mis­
takes. A journal, forum, or collection could be created w here all results 
will be made publicly available as a requirem ent in taking part in clinical 
trials. Finally, a simple suggestion for a continued effort of scientific crit­
icism and skepticism is recommended. In more than one of the drugs 
presented in this paper, negative results w ere found in clinical studies 
that were also present (and should have been addressed) in the preclin- 
ical studies. It would be wise to trust the bad news and be skeptical of 
the good. Still, one m ust acknowledge that great progress has indeed 
occurred in the fight against cancer and that many drug carriers have 
been approved w ith good reasons and have saved or improved the 
quality of countless lives.
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